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In this study, we sought to harness advanced protein engineering techniques to 
develop human and/or humanized allergen-specific antibodies as new treatment 
modalities to antagonize allergen-specific IgE. Using hybridoma technology, we 
have generated and characterized murine monoclonal antibodies (mAbs) against 
Blo t 5, the major allergen from the common House Dust Mite (HDM) Blomia 
tropicalis. Epitope studies revealed that our anti-Blo t 5 mAb binds a linear epitope 
that overlaps with a previously reported conformational IgE epitope. Results from 
the inhibition ELISA suggested that our anti-Blo t 5 mAb is capable of 
antagonizing the binding of allergen-specific IgE from a Singaporean cohort of Blo 
t 5-sensitized patients. We further investigated the potential of anti-Blo t 5 mAb as 
a treatment modality in vivo in a murine model of severe allergic asthma driven by 
Blo t 5. Administration of our anti-Blo t 5 mAb resulted in an overall amelioration 
of asthma symptoms coupled with reduced eosinophilia and airway remodeling. 
The elevated serum total and Blo t 5-specific IgE levels were also suppressed back 
to levels comparable to that in naive mice. Molecular cloning was employed to 
generate chimeric variants of our anti-Blo t 5 mAb in which the Fc regions were 
modified to specific human IgG subclasses including IgG4. A flow cytometry based 
basophil activation test was utilized to study the impact of chimeric versions of our 
anti-Blo t 5 mAb on allergen-specific human basophil activation. We demonstrate 
that basophils derived from Blo t 5-sensitized donors displayed lower activation 
levels in the presence of our mAb as indicated by the expression of well-defined 
basophil activation marker CD63. Lastly, we constructed a human immune library 
which can potentially be used to isolate fully-human antibodies against the major 
allergens from another clinically relevant HDM Dermatophagoides pteronyssinus. 
Taken together, this work has important implications on the fundamental 
understanding of allergic asthma and may assist the future design of targeted 













1.1  Asthma 
Asthma was first named and recognized as a respiratory disorder by Hippocrates, 
approximately 450 BC1. The word "asthma" originated from the Greek which 
meant "shortness of breath"2. The definition of asthma was later refined by the 
English physician Henry Hyde Salter in 18602-4. Salter defined asthma as 
"paroxysmal dyspnoea of a peculiar character with intervals of healthy respiration 
between attacks" and attributed the narrowing of airways to the contraction of 
smooth muscles2-4. Despite the discoveries of the eosinophil and the mast cell by 
Paul Ehrlich in the late 1870s5, asthma was never considered an allergic 
inflammatory disease until the 1980s1.  
Today, asthma is defined as a complex respiratory disorder of the conducting 
airways that is clinically characterized by recurrent episodes of wheezing, 
coughing, breathlessness and chest tightness1, 6. It is caused by chronic airway 
inflammation arising from aberrant CD4+ TH2 cell responses and effector functions 
of their cytokines, mainly IL-4, 5, 9 and 137, 8. The hallmark features of an 
asthmatic airway include airway hyper-responsiveness (AHR), mucus hyper-
secretion and the persistent pulmonary infiltration of eosinophils, neutrophils and 
mast cells. Furthermore, airway remodeling and the pro-inflammatory 
microenvironment contributes to reversible AHR, airway obstruction and an 
overall deterioration  of airway function. 
 
  






Asthma affects a sizable proportion of the world's population, especially in 
developed countries. Approximately 300 million people worldwide are currently 
suffering from asthma and it is estimated that the prevalence of asthma increases 
globally by 50% every ten years9, 10. The global prevalence of asthma is depicted 
by Figure 1.1. Countries with the highest incidence of asthma include the United 
Kingdom (>15%), New Zealand (15.1%), Australia (14.7%), the Republic of 
Ireland (14.6%), Canada (14.1%) and the United States (10.9%)9. The prevalence 
of asthma is also increasing in countries experiencing rapid urbanization such as 
China and India, which intensifies the economic burden on these countries with 
such large populations9.  
The mortality rates of asthma are shown in Figure 1.2. Asthma fatality rates are the 
highest in China (36.7%), Russia (28.6%), and Uzbekistan (27.2%). Amongst 
countries in Southeast Asia, Singapore has the highest asthma death rates (16.1%) 
as compared to other countries in the region such as Thailand (6.2%)9. Despite a 
decrease in asthma mortality from 7 to 2 deaths per million in Singapore from the 
late 1990s to 2010, advances in the health care system has also reduced the asthma 
mortality rates in most countries11. As such, asthma-related death remains a 
persistent problem in Singapore and an insightful report by Lim and Chay (2012) 
attributes this to the lack of proper disease monitoring and suboptimal treatment as 
a result of improper corticosteroid usage11. 






Figure 1.1: Global prevalence of asthma. (Adapted from Mazoli et al., 2004). 
 
Figure 1.2: Mortality rates of asthma. (Modified from Mazoli et al., 2004). 





1.1.2 Pathophysiology of allergic asthma 
1.1.2.1 Airway hyper-responsiveness 
The hallmark pathophysiology of an asthmatic patient is airway hyper-
responsiveness (AHR) in which there is a dramatic increase in the sensitivity and 
reactivity of the airways12. As such, allergen challenge and/or exposure to other 
factors such as cold air and exercise can easily trigger the acute contraction of the 
bronchial smooth muscles13, 14. Resident immune cells in the airway such as mast 
cells and basophils, as well as inflammatory cells like eosinophils that infiltrate into 
the airway mucosa are capable of producing numerous inflammatory mediators 
such as histamine, cysteinyl leukotrienes (cys-LTs) and prostaglandins13. These 
inflammatory mediators can further increase the contractibility of the bronchial 
smooth muscle, resulting in excessive narrowing of the airways. 
Bronchoconstriction dramatically decreases the diameter of the airways and 
increases the resistance of airflow into the lungs which results in clinical symptoms 
such as wheezing and breathlessness. 
1.1.2.2 Airway obstruction 
Another pathophysiological aspect of asthma is the obstruction of airways. Airway 
obstruction can either be intermittent, persistent and/or progressive and can be 
totally, partially and/or irreversible. Airway obstruction could be a result of 
multiple factors that contribute individually or together to the narrowing of the 
airways. Factors contributing to airway hyperresponsiveness may play a role in 
mediating airway obstruction. The inflammatory mediators that cause bronchial 





smooth muscle contraction also increase the permeability of the capillary 
membrane, leading to mucosal edema which causes the obstruction of the airway 
flow13. In addition, the overproduction of mucus due to goblet cell hyperplasia and 
metaplasia in response to repeated allergen stimuli can mechanically narrow the air 
passage. In severe cases, hyper-secretion of mucus may potentially form mucus 
plugs that fully block the airway and lead to the aggravation of asthma symptoms 
as well as compromise the airway lumen integrity13. 
1.1.2.3 Airway remodelling 
Inflammation is a natural response of the body’s immune system to injury or 
invading pathogens. Under normal circumstances, inflammation is protective; 
beneficial to the host and is usually self-limiting. However, in the asthmatic airway, 
abnormal immune responses are generated against non-pathogenic stimuli. Acute 
inflammation in the asthmatic airway often fails to resolve even in the absence of 
the allergen, and this may lead to chronic inflammation of the airways. In addition, 
untreated acute symptoms of allergy could also lead to chronic inflammatory 
conditions especially under constant allergen exposure15.  
Underlying chronic inflammation results in a continuous infiltration of activated 
immune cells into the airway which produce inflammatory mediators such as 
cytokines that drive a series of structural changes in the airway12. These changes, 
collectively known as airway remodeling, occur as part of the injury-repair process 
in response to chronic inflammation and compromises the integrity and function of 
the lungs6, 16. 





While airway dysfunction develops initially as a result of acute inflammation in 
response to allergen challenge, chronic inflammation causes long-term structural 
changes in the airway and sustained airway dysfunction 17. Airway remodeling is a 
phenomenon that describes the changes in the composition, organization and 
function of the airway epithelium which negatively impacts upon the integrity and 
function of the lungs17, 18.  
Fibrosis and thickening of the airway walls are mainly caused by the dysregulated 
deposition of extracellular matrix proteins such as collagen and laminin in the 
lamina reticularis that lies beneath the epithelial basement membrane19. The airway 
smooth muscle layer often increases in thickness due to enhanced recruitment and 
proliferation of myofibroblasts16, 17. Myofibroblasts are the precursors of bronchial 
smooth muscle cells that could contribute to both airway wall thickening and 
accelerated deposition of extracellular matrix proteins.  
There is evidence that the bronchial epithelium is structurally and functionally 
abnormal in an asthmatic patient20. Furthermore, studies have shown that the 
bronchial epithelial cells from asthmatic patients are more prone to apoptosis 
induced by oxidation related stresses and are more susceptible to insults by 
environmental pollutants like nitrogen dioxide20, 21. As a result of its vulnerability, 
bronchial epithelial cell shedding is a typical attribute of asthma20, 22. In addition, 
epithelium injuries due to the action of immune cells causes the release of growth 
factors that promote the proliferation and differentiation of fibroblasts and 
contribute to thickening of the airways20. 





Coupled with increased mucus production due to goblet cell metaplasia and 
hyperplasia, thickened airway walls plays a crucial role in the pathogenesis of 
asthma. It is associated with an augmentation of AHR and airway obstruction that 
leads to severe breathlessness, wheezing and coughing. 
  





1.1.3 Immunological mechanisms 
Allergic asthma is a consequence of persistent airway inflammation initiated by 
allergic responses upon allergen exposure. The immunological basis of allergic 
asthma development can be divided into four main stages - Sensitization, 
immediate, late phases of allergic reaction and chronic allergic inflammation.  
1.1.3.1 Sensitization 
Sensitization marks the beginning of the immune response in allergy. An individual 
becomes sensitized to the allergen through the production of allergen-specific IgE 
antibodies. Sensitization usually occurs in early childhood in susceptible 
individuals. The extent of allergen sensitization is dependent on many factors 
including the type of allergen, its concentration in the environment; the dose at 
which the individual is exposed to; the frequency of exposure, and finally, the route 
of allergen exposure18, 23. The initiation of allergen sensitization, in the case of 
respiratory allergens discussed here, can be accomplished with minute amounts of 
antigen.   
During sensitization, allergens from the mucosal surfaces are actively sampled by 
antigen–presenting cells (APCs), primarily the dendritic cells (DCs) located at the 
basolateral layer of the airway epithelium. DCs are also capable of extending 
processes into the airway lumen to directly contact the antigens without perturbing 
the epithelial barrier function by forming tight junctions with adjacent epithelial 
cells24. Upon uptake of the allergen, DCs mature and migrate to the regional lymph 
node. 





Mature DCs then present peptides from the processed allergen on major 
histocompatibility complex (MHC) class II complexes to naïve T cells in the T cell 
area of the draining lymph node18, 25. Under the influence of an early source of IL-
4,  naïve T cells then adopt the CD4+ TH2 phenotype, undergo clonal expansion 
and produce a panel of cytokines such as IL-4, IL-5, IL-9, IL-13 and GM-CSF18, 25. 
Under the influence of IL-4, the naïve B cell population expands and initiates the 
production of allergen-specific IgE via the immunoglobulin class-switch 
recombination process18, 25. Subsequently, IgE sensitizes mast cells and basophils 
that reside in the airway tissue by binding to its high-affinity receptor, FcεRI on the 
surface of these cells25. 
In recent years, extensive research has unravelled the influences that airway 
epithelial cells potentially exert on the allergen sensitization process. Apart from 
the established function of the epithelial cell layer as a physical barrier to allergens, 
epithelial cells also produce a plethora of cytokines and chemokines which 
influences the sensitization process in a variety of ways. As illustrated in reviews 
by Holgate (2012) and Lambrecht & Hammad (2010), allergens present in house 
dust are very often contaminated with endotoxins that provide the adjuvant effect 
during sensitization24, 26. This adjuvant effect is attributed to the activation of 
several surface receptors on epithelial cells lining the airway lumen such as Toll-
like receptors (TLRs). Activated epithelial cells in turn produce cytokines such as 
thymic stromal lymphopoietin (TSLP) and GM-CSF that enhances the activation 
and antigen-presenting capacity of DCs as well as TH2 polarisation. 
 







Figure 1.3: Sensitization to allergens in the airway (Modified from Galli et al., 
2008). 
Resident dendritic cells that constitutively sample the airways are capable of 
allergen uptake. In addition, airway epithelial cells could be activated by allergens, 
bacteria and viruses. The activated airway epithelium produces cytokines which 
promote the migration and maturation of dendritic cells. In the regional lymph 
nodes, dendritic cells present peptides from the processed allergen to naive T 
lymphocytes. IL-4 and cytokines secreted by the airway epithelial cells induces the 
polarization of naive T cells to a TH2 phenotype. TH2 cells subsequently activate 
and induce IgE production from B cells. IgE produced by activated B cells binds to 
its high affinity receptor, FcεRI, located on the surface of resident tissue mast cells. 
At this point, the sensitization phase is complete. 
  





1.1.3.2 Early phase 
The early or immediate phase of allergic inflammation occurs within minutes of 
allergen exposure. This phase of allergic inflammation is mainly mediated by 
resident mast cells in tissues which possess allergen-specific IgE bound to the high 
affinity IgE receptors (FcεRI) on the surface of the cell. Binding of allergens to 
allergen-specific IgE results in cross-linking of adjacent IgE molecules and triggers 
a complex intracellular signaling pathway that ultimately leads to the release of 
inflammatory mediators. These inflammatory mediators fall into three broad 
categories: those mediators stored in the cytoplasmic granules, lipid-derived 
mediators and newly synthesized cytokines, chemokines and growth factors. 
Examples of released mediators include histamine, proteoglycans and proteases. In 
addition, activated mast cells metabolize arachidonic acid through the 
cyclooxygenase and lipoxygenase pathways which results in the production of 
prostaglandins, particularly prostaglandin D2 (PGD2), leukotrienes and cysteinyl-
leukotrienes (cys-LTs). The secretion of mediators occurs through degranulation, 
which involves the fusion of cytoplasmic granules within the mast cells with the 
plasma membrane, leading to the exocytosis of granule contents to the external 
environment.  
The acute symptoms associated with the early phase are caused by the local effects 
of the released mediators. Some of the effects include vasodilation and erythema, 
swelling due to an increase in vascular permeability as well as airway obstruction 
resulting from bronchoconstriction and increased mucus secretion. Mast cells also 
release chemokines which leads to the recruitment of eosinophils and neutrophils to 
the site of inflammation. Eosinophils and neutrophils are important in propelling 





the late phase of allergic inflammation. As such, mast cells are not only key 
mediators of the immediate immune response but also act as the bridge to the late 
phase of the allergic reaction.  
  








Figure 1.4: Immediate hypersensitivity. (Modified from Galli et al., 2008). 
Upon re-encounter of the allergen, cross-linking of FcεRI-bound surface IgE 
activates resident mast cells and induces their degranulation. Degranulation of mast 
cells results in the release of a plethora of pre-formed and newly synthesized 
inflammatory mediators including histamine, prostaglandins and cys-LTs. These 
mediators act on blood vessels, airway epithelial cells and the airway to cause 
vasodilation, increased vascular permeability, increased mucus secretion and 
bronchoconstriction. More importantly, mediators released by mast cells in this 
phase facilitate the transition to late phase of the allergic reaction by recruiting 






















1.1.3.3 Late phase 
An allergic reaction typically progresses from the early phase to the late phase in 
two to six hours post allergen challenge and often peaks after six to nine hours 
before full resolution in one to two days18. The late phase reaction is triggered by 
mediators released from mast cell degranulation in the early phase. Cytokines and 
chemokines released from the degranulation of mast cells in the early phase trigger 
the migration of allergen-specific TH2 cells to the site of allergen exposure. Under 
the influence of cytokines released by mast cells, these allergen-specific TH2 cells 
are reactivated and clonally expands. These TH2 cells have a distinct cytokine 
profile and play key roles in mediating the late phase reactions.  
In addition to the recruitment of allergen-specific TH2 cells to the site of allergen 
challenge, the infiltration of eosinophils to the exposure site in response to IL-5 
secreted by TH2 and mast cells is also a distinct feature in late phase allergic 
reaction. Eosinophil recruitment could also be enhanced by the variety of cytokines 
secreted by activated epithelial cells such as TSLP, IL-33 and IL-2527. Eosinophils 
constitute a significant proportion of the immune cells recruited into the inflamed 
airway tissue. Studies have shown the presence of eosinophils in the lung tissue 
and bronchoalveolar lavage (BAL) fluid in asthmatic patients16, 28. Moreover, 
eosinophilia has been linked to corticosteroid resistance in some asthmatic 
patients16, 29. The correlation between the degree of eosinophilia and disease 
severity therefore suggests a role for eosinophils in the pathogenesis of chronic 
allergies in the airways. 





The relationship between eosinophilia and allergic disease severity was established 
based on the fact that the recruited and activated eosinophils secrete mediators such 
as cysteinyl-leukotrienes (cys-LTs) LTC4, LTD4 and LTE4, which are now known 
to be important in the pathogenesis of airway inflammation by increasing mucus 
production, inflammatory cell recruitment and pulmonary vascular leakage12, 30. In 
addition, eosinophilia contributes to airway remodeling, specifically the thickening 
of the basement membrane12, 29. Eosinophils also cause damage to the epithelial 
cell barrier in the airway lumen by secreting toxic mediators such as major basic 
proteins (MBPs) and eosinophil peroxidase (EPO) that function to eradicate 
infecting parasites in the physiological TH2 immune response against parasites27. 
While eosinophils represent the most abundant granulocyte in the allergic airway, 
basophils, on the other hand, are the least abundant granulocytes present in the 
allergic airways. Basophils are recruited via similar mechanisms as the eosinophils 
and are therefore thought to complement T-cell dependent allergic eosinophilia12. 
The exact role of basophils in the pathogenesis of asthma has not been well 
established. However, basophils do express FcεRI and are therefore capable of 
contributing to inflammatory symptoms and AHR via degranulation and the release 
of histamines, eicosanoids and cytokines such as IL-412, 31. Moreover, basophils 
have also been shown to affect the functions of antigen presenting cells and might 
therefore play important roles in the initiation and augmentation of TH2 effector 
cell function and the pathogenesis of the late phase allergic reaction12, 31-33. 
Studies have also discovered the presence of another subset of T helper cells, TH17 
cells, that contributes to the initiation of tissue inflammation and host protection 
against extra-cellular pathogens. TH17 cells have been implicated in the pathology 





of autoimmune diseases and have also been found to play a significant role in the 
late phase allergic reaction. TH17 cells possess a cytokine profile that is different 
from TH1 and TH2 cells, in that they secrete a family of IL-17 (IL-17A to F) 
cytokines which play a role in tissue inflammation by upregulating other pro-
inflammatory cytokines and chemokines26, 34, 35. In addition, the IL-17 family of 
cytokines is also capable of inducing chemotactic molecules such as IL-8 to direct 
the influx of neutrophils into the inflamed airway tissue18, 26, 35. The influx of 
neutrophils may further compromise the airway epithelium by secreting elastase 
that activates proteases known as matrix metalloproteases (MMPs) which degrade 
















Figure 1.5: Late phase of allergic airway inflammation. (Modified from Galli 
et al., 2008). 
Immune cells in addition to mast cells are important in driving the late phase of 
allergic inflammation. These include eosinophils, basophils, neutrophils and TH2 
lymphocytes. The activation and degranulation of eosinophils results in the 
secretion of MBP and EPO which are capable of inducing epithelial cell damage. 
Furthermore, IL-13 produced by these cell types contributes to sustained 
bronchoconstriction and mucus production, which aggravate airway obstruction 
























1.1.3.4 Chronic inflammation 
While most allergic reactions experienced by non-atopic individuals usually 
resolve after the late phase, atopic individuals often experience prolonged episodes 
of allergic reactions. These prolonged allergic reactions often arise from continuous 
or repeated allergen challenges, resulting in the failure to resolve the inflammation. 
Maintenance of the pro-inflammatory environment requires the presence and 
participation of both the innate and adaptive effector cells that infiltrate from the 
circulation into the airway tissues similar to the late phase reaction. 
As mentioned in earlier section on late phase allergic reaction, eosinophils play a 
major role in promoting inflammation as well as inducing epithelial injuries. 
Acting in concert with TH2 cytokines, repetitive epithelial injury due to chronic 
allergic inflammation results in the establishment and/or reactivation of the 
epithelial-mesenchymal trophic unit (EMTU). The EMTU is normally involved in 
the structural development and modeling of the airways during embryonic 
development and reflects the complex interplay between the affected epithelial 
cells and the underlying mesenchymal cells12, 18, 20, 36-38.  
However, when it is re-activated under chronic inflammatory conditions as in 
asthmatic patients, the EMTU is capable of driving remodelling of the airways and 
exacerbating the manifestations of asthma. Collectively, the EMTU and its cellular 
components create a microenvironment that is thought to be able to prolong the 
TH2-mediated inflammation, promote the sensitization to additional allergens or 
allergen epitopes and importantly, propel remodelling in the asthmatic airway18, 20, 
37, 38.  






Figure 1.6: Chronic inflammation of allergic airways. (Modified from Galli et 
al., 2008). 
Repeated insults by allergens trigger a perpetual injury-repair process mediated by 
the major cell players in the late phase of allergic inflammation. Sustained 
activation of these effector cells lead to the formation of the epithelial-
mesenchymal transition unit (EMTU). The EMTU is responsible for creating a 
TH2 microenvironment which eventually results in airway remodelling. The 
phenotypic features of a remodelled airway include airway smooth muscle 
hyperplasia, basement membrane thickening and mucus hypersecretion. 












































1.2  House dust mite (HDM) 
It is now well-established that house dust mite (HDM) allergens are major 
contributors of indoor allergens that lead to the development of allergic conditions 
such as atopic dermatitis and allergic rhinitis. Moreover, HDM allergens pose as a 
primary risk factor in the initiation of asthma in atopic individuals who are 
genetically predisposed to generating exaggerated IgE antibody responses. 
HDM are athropods that belong to the class Arachnida. There are four known main 
families of HDMs, namely Acaridae, Pyroglyphidae, Glycyphagidae and 
Echimyopodidae39. The Dermatophagoides pteronyssinus (D. pteronyssinus) and 
Blomia tropicalis (B. tropicalis) are the two species of HDM that predominate in 
tropical and subtropical areas of the world that include countries such as Singapore, 
Malaysia, Hong Kong, Taiwan and certain states of the United States39-43. Even 
though D. pteronyssinus and B. tropicalis often co-exist in households, they belong 
to different families and possess some differences in their allergens. The D. 
pteronyssinus HDMs belong to the Pyroglyphidae family of mites while B. 
tropicalis belong to the Echimyopodidae family39 (Figure 1.7).  
Over the years, the Dermatophagoides mites and their allergens have been more 
intensively studied than B. tropicalis. However, in the recent years, it has been 
demonstrated that allergens from B. tropicalis could be more clinically relevant and 
important especially in regions such as Singapore and Malaysia where they are the 
predominant species found in households. 
 







Figure 1.7: Phylogenetic tree depicting the clinically important mites. 
(Modified from Chua et al., 2007). 
The HDM species Dermatophagoides pteronyssinus and Blomia tropicalis, despite 









1.2.1 Blomia tropicalis 
B. tropicalis is a globular-shaped storage mite characterized by numerous long 
dorsal bristles, no dorsal shield and no anal suckers44. In addition, their bodies are 
covered by minute papillae44, 45. B. tropicalis thrives well in areas where the 
temperatures and humidity are high40, 44. With a constant range of temperatures 
from 24°C to 31°C and relative humidity levels of 64% to 96% throughout the 
year, Singapore presents an ideal environment for the growth and breeding of dust 
mites like B. tropicalis40, 43.  
As such, B. tropicalis is the most abundant mite found in house dust in this region, 
followed by the D. pteronyssinus species43. Yi et. al. set out to explore the impact 
of the high prevalence of B. tropicalis in households40. In their study conducted on 
atopic individuals with asthma or allergic rhitinis, it was revealed that 
approximately more than 90% of the Singaporean population are sensitized to 
HDM40. Approximately 30% of young atopic children in Singapore are sensitized 
to HDM before the age of 3 and the sensitization of B. tropicalis appeared to be 
more prominent in comparison to D. pteronyssinus46. In the study cohort of 
asthmatic children aged between six and fourteen years old, more than 90% of 
them were sensitized to both B. tropicalis and D. pteronyssinus (97.5% B. 
tropicalis, 94.1% D. pteronyssinus)46. This high prevalence of sensitization could 
be due to the presence of HDM in common households and the resultant constant 
exposure to high concentrations of HDM allergens all year round. 
Due to its co-existence with the D. pteronyssinus species of mites, dual 
sensitization of atopic individuals to B. tropicalis and D. pteronyssinus is fairly 





common in these geographical regions of the world43. Interestingly, despite their 
co-existence, studies have demonstrated that there is limited cross-antigenicity and 
cross-allergenicity between B. tropicalis and D. pteronyssinus43, 47.  
 
1.2.1.1 Blo t 5 
Unlike D. pteronyssinus in which Der p 1 and 2 are the major allergens, Blo t 5 is 
the major allergen of B. tropicalis and is the allergen of interest in this project. Blo 
t 5 is a protein that contains 134 amino acid residues consisting of a 17-residue 
signal peptide and a 117-residue mature protein48. Blo t 5 has a molecular weight of 
14kDa and shares a sequence identity of 42% with Der p 5, an allergen isolated 
from the other closely related dust mite species D. pteronyssinus. Blo t 5 exists as 
monomers in solution at neutral pH39, 48 and polymerize irreversibly at acidic pH48.  
Recent structural analysis has revealed that Blo t 5 is relatively distinct from its 
Dermatophagoides counterpart. By means of nuclear magnetic resonance (NMR), 
Chan et. al. and Naik et. al. elucidated the structure of Blo t 5 for the first time48, 49.  
In contrast to the coiled-coil helical structure for Der p 5 as illustrated in the study 
conducted by Liaw et. al.50, the structure of Blo t 5 as depicted in Figure 1.8, is 
comprised of three α-helices which are arranged in an anti-parallel fashion48, 49.  






Figure 1.8: Different views of the NMR structures of Blo t 5. (Edited from 
Chan et. al., 2008).  
The structure of the Blo t 5 protein was resolved by NMR to be a triple α-helical 
bundle with the three anti-parallel α-helices separated by tight turns. A combination 
of 10 best NMR-resolved structures of Blo t 5 (A) and the ribbon diagram of the 
Blo t 5 protein as modeled by the program PyMOL (B). 
 
Results from skin test reactions that were conducted by Tsai et. al. have suggested 
that the C-terminus of Blo t 5 could be the major IgE binding site39, 41. In 
conjunction with that speculation, further experiments conducted by Chan et. al. 
have also ascertained that the major IgE binding epitopes are acidic residues Glu76, 
Asp81, Glu86 and Glu91 located on the loop region between helices α2 and α3 as 
shown in Figure 1.948. In addition, the study conducted by Naik et. al. also 
identified the presence of a conformational IgE epitope consisting of amino acid 
residues, Asn46, Lys47, Lys54 and Arg5749. 
Whilst ongoing research is being conducted to understand this major allergen from 
B. tropicalis, much of the biochemical and physiological functions of Blo t 5 have 





yet to be determined. Despite this, Blo t 5 was classified as the key allergen of B. 
tropicalis based on the fact that it has a relatively high allergenic potency and 
showed more than 70% of IgE reactivity with asthmatic patients. Furthermore, 
evidence from sensitization studies which were conducted in tropical countries 
such as Singapore, Indonesia and Thailand revealed that Blo t 5 sensitization is the 
most prevalent amongst all other known allergens of B. tropicalis40. In children 
with asthma and eczema, 96.7% and 86.7% were tested positive for IgE responses 
to Blo t 5, respectively51. The importance of Blo t 5 as a major allergen in the 
subtropical and tropical regions is also asserted by data that demonstrated higher 
IgE titers for Blo t 5 as compared to Der p 5 in an asthmatic study cohort from 
South East Asian countries such as Singapore and Malaysia52. 
 
 
Figure 1.9: The amino acid residues constituting a major linear IgE binding 
epitope. (Extracted from Chan et. al., 2008). 
The ribbon diagram (A) and surface diagram (B) depicting the location of the four 
main amino acid residues contributing to the major IgE binding epitope on the Blo 
t 5 protein. Major IgE binding sites are located on the four acidic residues found at 
the loop region between helices α2 and α3. These amino acid residues are namely 
Glu76, Asp81, Glu86 and Glu91. 






Interestingly, the IgE cross-reactivity between Blo t 5 and Der p 5 is low despite 
the sequence homology between the group 5 allergens43, 52. Hence, the IgE 
antibodies generated in response to B. tropicalis sensitization was found to have 
limited cross-reactivity against allergens from D. pteronyssinus and vice versa. 
Reasons being postulated for this limited cross-reactivity are that the identical 
amino acid residues are scattered along the whole Blo t 5 and Der p 5 protein 
molecules and that a conserved protein motif is absent39, 50. This lack of cross-
reactivity also suggests that allergens arising from B. tropicalis are unique and 
species specific. 
  





1.3 Biologics in allergic asthma treatment 
In the recent years, there has been a shift in focus on the development of novel 
immunotherapeutic strategies targeting allergies. Recent approaches in 
immunotherapy are centered on engineering antagonistic monoclonal antibodies 
specific for the different inflammatory mediators involved in the allergic cascade 
that eventually result in the development of full-blown allergic asthma. The TH2 
pathway appears to be the most widely targeted based on its importance in the 
pathogenesis of allergic asthma.  
 
1.3.1 Targeting IL-4 & IL-13 
Both IL-4 and IL-13 are essential in establishing the TH2 microenvironment. IL-4 
plays a critical role in the immunopathogenesis of allergic asthma by promoting 
TH2 cell differentiation, inducing IgE production by B cells and recruiting 
eosinophils4, 53, 54. Another TH2 cytokine, IL-13, has a 70% sequence homology to 
IL-4 and is also central in the driving allergic inflammation in the airways53. In 
addition to the functions of IL-4, IL-13 acts on the airway epithelium to cause 
airway hyper-responsiveness and remodelling30, 53. As such, targeting IL-4 and IL-
13 represents an attractive strategy for the treatment of allergic asthma.  
IL-4 and IL-13 exert their effects by signalling through the IL-4-receptor and IL-
13-receptor complex. As a result, there is considerable redundancy between IL-4 
and IL-13 and inhibiting one or the other did not result in any significant 
improvement with regards to asthma control4. Efforts at inhibiting both IL-4 and 
IL-13 are still in the preliminary stages. One of the more promising candidates, 





Dupilumab, is a fully human mAb directed against the α-subunit of the IL-4 
receptor55. Since this subunit is also involved in the IL-4Rα/IL-13Rα1 
heterodimeric receptor complex, Dupilumab is capable of inhibiting both IL-4 and 
IL-13 signalling55, 56. In a phase IIa study, patients with moderate-to-severe asthma 
received subcutaneous injections with Dupilumab or placebo for 12 weeks54-56. 
Dupilumab treatment appeared to reduce serum IgE, eotaxin-3 and other related 
TH2 inflammatory mediators54-56. However, the short study period and the 
definition of the primary outcomes of disease exacerbation did not represent 'real-
world' asthma56. Hence, larger trials with longer durations were required to 
substantiate their findings for a fairer assessment of the utility of this approach56. 
Nonetheless, the dual inhibition of both IL-4 and IL-13 remains a promising option 
for the development of biologics for asthma treatment. 
 
1.3.2 Targeting IL-5 
IL-5 orchestrates all stages of eosinophil development, from proliferation in the 
bone marrow, their release into the bloodstream, to final differentiation, 
maturation, survival and activation at the target sites57. Therefore, neutralizing the 
effects of IL-5 has the potential of eliminating eosinophilia which is commonly 
observed in allergic asthma4, 58. Efforts in IL-5 antagonism led to the development 
of two humanized mAbs, Mepolizumab and Benralizumab, which targets IL-5 and 
the IL-5 receptor, respectively. The efficacy of Mepolizumab on severe 
eosinophilic asthma was assessed in a multicentre, double-blind, placebo-
controlled trial59. Mepolizumab reportedly was effective in depleting eosinophil 
numbers in the bone marrow, airways and blood. However, treatment with 





Mepolizumab did not result in any impact on the signs of clinical asthma and lung 
function55, 59-61.  
In contrast, Benralizumab targets the IL-5 α receptor that is expressed by mature 
eosinophils and their progenitors60. Benralizumab was examined for its therapeutic 
effects on asthma and chronic obstructive pulmonary disorder (COPD). In the trial 
involving patients with uncontrolled eosinophilic asthma, Benralizumab treatment 
resulted in a reduction in eosinophil counts in the blood, fewer exacerbations and 
improved lung functions60, 62. Currently, Benralizumab is in a phase III trial to 
investigate its efficacy on COPD exacerbation rate in patients with moderate to 
very severe COPD60.  
Based on these reports, targeting IL-5 or its receptor appears to be relatively 
successful in reducing asthma exacerbations and improving asthma symptoms. 
However, targeting IL-5 alone, restricts the target patient cohort to only those 
whose asthma phenotype is dependent on the action of eosinophils. Moreover, 
many anti-IL5 trials have documented the presence of tissue eosinophilia despite 
the complete eradication of eosinophils in the blood63. This highlights the 
complexity of the eosinophil pathway and its contribution to asthma, suggesting 










1.3.3 Targeting IgE 
One of the key mediators that contributes to the pathogenesis and symptoms of 
allergies is IgE, making it a potential target to develop therapeutics against in 
attempts to attenuate the allergic symptoms. Approximately 25 years after the 
discovery of IgE as the culprit behind the pathogenesis, a successful therapeutic 
antibody candidate, Omalizumab was developed. 
Omalizumab is a recombinant humanized monoclonal antibody targeting IgE64, 65. 
Some of the key effector mechanisms by which Omalizumab functions to alleviate 
allergic responses are shown in Figure 1.10. Omalizumab is able to bind to free 
IgE in the serum to form trimers or hexamers which are relatively small and 
biologically inert64. Minimal or no tissue damaging immune complexes are formed 
as Omalizumab-IgE complexes have been found to be efficiently cleared and does 
not activate the complement system64. Omlizumab was also found to downregulate 
the expression of the high-affinity FcεRI IgE receptors on effector cells such as 
mast cells, basophils and antigen-presenting cells65. Furthermore, an important 
aspect of this antibody lies in its inability to bind to IgE bound to cells bearing the 
FcεRI or FcεRII as the epitope on IgE to which they are directed against is masked 
due to the attachment of those receptors to the mast cells surfaces64. As such, mast 
cell and basophil activation and degraulation are avoided with the use of 
Omalizumab64.  
Omalizumab is currently in use as an add-on therapy for moderate-to-severe 
persistent allergic asthma and the only licensed therapy for chronic spontaneous 
urticaria which are unresponsive to H1-receptor antihistamines60. The efficacy of 





Omalizumab in relieving some for the symptoms in allergic asthma such as airway 
hyper-responsiveness and improving the quality of life of patients have been 
proven in several clinical trials64. In addition, Omalizumab is found to be safe and 
well-tolerated by adults with no serious adverse effects even though systemic 
urticaria was reported in a few cases64. The incidence of anaphylaxis was 
reportedly 0.2% in a pool of 57,300 patients66. Despite the optimistic profile of 
Omalizumab as a therapeutic agent for the treatment of allergies, the cost of 
treatment by Omalizumab is very high ranging from approximately $10,000 to 
$30,00067 and the cost effectiveness was shown to be low in patients with moderate 
to severe allergic asthma compared to clinical benefits61. Nevertheless, the 
emergence and success of Omalizumab has opened new opportunities and present 
possibilities in the development of novel immunotherapies in the form of 
antibodies for allergies and allergic asthma. 
  







Figure 1.10: Mechanisms of action of Omalizumab. (Edited from Holgate & 
Polosa, 2008). 
Omalizumab is a monoclonal antibody targeting IgE antibodies. Upon binding to 
free IgE, Omalizumab decreases circulating and cell-bound IgE. Secondly, by an 
unknown mechanism, Omalizumab reduces the expression of FcεRI on effector 
cells such as mast cells and basophils. With fewer FcεRI and lower levels of 
circulating IgE, effector cells are less likely to be activated. Lower activation of 
effector cells results in a decrease in the release of inflammatory mediators, thereby 
alleviating allergic symptoms and preventing episodes of exacerbations.  
 
   





1.4  Allergen-specific Immunotherapy 
Treatment regimes for allergic asthma and allergic rhinitis are guided by the Global 
Initiative for Asthma (GINA)68 and Allergic Rhinitis and its Impact on Asthma 
(ARIA)69 guidelines, respectively. Symptoms in allergic asthma and allergic 
rhinitis are effectively controlled by pharmacological agents. The first-line of 
treatment in both allergic respiratory diseases is by inhaled corticosteroids like 
Budesonide or Fluticasone to combat active inflammation. In the case of allergic 
rhinitis, corticosteroid treatment is usually accompanied by add-on medications 
like anti-histamines. Contrastingly, in allergic asthma, inhaled corticosteroids are 
coupled with long acting β2-agonists such as Salmeterol to promote 
bronchodilation68. Antagonists against downstream mediators like leukotrienes 
may also be prescribed.  
The majority of treatment options currently available are centered on alleviating the 
symptoms in a non-allergen-specific manner rather than modifying the immune 
mechanisms underlying the allergic disease. More than half a century ago, the 
presence of blocking antibodies in allergic patients undergoing vaccination with 
allergen extracts was first reported by Robert A. Cooke70. A few years later, Mary 
H. Loveless discovered that the inhibiting antibodies reported by Cooke were 
allergen-specific and that they hindered interactions between the allergen and 
sensitising antibodies71, 72. Over the years, immunotherapy surfaced as a potential 
solution that provides treatment of allergies which are specific to the different 
allergens. Allergen-specific immunotherapy (SIT), as the name suggests, is 
allergen-specific and the therapeutic effects are allergen dose- and time-dependent.  





Traditional methods of immunotherapy involves the repeated administration of 
gradually increasing doses of adjuvant-bound allergen extracts via subcutaneous 
injections to atopic patients25, 73, 74. The allergen doses are increased gradually over 
a period of 8 - 16 weeks, followed by monthly maintenance injections for a period 
of 3 - 5 years73. The main objective to immunotherapy is to induce a state of 
tolerance or non-responsiveness to specific allergens through alterations of the 
immune responses towards these allergens upon exposure. 
While the traditional method of administering adjuvant-bound allergen extracts has 
been proven to be effective, there is a prevailing risk of developing IgE-mediated 
systemic side effects, and rarely anaphylaxis, for example in chronic asthma 
patients, due to the activation of IgE-mediated hypersensitivity as a result of 
allergen challenge75. Advances in immunotherapy include a plethora of strategies 
such as the use of recombinant allergens or engineered allergen derivatives and 
delivering T-cell and/or B-cell-epitope-containing peptides. 
  





1.4.1 Common methods in allergen-SIT 
1.4.1.1 Recombinant allergens 
One of the more established methods of immunotherapy includes the use of 
recombinant allergens. Recombinant wild-type allergens have been shown to be 
relatively efficient for diagnostic and disease monitoring purposes because 
administration to the skin or nasal mucosa allows for the study of the level of 
provocation, cellular activation and antibody responses15, 23, 25. Since IgE 
predominantly recognizes conformational epitopes, the usage of recombinant 
allergens has obvious advantages compared to allergen extracts as the former retain 
the sequence and conformation of the natural allergen23, 25. Moreover, standardized 
formulations are possible with the use of recombinant allergens because the active 
ingredients are present in defined quantities25. Highly successful clinical studies 
have been performed to prove the efficacy of using recombinant allergens in grass 
pollen-induced immediate hypersensitivity23, 76. However, the only but major 
disadvantage of administering recombinant allergens is the risk of initiating 
adverse allergic events due to the reactivity of IgE25.  
Recent developments have produced recombinant hypoallergens which are safer to 
administer owing to the lack of IgE-mediated side effects induction while 
maintaining the T cell epitopes23, 25, 77. Furthermore, recombinant hybrid proteins 
have been created for the use as combination vaccines whereby hybrid allergen 
proteins possess a range of T-cell epitopes from more than one allergen fused into 
one or a few molecules25, 78, 79. Studies conducted on a hybrid allergen protein 





containing three major bee venom allergens in one molecule displayed 
hypoallergenicity in human skin-prick tests and also showed potential in preventing 
allergic sensitization to bee venom in a mouse model25, 78. Similar observations 
were also reported in studies conducted using hybrid allergen proteins of dust mite 
allergens Der p 1 and Der p 2, as well as pollen allergens80-82. The use of such 
hybrid allergen proteins, albeit showing potential in laboratory studies, have not yet 
been clinically proven to be the safest and most efficacious. 
1.4.1.2 Route of administration 
Efforts in improving the safety of allergen-SIT have led to the introduction of the 
sub-lingual route of administration. Sub-lingual Immunotherapy (SLIT) is 
currently established in Europe as a authenticated method of non-invasive allergen-
specific immunotherapy. SLIT involves the administration of allergen extract 
preparations in the form of tablets or droplets under the tongue, kept under the 
tongue for 1 to 2 minutes before swallowing83. In comparison to the conventional 
sub-cutaneous route, SLIT boasts an enhanced safety profile with similar efficacy. 
Clinical trial studies have provided strong evidence on the utility of SLIT in 
treating paediatric grass-pollen allergic rhinitis61, 84. SLIT has been proven safe for 
patients who are sensitized to house dust mites85. However, owing to the high 
heterogeneity of studies investigating the efficacy of SLIT in HDM-induced 
allergic rhinitis and allergic asthma, more consistent trials are needed to validate 
the value of SLIT in the context of house dust mite-driven allergic rhinitis and 
asthma84, 85. 
 





1.4.1.3 Peptide immunotherapy (PIT) 
Recently, peptide immunotherapy in allergen-SIT has drawn a substantial amount 
of interest. Peptide immunotherapy involves the administration of synthetic 
peptides via sub-cutaneous or intra-dermal injections86. These peptides are 
identified as regions within protein allergens to which CD4 T cells react86. The 
major attraction of PIT lies in its superior safety profile as compared all the other 
methods of allergen-SIT. Adverse side effects are greatly reduced as the peptides 
are incapable of cross-linking IgE and activate downstream effector cells such as 
mast cells and basophils86, 87. As such, PIT can be extremely useful for allergens 
like bee venom which is well-known to induce severe adverse side effects during 
conventional immunotherapy. In addition, standardized preparations of synthetic 
peptides can be easily manufactured, purified and are stable in lyophilized form88. 
The detailed immune mechanism behind PIT are still poorly understood but 
appears to involve the induction of peripheral T cell tolerance through an increase 
in Foxp3+ regulatory T cells87-90. In contrast to observations made in traditional 
allergen-SIT, peptide immunotherapy did not cause any major changes in serum 
levels of allergen-specific IgE and IgG487, 90, but re-challenge with the allergen 
favours the production of IgG491. Results obtained from clinical trials are in full 
support of the therapeutic utility of PIT in cat and bee venom allergies, although no 
licensed products are available yet and studies are ongoing for assessing the use of 
peptide immunotherapy in ragweed and HDM allergies87.  
However, peptide immunotherapy is not without any challenges. Given the 
importance of the Major Histocompatibility Complex (MHC) in the T cell 





response, population variations in the human leukocyte antigen (HLA) region may 
affect how well the peptides bind to the MHC molecules88. Hence, in a HLA-
diverse patient population, not everyone will benefit equally from this mode of 
treatment92. Secondly, the current routes of administration for the synthetic 
peptides are still invasive and this impedes the use of PIT in children, especially for 
the case of respiratory allergies86. Lastly, there is considerable variation in the dose 
and regimen of peptide delivery across many trials86. Different  regimens may 
affect the tolerogenic mechanisms needed for the protection against allergic 
symptoms. It has been documented that a high dose regime may inhibit the 
development of tolerance93 while a lower or multi-dose regimen is likely to induce 
IL-10 producing regulatory T cells94. Moreover, little is known about the minimum 
duration of PIT required for the establishment of long-term tolerance since most 
PIT studies to date have focused on short-term clinical outcomes86. Therefore, the 
work on PIT is still in the preliminary stages and more studies are required to 










1.4.2 Antibody responses in allergen-SIT 
The most prominent class of antibodies induced by long-term treatment by 
allergen-SIT belong to the IgG4 subclass. Table 1.1 shows that the induction of 
allergen-specific IgG4 antibodies is commonly observed throughout the course of 
allergen-SIT, regardless of the allergen used for immunotherapy. Some properties 
of the IgG4 subclass antibodies are illustrated in Figure 1.11. IgG4 is the least 
abundant IgG subclass that is present in serum and does not activate the classical 
complement pathway as it exhibits negligible binding to the C1q protein complex95, 
96. Compared to the other IgG subclasses, IgG4 has a more flexible hinge region 
and the two disulphide bonds holding the heavy chains together are susceptible to 
chemical reduction95. Reduction of the disulphide bonds results in a phenomenon 
unique only to the IgG4 antibodies known as Fab arm exchange. Fab arm exchange 
occurs when reduction of the disulphide bonds causes the separation of the heavy 
chains and then randomly re-associate to produce bi-specific antibodies which are 
functionally monomeric95, 96 as shown in Figure 1.11B. 
The mechanisms through which IgG4 antibodies function in the attenuation of 
allergies are multi-fold and are illustrated in Figure 1.12. Firstly, as mentioned 
earlier, recombinant allergen administration in allergen-SIT holds the risk of 
initiating adverse allergic events as a result of IgE reactivity25. IgG4 administration, 
on the other hand, eliminates this potential risk factor as the therapy does not 
involve the use of allergen extracts or allergic components. 
Secondly, IgG4 antibodies generated in immunotherapy are often known as 
'blocking antibodies' as it has the ability to compete with IgE for allergen binding. 





These antibodies thereby reduce the incidence of allergic inflammation by blocking 
the release of inflammatory mediators from activated mast cells and basophils25, 75. 
Furthermore, IgG4 is able to bind to IgE-allergen complexes and subsequently bind 
to the IgG (FcγRIIb) receptors75. Binding of FcγRIIb induces the cross-linking and 
co-aggregation with mast cell IgE (FcεRI) receptors and inhibits mast cell 
degranulation75. The allergen-blocking activity of the IgG4 subclass of antibodies 
can also be enhanced by the Fab arm exchange reaction, which result in bi-specific 
antibodies that are functionally monomeric96, 97. As such, it is able to bind allergens 
but the possibility to initiate cross-linking and subsequently mast cell degranulation 
is decreased. 
Another mechanism through which IgG4 act to prevent the manifestation of IgE-
mediated hypersensitivity in the late phase is to decrease IgE-mediated antigen 
presentation ability of B cells75. IgE-allergen complexes are able to bind to its low 
affinity receptor, FcεRII (CD23) on B cells to promote antigen presentation to the 
T cells. Binding of IgG4 to IgE-allergen complexes eliminates the ability of IgE-
allergen complexes to associate with FcεRII and therefore inhibits B cell antigen 
presentation to the T cells.  In this way, T-cell proliferation and the production of 














Figure 1.11: IgG subclasses and the Fab arm exchange phenomenon.  
(A) Schematic diagram illustrating the basic properties of the different IgG 
subclasses with IgG1 and IgG4 being the most and least abundant in the serum, 
respectively. (B) IgG4 antibodies are also especially susceptible to a unique 
phenomenon known as the Fab arm exchange, in which the disulfide bonds in the 
hinge region undergo reduction and results in the formation of monospecific heavy 
chains. Under physiological conditions, this single antibody arm is capable of re-
associating with another heavy chain targeting a different antigen, thereby giving 
rise to bispecific antibodies. 
 
  








Figure 1.12: Mechanisms of action of IgG4 as blocking antibodies. 
Allergen-SIT induces class switching in B cells, leading to an increase in the 
plasma concentration of allergen-specific IgG4 antibodies. Allergen-specific IgG4 
antibodies are capable of exerting protective anti-allergic effects through several 
mechanisms. Firstly, with similar specificity and affinity to the allergen, IgG4 
antibodies compete with IgE for allergen binding so that IgE can no longer form 
immune complexes and trigger downstream effects. Secondly, by binding to the 
inhibitory FcγRIIb, IgG4 antibodies are able to neutralize the activation signal 
generated by the cross-linking of FcεRI. Lastly, IgG4 antibodies can inhibit 
facilitated antigen presentation (FAP), a process through which IgE-allergen 
immune complexes bind to FcεRII (CD23) on B cells and stimulating the 
polarization of T cells to TH2 cells upon contact with the antigen-presenting B 
cells. 
  










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.5 Key Project Objectives 
Many studies on allergen immunotherapies have reported disease modifying effects 
of immunotherapy and attributed these benefits to an increase in allergen-specific 
IgG4 antibody levels. However, treatment protocols in various immunotherapies 
often span months to years and most patients will only experience an alleviation of 
allergic symptoms several months after receiving immunotherapy.  
Given that long-term immunotherapy increases the levels of functional blocking 
IgG antibodies and that these antibodies are capable of inhibiting the initiation of 
allergen-specific allergic symptoms, passive immunization with allergen-specific 
IgG4 antibodies may provide similar protective effects without the patient having 
to go through the length immunotherapy regime. Also, there are currently limited 
studies assessing the utility of allergen-specific monoclonal antibodies as a 
treatment option in allergic diseases. With these two aspects in mind, we attempt to 
investigate the potential of allergen-specific monoclonal antibodies in the treatment 
of allergy, with particular focus on Blo t 5, the major allergen derived from the 
clinically important HDM species, Blomia tropicalis. 
The key experimental objectives of this study are as follows:  
1. Generate and characterize high affinity monoclonal antibodies targeting the 
allergen of interest. In this study, Blo t 5, the major allergen originating from 
Blomia tropicalis is the allergen of interest.  
 
2. Examine the therapeutic potential of the anti-Blo t 5 mAb generated in 
objective 1 using a murine model of allergic asthma. 






3. Engineer the anti-Blo t 5 mAb into chimeric variants possessing human IgG1 
and IgG4 Fc domains, followed by the investigation of the in vitro effects of 
these chimeric anti-Blo t 5 mAb on human basophil activation. 
 
4. Construct a human immune library from which fully human anti-allergen 

















2.1 Buffers & solutions 
The composition of the buffers and solutions used in this study are as follows: 
2.1.1 General buffers 
Phosphate Buffered Saline (PBS): 10x PBS (1st Base) was diluted 1:10 with water 
and autoclaved for sterilization. 
0.05% and 0.2% (v/v) PBS-Tween20 (PBST): 500 μl and 2 ml of Tween-20 
(Sinopharm Chemical Reagent) was added to 1L of 1x PBS respectively. 
2.1.2 Buffers for bacteria cultures & protein expression 
Luria-Bertani (LB) medium: 10g of tryptone (BD), 5g of yeast extract (BD) and 
10g sodium chloride (NICE Chemicals) was dissolved in 1L of milliQ water and 
sterilized by autoclaving. 
Luria-Bertani (LB) agar medium: 10g of tryptone, 5g of yeast extract, 10g sodium 
chloride and 15g of bacto-agar powder (Sigma) was dissolved in 1L of milliQ 
water and sterilized by autoclaving.  
Kanamycin (Kan) and Ampicillin (Amp) antibiotics: Stock solutions were prepared 
as 1 mg of powder dissolved in 1 ml of water and sterilized by filtering through 
0.22 μm filter. Stock solutions were stored at -20°C and diluted to the respective 
concentrations when needed. 
Solubilization buffer: Contains 50 mM Tris-HCL,  25% Sucrose (Sigma), 1 mM 
EDTA, 0.1% sodium azide in final volume. pH was adjusted to 8 and topped up 
with water. 





Lysis buffer: Contains 50 mM Tris-HCL, 100 mM sodium chloride, 1% Triton X-
100 and 1 mM EDTA.  
Saturated ammonium sulfate solution: 21.5g of ammonium sulfate (Sigma) was 
dissolved in 30 ml of 50 mM Tris (pH 7.5) buffer 
2.1.3 Buffers for hybridoma and cell cultures 
RPMI-10% (v/v) Fetal Bovine Serum (FBS): 50 ml of FBS was added to 450 ml of 
RPMI medium (Hyclone). 
Polyethylene glycol (PEG): 4g of PEG-4000 (Merck) was dissolved in 6 ml of 
RPMI. pH was adjusted with 2M NaOH and sterilized by filtering through 0.22 μm 
filter. 
Hypoxanthine-Aminopterin-Thymidine (HAT) medium: 50x HAT powder (Sigma) 
was reconstituted in 10 ml water and added to 500 ml of RPMI-10% FBS medium.  
Hypoxanthine (HT) medium: 50x HT powder (Sigma) was reconstituted in 10 ml 
water and added to 500 ml of RPMI-10% FBS medium. 
2.1.4 Buffers for western blot 
Stacking Gel Tris Buffer: A 4x stock solution was prepared by dissolving 24.2g 
Tris base in 376 ml of water and filter sterilized. 16 ml of 10% sodium dodecyl 
sulfate (SDS) was added and pH adjusted to 6.8. 
Resolving Gel Tris Buffer: 91g of Tris base was dissolved in 400 ml of water and 
pH was adjusted to 8.8 with HCl. Water was added to 480 ml and the solution was 
filter sterilized before 20ml of 10% SDS was added and water was added to a final 
volume of 500 ml.  





SDS-PAGE Running Buffer: A 5x stock solution was prepared by dissolving 60g of 
Tris base, 288g Glycine in 3L of water. 100 ml of 20% SDS was added and 
additional water was added to a final volume of 4L. The stock solution was diluted 
1:5 with water for each use.  
Transfer Buffer: A 10x stock solution was made with 60.4g of Tris base and 288g 
Glycine dissolved in 2L of water. The stock solution was diluted 1:10 with water 
before each use. 
2.1.5 Buffers for DNA gel electrophoresis 
1x Tris-acetate-EDTA (TAE) Buffer: 10x TAE buffer (1st Base) was diluted 1:10 
with water. 
2.1.6 Buffers for in vivo study 
MACS Buffer: 2% FBS and 5 mM EDTA was added to 1x PBS and stored at 4°C. 
ACK red blood cell lysis Buffer: A 10x stock solution was prepared by dissolving 
8.3g ammonium chloride, 0.84g sodium bicarbonate and 0.03g EDTA in 100 ml of 
water and sterilized by filtering through a 0.22μm membrane. A working 1x 















































2.3 Blo t 5 Purification 
2.3.1 Bacterial Cultures 
BL21 bacteria containing the plasmid that expresses Blo t 5 (pET28-Blo t 5) were 
inoculated in 200 ml of LB medium with Kanamycin (Kan) added to a final 
working concentration of 30 μg/ml. The culture was incubated overnight at 37°C in 
a shaking incubator. 20 ml of the overnight culture were transferred to 1 litre of 
Kan-containing LB medium and incubated for 1 hour at 37°C in a shaking 
incubator or until the optical density O.D600nm reaches 0.5 to 0.6. At this point, 
approximately 500 μl of pre-induced bacterial culture was collected and pelleted by 
centrifuging at 4000 g for 2 mins. Supernatant was discarded and the pellet was 
frozen at -20°C until further analysis. 
2.3.2 Induction of Blo t 5 protein expression 
Upon obtaining the optimal optical density, induction of Blo t 5 protein expression 
was conducted by the addition of Isopropyl-beta-D-thiogalactopyranoside (IPTG) 
at a final concentation of 1 μM. The bacterial cultures with IPTG were incubated 
for 3 hours at 37°C with shaking. At this point, approximately 250 μl of this post-
induced bacterial culture was collected as the O.D.600nm was doubled after IPTG 
induction. This culture aliquot was pelleted by centrifugation at 4000 g for 2 min 
and the pellet was stored at -20°C until further analysis. The remaining bacterial 
culture was centrifuged at 6000 g for 15 mins at 4°C. The LB medium was 
discarded and the pellet was washed with 1X PBS buffer, followed by 
centrifugation at 6000 g for 15 mins at 4°C. The pellet was frozen at -80°C until 
further processing. 





2.3.3 Inclusion bodies isolation 
The bacterial pellet was thawed at room temperature and resuspended in 13 ml of 
cold solubilization buffer in the presence of DTT, protease inhibitor (Roche), 
DNAse I, lysozyme and MgCl2 (Sigma). The suspension was left on ice for 1 hour. 
Following which, cold lysis buffer was added and the mixture was left on ice for 
another 15 mins. The mixture was then sonicated and EDTA was added post-
sonication. Next, centrifugation at 12,000 rpm was carried out for 30 mins at 4°C. 
The supernatant containing the protein of interest was collected and stored at 4°C 
until further processing.  
2.3.4 Ammonium sulfate precipitation  
To clear the contaminating proteins from the bacterial lysates before loading onto 
the FPLC column, precipitation of proteins with increasing concentrations (40%, 
50%, 60% saturation) of ammonium sulfate was performed. To obtain a 40% 
saturation, 667 μl of saturated ammonium sulfate solution per ml of cell lysate was 
added. The mixture was incubated for 30 min at 4°C with constant rotation. 
Following which, the suspension was subjected to centrifugation at 16,000g for 15 
min at 4°C. 250 μl of the supernatant fraction was kept for gel analysis. The 
supernatant fraction was transferred to a fresh tube and 333 μl of saturated 
ammonium sulfate solution per ml of cell lysate was added to obtain a 50% 
saturation. The same incubation and centrifugation procedure described earlier was 
repeated. Finally, 500 μl of saturated ammonium sulfate solution per ml of cell 
lysate was added to obtain 60% saturation, followed by incubation and 
centrifugation. The cell pellet after precipitation at 60% saturation contains the 
protein of interest and was resuspended in 5 ml of 50 mM Tris (pH 8) buffer. The 





resuspended pellet was subjected to dialysis overnight in 50 mM Tris (pH 8) buffer 
at 4°C.  
2.3.5 Purification of recombinant Blo t 5 by FPLC 
After dialysis, the solution was centrifuged at 300 rpm for 10 min at 4°C to remove 
undissolved ammonium sulfate. The protein-containing fraction was filtered with 
0.22 μm filter before loading onto the FPLC column. Recombinant Blo t 5 was 
purified by anion exchange with the MonoQ 5/50GL column (GE Healthcare) and 
size exclusion chromatography with the Superdex75 HiLoad 16/60 column (GE 
Healthcare). Fractions corresponding to the peaks obtained from the chromatogram 
were analyzed on SDS-PAGE. The fractions of interest were pooled and dialyzed 
overnight in 1x PBS buffer at 4°C before freezing down at -80°C for long term 
storage. 
2.3.6 Measurement of protein concentration 
Protein concentration was measured by the Bradford method. 200 μl of protein 
assay reagent (Bio-rad) was added to 5 μl of sample or protein albumin standards 
(Thermo Scientific) in a flat-bottom 96-well plate and incubated for 10 mins at 
room temperature before reading with a microplate reader at an optical density of 
595nm. A protein standard curve was generated to determine protein 
concentrations.  
  





2.4 Generation of monoclonal antibodies 
2.4.1 Immunization of mice 
Immunization with recombinant Blo t 5 were carried out over a span of 45 days on 
3 BALB/c female mice which were 8-12 weeks old (IACUC Protocol Number: 
106/10). On day 0, 25 μg of recombinant allergens in 400 μl 1X phosphate buffered 
saline (PBS) and 400 μl of Complete Freund's adjuvant (Sigma-Aldrich) was 
prepared and were injected intra-peritonealling into each mouse in equal volumes. 
On days 21, 35 and 42, booster immunizations were administered intra-peritoneally 
in equal volumes using 12.5 μg of allergens in 400 μl PBS and 400 μl of 
Incomplete Freund's adjuvant (Sigma-Aldrich). The mice were sacrificed on day 45 
and their spleens were harvested.  
2.4.2 Preparation of macrophage feeder layers 
Female BALB/c mice were sacrificed and fur around the peritoneal cavity was 
removed to reveal the peritoneal membrane. A small incision was made, followed 
by the injection of 5 ml of cold RPMI medium into the peritoneal cavity of each 
mouse. Macrophages in the peritoneal cavity were dislodged by gentle massaging 
of the mouse abdomen containing RPMI and repeated pipetting of the RPMI 
medium in the peritoneal cavity using sterile Pasteur pipettes. The RPMI medium 
was then pipetted out using sterile Pasteur pipettes and collected in 50 ml Falcon 
tubes. This process was repeated four to five times to ensure that almost all the 
macrophages were obtained. The cell suspension was then centrifuged at 1600 rpm 
for 5 mins. The supernatant was discarded and cell pellet was resuspended in 50 ml 
of warm HAT medium. The cell suspension was then plated on 96-well plates by 





pipetting 100 μl per well. The plates were incubated in a CO2 incubator overnight 
at 37°C.  
2.4.3 Harvesting of NS-1 Cells 
NS-1 myeloma cells were cultured in RPMI-10% fetal-bovine serum (FBS) 
medium in 175 mm
2
 flasks until they reached confluency. Cultured NS-1 cells were 
transferred into 50 ml Falcon tubes and harvested by centrifuging at 1200 rpm for 5 
mins. The supernatant was discarded and the cells were resuspended in 30 ml of 
RPMI medium. The cell suspension was centrifuged again and the supernatant was 
discarded. This was performed to ensure the complete depletion of FBS which may 
interfere with the subsequent fusion step. The cell pellet was resuspended in 20 ml 
of RPMI medium and the tubes were incubated in a CO2 incubator at 37°C.  
2.4.4 Fusion 
Immunized mice were sacrificed by CO2 narcosis and their spleens were removed 
under sterile conditions. The spleens were washed with 5 ml RPMI medium in 6-
well plates and homogenized using a sterile cell strainer and RPMI medium. The 
resultant single cell suspension was left to stand for 5 mins to allow large tissue 
fragments to settle before the upper cell suspension was passed through a clean cell 
strainer again and collected in new 50 ml Falcon tubes. Splenocytes were collected 
by centrifugation for 5 mins at 1100rpm. The cell pellet was gently agitated and 1 
ml of pre-warmed PEG was added at a speed of 1 ml/min. The mixture was 
incubated at 37°C for 1 min before it was diluted with 3 ml of pre-warmed plain 
RPMI at a speed of 1 ml/min. The sides of the tubes were then rinsed with 5 ml of 
RPMI. The fused cells were washed by centrifugation and the pellet was 





resuspended gently in 20 ml of HAT medium followed by a 3 hour recovery 
incubation at 37°C. After that, HAT medium was added to a final volume of 100 
ml and the cells were plated into 96-well feeder layer plates at 100 ul per well and 
cultured for 2 weeks. The resulting hybridoma clones were identified and 
superntatants from wells with clonal growth were harvested into new 96-well cell 
culture plates for further screening. 
2.4.5 Sub-cloning by limiting dilution 
Hybridoma clones selected based on binding activity were progressively expanded 
from 96-well plates to 6-well plates. Culture supernatants were periodically 
assayed for anti-Blo t 5 responses. Clones which retained good binding activities 
were sub-cloned by limiting dilution to achieve monoclonality. Hybridoma cells 
were harvested and centrifuged at 1200 rpm for 5 mins. The pellet was resuspended 
in a concentration of 100 cells per ml. Following which, the cell suspension was 
serially diluted to a final concentration of 1 cell per ml and 100 µl of cells was 
added to each well in a 96 well plate. The plates were incubated at 37°C, 5% CO2 
until clones become visible. 
2.4.6 Screening for clones producing anti-Blo t 5 antibodies by ELISA 
Maxisorp™ plates (NUNC, Denmark) were coated overnight at 4°C with 5ug/ml of 
recombinant Blo t 5 protein per well. The negative control was coated with PBS. 
The next day, the plates were washed four times with 0.05% PBST and blocked 
with 5% skimmed milk (Sigma-Aldrich) for 1 hour at room temperature. 
Supernatants were harvested from the wells containing hybridoma clones and 
added to the ELISA plates at 100 ul per well. The ELISA plates were incubated 





with the supernatants for 1 hour at room temperature and subsequently washed four 
times with PBST. Following which, goat anti-mouse IgG conjugated with Horse-
Radish Peroxidase (Thermo Fisher Scientific) was diluted 1:5000 in blocking and 
100 ul was added to each well. The plates were incubated with the secondary 
detection reagent for another hour at room temperature before washing four times 
with PBST. Finally, 100 ul of 3,3',5,5′-tetramethylbenzidine (TMB) (Thermo 
Fisher Scientific Inc.) was added to each well and an equal volume of 1M H2SO4 
was added to quench the chemical reaction once the desired colour change has been 
obtained. The plates was read at 450nm. Optical density (O.D) values above 0.7 at 
450nm was set as the cut-off and wells with absorbance values of >0.7 were 
considered to be positive for anti-Blo t 5 antibody responses. 
2.4.7 Validation of monoclonality 
Total RNA was extracted from one million hybridoma cells according to 
manufacturer's instructions using the High Pure RNA Isolation Kit (Roche 
Diagnostics GmbH). The heavy and light chain sequences were amplified with 
primers from the Mouse Ig-Primer Set (Novagen®, Merck Millipore) and the 
QIAGEN® OneStep RT-PCR kit (QIAGEN). Components of the 25 µl reaction 
mix per primer was prepared as follows: 12.5 µl of RNase-free water, 5 µl of 5x 
Qiagen OneStep RT-PCR Buffer, 1 µl of dNTP, 1.25 µl of each forward and 
reverse primer, 1 µl of QIAGEN OneStep RT-PCR Enzyme Mix, and 3 µl of 
extracted template RNA. 
Cycling parameters were as follows, with annealing temperatures differing 
depending on the primer used: Reverse transcription at 50°C for 30 min, activation 
at 95°C for 15 min, followed by 34 cycles of denaturation at 94°C for 1 min, 





primer annealing at 50°C or 60°C for 1 min, extension at 72°C for 2 min, and final 
extension at 72°C for 6 min. PCR products were separated on 1% agarose gel. 
Bands of the desired size of 500bp was excised and DNA was extracted from the 
excised gel slices using QIAquick® Gel Extraction Kit (QIAGEN) according to 
manufacturer's instructions. The purified DNA was then sent for sequencing in 
order to determine its nucleotide sequence for further analyses.  
 
  





2.5 Characterization of Anti-Blo t 5 mAb 
2.5.1 SDS - PAGE Gel 
SDS-PAGE gel electrophoresis was used for the visualization and characterization 
of the proteins of interest. Separating and stacking gels used were comprised of 
15% and 4% acrylamide respectively. Gels were cast using Bio-rad Mini-
PROTEAN Electrophoresis System (Bio-rad). The following components were 
added to produce gels of 1.5mm thickness. 
Reagents 15% Separating Gel 4% Stacking Gel 
RO Water 5ml 6 ml 
30% Acrylamide/Bis 10 ml 1.5 ml 
Resolving Gel Buffer 5 ml - 
Stacking Gel Buffer - 2.5 ml 
Temed 15 μl 10 μl 
10% Ammonium Persulfate 
(APS) 
100 μl 100 μl 
Each sample was mixed with 5X Lammeli sample buffer in 1.5ml microcentrifuge 
tubes and subsequently boiled at 95°C for 5 mins to 10 mins before loading into the 
wells of the gels. For reference, a protein marker is also loaded. Electrophoresis 
was carried out at a constant voltage of 75V for approximately 2 hours until the dye 
front reached the bottom of the gel. Separated proteins on the SDS-PAGE gel was 
then visualized by staining with Commassie blue staining solution and destained by 
soaking in water for 2 days with gentle shaking before drying with a gel dryer.  
 
 





2.5.2 Native PAGE  
Separating and stacking gels used were comprised of 15% and 2.5% acrylamide 
respectively. Gels were cast using Bio-rad Mini-PROTEAN Electrophoresis 
System (Bio-rad). Gels which were 1.5 mm in thickness were produced by adding 
the reagents listed in the table below. 
Reagents 15% Separating Gel 2.5% Stacking Gel 
RO Water 4.5 ml 5 ml 
30% Acrylamide/Bis 9 ml - 
4X Resolving Gel Buffer 4.5 ml - 
8X Stacking Gel Buffer - 1 ml 
10% Acrylamide/Bis - 2 ml 
10% Ammonium Persulfate 
(APS) 
120 μl 50 μl 
The resolving gel was prepared first and left to polymerize for at least 2 hours at 
room temperature. Following which, the stacking gel was added above the 
polymerized resolving gel and also left to polymerize for 2 hours at room 
temperature before using for electrophoresis. 
Each sample was mixed with 20 μl of native sample buffer (Bio-rad) and loaded 
directly into the wells. The electrophoresis was carried out in 1X non-denaturing 
running buffer under a constant current of 20 mA for 4-5 hours at 4°C until the dye 
front reaches the bottom of the gel.  
2.5.3 Western blot 
Using a Mini Trans-Blot Cell (Bio-rad), the gel containing the separated proteins 
were transferred onto a Polyvinylidene Difluoride (PVDF) membrane (Bio-rad) 





after gel electrophoresis. The PVDF membrane was first activated by wetting it 
with 100% methanol for several minutes and rinsed with RO water before 
equilibrating in 1X transfer buffer with shaking. Thereafter, a gel sandwich was 
assembled on the cathode side of the cassette in the following order: filter pad, 
filter paper, SDS-PAGE or native gel, PVDF membrane, filter paper and finally 
filter pad. Caution was taken to ensure that there were no air bubbles trapped 
between these layers which could adversely affect the transfer of proteins onto the 
PVDF membrane. The transfer was carried out at a constant current of 200mA for 
2 hours at 4°C in 1X transfer buffer.  
Following the transfer of the proteins onto the PVDF membrane, the membrane 
was removed from the cassette and blocked with 5% milk for 1 hour at room 
temperature on a shaker. After which, the membrane was incubated with the 
respective primary antibody diluted in 3% milk (1:1000) overnight at 4°C on a 
shaker. The following day, the membrane was washed at room temperature with 
PBS-0.2% Tween20 buffer for three times, each lasting 7 minutes with shaking. 
The membrane was then incubated with a specific HRP-conjugated secondary 
antibody that was diluted in 3% milk (1:10,000) for 1 hour at room temperature on 
a shaker. Post-incubation with the secondary antibody, the membrane was washed 
for 7 minutes thrice with PBS-0.2% Tween20 with shaking. Thereafter, a 
developing solution (Western Lightning Chemiluminescence, Perkin Elmer, MA, 
USA) was added to the membrane. Exposure using light-sensitive film was then 
performed in the dark room to develop and visualize the signals on the membrane.  
 





2.5.4 Antibody isotyping 
The Isostrip Mouse Monoclonal Isotyping kit (Roche) was used to determine the 
subclass of the hybridoma clone. Hybridoma cell culture supernatant was collected 
and placed into the development tube containing latex beads. The tube was then 
vortexed briefly and incubated at room temperature for 30 sec. Following which, 
the isotyping strip was placed into each tube and incubated until the distinctive blue 
bands appear. The bands are indicative of the subclass and light chain composition 
of the antibody found in the supernatant. 
2.5.5 Immuno-dot blot 
A peptide library of the Blo t 5 protein comprising of 15-mer peptides with 10 
overlapping amino acids was used. 5 ug of each peptide was dotted onto pre-
activated PVDF membrane and 1 ug of recombinant Blo t 5 protein was used as 
positive control. The membrane was air dried and blocked with 5% skimmed milk 
before incubating with the anti-Blo t 5 mAb (1:500 in 5% skimmed milk). The 
membrane was then washed thrice with PBS-0.2% Tween-20 for 7 min each 
followed by incubation with goat anti-mouse IgG conjugated with HRP (1:10,000 
vol/vol in 5% skimmed milk; Thermo Scientific). Washing with PBS-0.2% Tween-
20 was repeated. Finally, the membrane was developed with Western Lightning 
Plus Enhanced Chemiluminescence (ECL) (Perkin Elmer, USA) and the signals on 
the membrane were captured on light-sensitive film in the dark room. 
 
 





2.5.6 Affinity determination by ELISA 
Briefly, varying concentrations of recombinant Blo t 5 protein (125 ng/ml - 2 
μg/ml) were diluted in 0.1M Sodium Bicarbonate coating buffer and coated onto 
Maxisorp plates, overnight at room temperature. The plates were washed with 
PBS-0.05% Tween-20, blocked with 0.2% Bovine Serum Albumin (BSA) and 
incubated overnight with serial dilutions of anti-Blo t 5 mAb. The plates were 
washed again and incubated with goat anti-mouse IgG conjugated with horseradish 
peroxidase (HRP) (1:5000 vol/vol in 0.2% BSA; Thermo Scientific). Subsequently, 
the plates were developed with 1-Step Ultra TMB-ELISA Substrate (Thermo 
Fisher Scientific) and quenched with 1M sulphuric acid. Optical density was 
acquired using a microplate reader at 450nm. Calculations of affinity and 
dissociation constants were performed as described previously. 
2.5.7 Generation of Blo t 5 double mutants 
Blo t 5 double mutants were generated with the Quikchange II XL Site-directed 
Mutagenesis Kit (Agilent Technologies). The site-directed mutagenesis PCR was 
performed with the following forward and reverse primers: BT5K54AR57A-For 
and BT5K54R57A-Rev, BT5K54ER57E-For and BT5K54ER57E-Rev. 
Components of the 50 μl PCR mix were prepared as follows: 5 μl of 10x reaction 
buffer, 1.1 μl  of each forward and reverse primer, 1 μl of dNTP mix, 1 μl of 
PfuTurbo™ polymerase, 1 μl of pET28-Blo t 5 dsDNA plasmid and 39.8 μl of 
ddH2O. The cycling conditions were 95°C for 30s, followed by 16 cycles of 95°C 
for 30s, 60°C for 1min, and 68°C for 6 min, and final extension at 68°C for 6 mins. 
1 μl of Dpn1 enzyme was added to the PCR reaction and incubated for 2 hours at 





37°C to digest the methylated parental template. Next, 1 μl of the PCR reaction 
was transformed into XL10 Gold Ultracompetent Cells (Agilent Technologies) by 
heat-shock and plated on LB/Kanamycin agar plates.  
The next day, colonies were picked and inoculated in 5 ml LB/Kan medium 
overnight. Plasmids were extracted from the inoculated cultures using the QIAprep 
Spin Miniprep Kit (QIAGEN) according to manufacturer's instructions. The 
presence of the double mutation was confirmed by sequencing before IPTG 
induction for protein expression.  
 
  





2.6 in vivo study of Anti-Blo t 5 mAb 
2.6.1 Animals 
Male C57BL/6 (8-10 weeks old) used for the asthma model were maintained under 
pathogen-free conditions at the Centre for Comparative Medicine. All experiments 
were performed in accordance with approved institutional guidelines of the 
Institutional Animal Care and Use Committee (IACUC) of the National University 
of Singapore, under protocol number 015/12. 
2.6.2 Sera collection by cardiac puncture 
Mice were sacrificed by carbon dioxide asphyxiation. Incisions were made to 
expose the upper thoracic region of the mouse. Blood was collected by cardiac 
puncture with a 25G needle (BD) and transferred to 1.7 ml eppendorf tubes. The 
blood was allowed to clot at room temperature for at least 2 hours before 
centrifuging at 5000 rpm for 10 mins, 4°C. Serum was carefully collected, 
transferred to a fresh eppendorf tube and stored at -80°C until further processing. 
2.6.3 Bronchoalveolar lavage (BAL) fluid analysis 
Mice were first culled by carbon dioxide asphyxiation. A small incision was made 
at the trachea and a 23G needle cannulated with polyethylene tubing was inserted. 
Three 0.8 ml aliquots of MACS buffer was used to flush the lungs and the 
recovered fluid was transferred to two sterile 1.7 ml eppendorf tubes. The BAL 
fluid was centrifuged at 450g for 5 mins, 4°C. The supernatant was transferred to 
new eppendorf tubes and stored at -80°C until further processing. RBC lysis was 
carried out by resuspending the pellet in 100 μl of ACK lysis buffer and incubated 





at room temperature for 1 min and quenched with 900 μl of MACS buffer. The 
suspension was centrifuged at 450g for 5 mins at 4°C and the resulting pellet was 
resuspended in MACS buffer. Cells were counted with the haemocytometer to 
determine the total cell count. Following which, the cells were stained with 
fluorophore conjugated antibodies: Siglec-F-PE (BD Biosciences), Ly-6G-APC 
(BD Biosciences), CD3-PB (Biolegend). Cells were stained for 30 min at 4°C and 
then washed twice with FACS buffer before acquiring on CyAn™ (Beckman 
Coulter).  
2.6.4 Measurement of total IgE and Blo t 5-specific IgE 
Serum was obtained via cardiac puncture. Total IgE was measured using the Mouse 
IgE ELISA Set (BD Biosciences) according to manufacturer's instructions. To 
measure Blo t 5-specific IgE, sera were pre-absorbed with Protein G Sepharose 4 
Fast Flow beads (GE Healthcare Life Sciences) before proceeding with the 
measurement of IgE as described earlier.  
2.6.5 Measurement of cytokines in BAL fluid by ELISA 
ELISA kits used to measure the levels of cytokines (IL-4, IL-5, IL-13, IL-10, IFNγ 
and Eotaxin) in the BAL fluid were purchased from R&D Systems and performed 
according to manufacturer's instructions. Briefly, maxisorp ELISA plates (NUNC) 
were coated with capture antibodies at concentrations specified by the kit. 
Following which, the plates were washed with 0.05% PBST and blocked with 1% 
BSA for at least 1 hour. BAL fluid samples (neat or diluted in blocking buffer) 
were then incubated for at least 2 hours at room temperature. Standards 
supplemented with the kits were diluted accordingly to obtain a standard curve for 





the calculation of sample concentrations. Biotinylated detection antibodies were 
used at the specified dilutions and incubated for 2 hours at room temperature. 
Streptavidin-HRP was diluted 1:200 in blocking buffer, added to the plate and 
incubated for 20 mins at room temperature. Finally, the plate was washed and 
incubated 20 mins in the dark with the substrate solution for development. The 
substrate reaction was quenched and the plate was read with a microplate reader at 
an optical density of 450nm. 
2.6.6 Lung histology and scoring 
PBS perfusion was performed and the lungs were fixed by inflating with 0.8 ml of 
4% paraformaldehye (Sigma-Aldrich). Lung tissues were further fixed for at least 
two days in 4% paraformaldehyde. Downstream sample processing and staining 
procedures were performed by the Advanced Molecular Pathology Laboratory 
(AMPL) situated at the A*Star Institute of Molecular and Cell Biology (IMCB). 
H&E-stained lung sections were scored on cell infiltration as previously 
described
104
. Similarly, PAS-stained lung sections were quantified for airway 









2.7 in vitro study of anti-Blo t 5 mAb 
2.7.1 Generating chimeric variants of anti-Blo t 5 mAb 
Total RNA was extracted from 1 x 10
6
 hybridoma cells using the High Pure RNA 
Isolation kit (Roche). Extracted RNA was converted to cDNA using Superscript III 
First Strand cDNA Synthesis Kit (Invitrogen). Variable regions of the heavy and 
light chains were PCR amplified with specific primers using the AmpliTaq® Gold 
DNA polymerase (Thermo Fisher Scientific). PCR products were analyzed by 
DNA gel electrophoresis, bands at corresponding sizes were excised and DNA was 
purified using QIAGEN Gel Extraction Kit. Purified PCR products were then 
digested with SfiI/BsmBI for the heavy chain and ApaLI/AscI for the light chain. 
Digested plasmids were analyzed on a 1% agarose gel and the corresponding bands 
were excised for DNA purification with QIAquick Gel Extraction Kit (QIAGEN). 
The heavy and light chain variable were then ligated into pTT5 heavy and light 
chain plasmid vectors which possess the human IgG constant regions (Courtesy of 
A/P Brendon Hanson). The ligated plasmids were transformed into JM109 
competent bacteria cells (Promega) and plated on LB/Ampicillin agar plates. 
Colonies were picked, inoculated in overnight cultures. Plasmids were extracted 
with QIAprep Spin Miniprep Kit (QIAGEN) for further qualification by 
sequencing before transfecting into HEK-6E suspension cells. 
2.7.2 Expression and purification of chimeric anti-Blo t 5 IgGs 
Antibody heavy and light chain plasmids were complexed with polyethyleneimine 
(PEI) and co-transfected into HEK293-6E cells (ATCC). HEK293-6E cells were 
cultured in suspension at a density of 10
6
 cells/ml in serum-free F17 medium. 





Heavy and light chain plasmids were added at 0.8 μg each per ml of cultured cells. 
The plasmid DNA was mixed with 150 mM NaCl solution, followed by the 
addition of PEI to a ratio of 3:1 (PEI:DNA). This mixture is immediately added to 
the culture and the cells were incubated in a shaking incubator at 125 rpm, 37°C, 
5% CO2. The next day, tryptone-N1 (Organotechnie) was added to a final 
concentration of 0.5% v/v. The cultures were maintained for one week before 
antibody recovery from the supernatant.  
One week later, the cultures were centrifuged at 8000g for 20 min. The supernatant 
fraction was retained and filtered through a 0.22μm filter before antibody 
purification. Protein A beads (GE Healthcare) was added to the supernatant and 
incubated overnight with rotation at 4°C. The next day, the beads were pelleted by 
centrifuging at 250g for 1min and the supernatant fraction was discarded with 5 ml 
remaining volume. The beads were loaded onto a 2ml polystyrene column (Thermo 
Scientific). The beads in the column were then washed with 1x PBS twice and the 
IgG antibodies were eluted four times from the protein A beads with IgG Elution 
Buffer (Thermo Scientific). Bradford assay was performed to determine which 
eluent contained the antibodies. Buffer exchange with 1x PBS was done with the 
Amicon Ultra 0.5ml centrifugal filters (Merck Millipore) and stored at -20°C. 
2.7.3 Basophil activation test (BAT) 
The BAT was performed as previously described
106
. Briefly, whole blood collected 
from sensitized donors was stained with Pacific-Blue™ Anti-human HLA-DR, 
APC Anti-human CD294 (CRTH2) and FITC Anti-human CD63 (Biolegend). 
Following which, stained whole blood was incubated with PBS, Blo t extract only 
or Blo t extract with varying concentrations of anti-Blo t 5 antibody for 20 minutes 





at 37°C. Activation was terminated with 3.8% EDTA and erythrocytes were lysed 
with ACK lysis buffer. Cells were then washed, resuspended in PBS and analyzed 
by flow cytometry on Fortessa FACScan. Basophils were identified as the HLA-
DR−/CRTH2+ population. A first gate was made around the lymphocyte 
population in the side scatter (SSC) versus forward scatter (FSC) dot plot. A 
second gate was placed at the cell singlet population in the FSC-H versus FSC-A 
dot plot, followed by gating around the CRTH2+ population in the HLA-DR versus 
CRTH2 dot plot. Stimulation was then analyzed by the percentage of CD63+ cells 
in the absence/presence of the Blo t Extract.  
2.8 Statistical analysis 
Data were expressed as means ± SEMs. All data analyses were performed with 
Graphpad Prism 5 software. Comparison between two groups were assessed with 
two-tailed unpaired Student T-test and results are considered to be statistically 







GENERATION & CHARACTERIZATION OF 













3.1  Introduction 
As discussed earlier, findings from multiple studies have indicated that Blo t 5 is a 
critical target for the development of therapeutics against B tropicalis-mediated 
allergic asthma. Despite its significance as the major allergen and key sensitizer 
from B. tropicalis, the availability of monoclonal antibodies against Blo t 5 protein 
remains limited. The first stage of this project was therefore centered on the 
development and characterization of Blo t 5-specific monoclonal antibodies. In 
collaboration with Prof. David M. Kemeny, a bacterial expression vector 
containing the insert encoding for recombinant Blo t 5 protein was devised. This 
enables the continuous production and purification of the Blo t 5 allergen to be 
used throughout this study.  
Purified recombinant Blo t 5 was used to immunize mice for the generation of Blo t 
5-specific monoclonal antibodies. First developed by Kohler and Milstein in 1975, 
the classical hybridoma methodology involves the fusion of mouse splenocytes 
with immortalized myeloma cells by polyethylene glycol. This methodology was 
employed in this study and the resultant antibody-secreting hybridoma clones were 
then screened for anti-Blo t 5 responses by ELISA. Clones secreting antibodies of 
high specificity and binding activity were sub-cloned by limited dilution to obtain 
monoclones from which the anti-Blo t 5 monoclonal antibodies could be purified. 
Western and dot blot were performed to delineate the binding epitope of the 
selected monoclonal antibody candidate. 
 




3.2  Results 
3.2.1 Generation of Anti-Blo t 5 Monoclonal Antibody 
An established protocol was used to express a truncated variant of the recombinant 
Blo t 5 protein void of the signal peptide as it was shown to exhibit higher 
expression quality and quantity as compared to its full-length counterpart. 
Expression of Blo t 5 was performed in the BL21 strain of E.coli bacteria by IPTG 
induction (Figure 3.1A). Following IPTG induction and protein expression, the 
recombinant Blo t 5, present as inclusion bodies of the bacteria was extracted by 
inclusion bodies preparation. In order to remove the contaminating proteins, 
recombinant Blo t 5 was precipitated using increasing concentrations (40%, 50% 
and 60%) of ammonium sulphate. Precipitated Blo t 5 protein was further purified 
according to its charge with the MonoQ 5/50GL anion exchange column (Figure 
3.1B) and size with the HiLoad 16/60 Superdex-75 gel filtration column (Figure 
3.1C). Finally, the purified recombinant Blo t 5 was dialyzed in 1xPBS overnight, 
sterile filtered and is ready for use in subsequent experiments. 
Purified recombinant Blo t 5 was used to immunize BALB/c female mice. Forty-
five days into the immunization regime, the mice were sacrificed and spleens were 
removed. Splenocytes were obtained by homogenizing the removed spleens with 
cell-strainers. Hybridomas were generated by fusing the splenocytes with the 
myeloma cell line NS1 using polyethylene glycol (PEG) according to an optimized 
protocol which was first developed by Kohler and Milstein (Kohler & Milstein, 
1975). Approximately 2 to 3 weeks post-fusion, wells with hybridoma clones were 




identified and the supernatants were harvested for screening by ELISA for anti-Blo 
t 5 responses.  
Positive clones were identified as having signals of O.D450nm>0.7. A total of 1584 
hybridoma clones were screened and 1.4% of the clones screened were positive for 
anti-Blo t 5 antibodies (Figure 3.2). Furthermore, Figure 3.3 depicts the 
representative binding profiles of hybridoma clones which were considered 
positive. While such strict criteria highly restricts the number of chosen hybridoma 
clones, it was necessary to ensure that only clones which display superior binding 

















Figure 3.1: Expression and purification of recombinant Blo t 5 protein. 
Recombinant Blo t 5 protein was expressed via IPTG induction in BL21 E.coli 
bacteria. The protein was isolated from inclusion bodies and cleared of 
contaminating proteins in the cell lysate by ammonium sulfate precipitation (A). 
The precipitated Blo t 5 was then further purified by FPLC with anion exchange 
(B) and size exclusion (C) columns, and purity was analyzed by SDS-PAGE. 
 





Figure 3.2: Overall percentage of hybridoma clones positive for anti-Blo t 5 
responses.  
Hybridomas giving an optical density (O.D.) readings of 0.7 or above were 
considered as positive hybridoma clones producing anti-Blo t 5 antibodies. A total 
of 1584 hybridomas were screened and 23 clones (1.4%) were positive for anti-Blo 
t 5 responses. 
 
Figure 3.3: Representative binding profiles of polyclonal candidates deemed 
positive for anti-Blo t 5 responses. 
Supernatants from hybridoma clones were screened by ELISA and those which 
displayed superior binding activities were further expanded in culture to 
subsequently obtain monoclones. 




3.2.2 Purification of Anti-Blo t 5 Monoclonal Antibody 
To obtain a monoclonal antibody, the selected clones were expanded and sub-
cloned by limiting dilution. Limiting dilution was performed such that 0.1-0.5 cells 
were seeded into 96 well plates. The plates were incubated for approximately 2 
weeks before scoring for growing hybridomas. Supernatants from selected clones 
were screened again for anti-Blo 5 responses by ELISA. Once a candidate was 
selected, it was expanded to T175 flasks and supernatant containing secreted 
monoclonal antibodies was collected. The anti-Blo t 5 monoclonal antibody was 
then purified from culture supernatant by FPLC using the Hi-Trap™ Sepharose G 
columns. As shown in Figure 3.4A, the FPLC trace for anti-Blo t 5 depicts a 
distinct peak at approximately 2020 ml of elution buffer with a UV absorbance 
value of about 2500 mAU. The fractions A3 to A7 were collected and pooled. 
These fractions were further analyzed by SDS-PAGE electrophoresis before 
dialyzing in 1xPBS. On the reducing SDS-PAGE gel (Figure 3.4B), two bands 
observed at approximately 50 kDa and 25 kDa corresponded to the heavy chain and 
light chain, respectively. In contrast to the culture supernatant before FPLC 
purification, the purified monoclonal antibody was void of any contaminating 
proteins. On the native SDS-PAGE gel (Figure 3.4C), only a single band at at 
approximately 150 kDa was observed. This signifies that the purified anti-Blo t 5 
monoclonal antibody was folded appropriately and retained their conformation as 
full length antibodies throughout the purification procedure. 
 
 





Figure 3.4: Purification of anti-Blo t 5 antibodies by FPLC. 
A single peak which corresponded to the elution of  anti-Blo t 5 antibodies was 
observed during the purification process (A). Further qualitative analyses on the 
collected fractions were performed by running the purified monoclonal antibodies 
on denaturing (B) and native (C) SDS-PAGE gels.   




3.2.3 Characterization of Anti-Blo t 5 mAb 
3.2.3.1 Isotype & Sequence Analysis 
The isotype of the murine anti-Blo t 5 mAb was determined with the murine 
monoclonal isotyping strip from Roche. The isotyping strips consist of two strips 
which enables for the detection of the heavy and the light chains of the monoclonal 
antibody. In addition to the bands corresponding to the positive controls, two bands 
(in blue) were also observed after incubating the strip with the supernatant of the 
monoclonal hybridoma. As seen in Figure 3.5, the anti-Blo t 5 mAb generated is 
an IgG1 with a kappa (κ) light chain. 
To further ascertain the monoclonality of the selected hybridoma clone, RNA was 
extracted and a reverse-transcription PCR (RT-PCR) was performed with primers 
specific for the variable regions of the subtypes of the murine heavy chain IgG1 and 
κ light chain. The RT-PCR kit utilized allows for the amplification of the variable 
regions of the antibody. PCR products were then analysed by agarose gel 
electrophoresis. From the gel photo in Figure 3.6A, our antibody expresses a 
single heavy chain template which was detected by the F primer, strongly 
suggesting that this antibody candidate is monoclonal. In addition, the RT-PCR 
also gave rise to products with the light chain primers A, B, C and G. Multiple 
bands were observed for the light chain because the myeloma cell line NS1 used 
for fusion expresses a κ light chain that is aberrant and non-functional, but is 
amplified with light chain primers B and C (Leitzgen et al., 1997). Therefore, only 
the single heavy chain band F and light chain bands A and G were excised for gel 
extraction and further analysis.  




The sequences obtained from gel extraction were compared in silico by translating 
in the correct frame of the protein sequence and aligned so as to determine the 
complementary determining regions (CDRs) of the heavy and light chains. 
Sequences of the heavy and light chains are shown in Figure 3.6B. Furthermore, 
the sequences were also analysed by IgBLAST to determine the uniqueness of the 
antibody.   
  








Figure 3.5: Isotype test for anti-Blo t 5 specific monoclonal antibody.  
The isotype of the anti-Blo t 5 monoclonal antibody was determined using the 
IsoStrip Mouse Isotyping Kit (Roche Diagnostics, USA). The blue bands (red 
arrows) present for both the heavy and light chains indicate that the test was 
positive for the corresponding panel. The isotype of the anti-Blo t 5 antibody is 
indicated by the blue band at IgG1 and kappa (κ) for heavy and light chains, 











Figure 3.6: IgG template & sequence analysis of anti-Blo t 5 mAb.  
The Novagen Immunoglobulin kit (USA) was used in the RT-PCR (A). Primers 
corresponding to the regions adjacent to the hyper-variable complementarity 
defining regions (CDR) were used to amplify and sequence the CDRs from the Ig 
heavy and light chains. A single PCR product for the heavy chain gene of clone F2 
indicates that this cell line is monoclonal. As depicted in the gel picture, there is 
more than one product amplified with the light chain primers. Bands B & C were 
contributed by the myeloma cell fusion partner while bands A & G were identified 
to be identical after sequencing and sequence analysis. Upon further sequence 
analysis, the amino acid sequences of the CDRs were found to be unique (B).   




3.2.3.2 Affinity Determination by ELISA 
An approximation of the binding affinity of the purified anti-Blo t 5 mAb to 
recombinant Blo t 5 protein was determined by performing an ELISA. The ELISA 
plate was coated with recombinant Blo t 5 protein at different concentrations, 
followed by incubation with serially diluted anti-Blo t 5 mAb. The respective 
binding curves for the different concentrations were plotted and antibody 
concentrations giving the half-maximal responses at different Blo t 5 
concentrations were determined. Using the above values, the affinity constant, KAFF 
and the dissociation constant, KD, could then be calculated. The binding affinity of 
our anti-Blo t 5 mAb to its antigen was calculated to be 1.528 x 10
-8
 M.  
 
Figure 3.7: Affinity determination of anti-Blo t 5 mAb by ELISA. 
The dissociation constant KD was calculated based on the binding curves obtained 
by serially diluting the anti-Blo t 5 mAb and recombinant Blo t 5 protein. 
 




3.2.3.3 Epitope Mapping 
Denaturing and non-denaturing western blots were carried out to determine 
whether this mAb recognizes Blo t 5 in its denatured or native state respectively. 
As seen in Figure 3.8A, the purified anti-Blo t 5 mAb recognizes the recombinant 
Blo t 5 protein regardless whether it exists in its denatured or native conformation. 
It can therefore be inferred that the binding epitope of this monoclonal antibody is 
a linear epitope that is likely to be on an exposed surface of the Blo t 5 protein.  
Since the purified anti-Blo t 5 mAb was found to bind a linear epitope, the next 
step was to delineate the exact location of this linear epitope on the Blo t 5 protein. 
To accomplish this, a dot blot was performed using a Blo t 5 peptide library which 
comprised of 15-mer peptides with a 10 amino acid overlap that covered the entire 
protein (Figure 3.8B). As the starting antigen used for antibody generation was a 
truncated protein without a signal peptide, the peptide library used subsequently for 
the dot blot did not include the peptides that code for the signal peptide. The dot 
blot revealed that our anti-Blo t 5 mAb binds to peptide 14 of the peptide library 
(Figure 3.8C). Software modelling by PyMOL enabled the structural localisation 
of peptide 14 on the Blo t 5 protein and it revealed that peptide 14 is located on an 
exposed surface of the protein (Figure 3.8D). Whilst the location of peptide 14 
does not coincide with the major linear IgE binding epitope as delineated in a 
patient cohort study conducted by Chan et. al., it appears to partially overlap with a 
region which was identified by Naik et. al. as a potential conformational IgE 
binding epitope
49, 107
. As such, the key amino acid residues present in this binding 
site may also be crucial in the recognition and binding of our anti-Blo t 5 mAb to 
the Blo t 5 protein.  





Figure 3.8: Epitope mapping for anti-Blo t 5 mAb. 
Recombinant Blo t 5 proteins were loaded and ran on SDS-PAGE gels under 
denaturing and native conditions. Western blot was subsequently performed with 
the anti-Blo t 5 mAb. Our anti-Blo t 5 mAb was able to detect the recombinant Blo 
t 5 protein in both its denatured and native state (A). A peptide library consisting of 
15-mer peptides with 10 amino acids overlap was used to determine the exact 
binding epitope of our anti-Blo t 5 mAb (B). The anti-Blo t 5 recognised peptide 14 
of the Blo t 5 peptide library as assessed by dot blotting the individual peptides 
onto the nitrocellulose membrane (C). Following modelling analysis by the 
PyMOL software, peptide 14 appears to be located at an exposed surface on helix 
B of the Blo t 5 protein (D), which partially overlaps with two residues that make 
up the conformation IgE binding site as described by Naik et. al. (2008). 
  




3.2.3.4 Blo t 5 mutants at positions K54 and R57 
As described earlier, the binding epitope of our anti-Blo t 5 mAb was shown to 
partially overlap with a previously reported conformational IgE binding epitope. 
Two basic residues, Lysine54 and Arginine57, which form part of this 
conformational IgE binding epitope, lie in the region of the binding epitope of our 
anti-Blo t 5 mAb (Figure 3.8). Hence, mutant Blo t 5 proteins were generated to 
validate the contributions of Lysine54 and Arginine57 residues to the binding of 
our anti-Blo t 5. Two types of mutations were designed as shown in Figure 3.9A - 
one in which both residues were mutated to Alanine (K54A-R57A), and the other 
harboured a harsher mutation whereby both basic residues were replaced by the 
acidic residue Glutamate (K54E-R57E). 
The mutant Blo t 5 proteins were expressed in BL21 E.coli bacteria and purified as 
described earlier with the wild type recombinant Blo t 5 protein. An ELISA was 
performed to assess whether our anti-Blo t 5 mAb displays any differential binding 
activity to the Blo t 5 double mutants. From the ELISA binding results (Figure 
3.9B), our anti-Blo t 5 mAb was capable of binding the Blo t 5 mutants to the same 
extent as the wild type Blo t 5 protein. Hence, Lysine54 and Arginine57 do not 
contribute critically to the binding of our anti-Blo t 5 to the Blo t 5 protein.  
  






Figure 3.9: Assessing the binding of anti-Blo t 5 to Blo t 5 double mutant 
proteins. 
Blo t 5 double mutant proteins were designed such that the Lysine and Arginine 
residues at amino acid positions 54 and 57, respectively, were both mutated to 
either Alanine or Glutamic acid for a harsher mutation (A). Blo t 5 mutant proteins 
were purified the same way as the wild-type Blo t 5 protein as described earlier in 
this chapter and were then used in the ELISA to assess the importance of these two 
amino acid residue in the binding of the anti-Blo t 5 mAb. Results from the ELISA 
showed that anti-Blo t 5 mAb was still able to bind to both mutants, suggesting that 










3.2.4 Antagonistic potential of Anti-Blo t 5 mAb 
Sera from a cohort of 25 Singaporean patients were first screened by ELISA for 
IgE binding activity to the Blo t 5 protein. An O.D450nm value of 0.9 was set as the 
cut off and six out of the 25 screened patients were selected for further experiments 
based on their good IgE response to Blo t 5 (Figure 3.11A). In order to assess the 
potential of our anti-Blo t 5 antibody in antagonising allergen-specific IgE in 
patients' sera, an inhibition ELISA was performed. Different concentrations of anti-
Blo t 5 were pre-incubated with recombinant Blo t 5 protein immobilized on the 
ELISA plate before the patients' sera were added and detected for anti-human IgE 
(Figure 3.10).  
As seen in Figure 3.11B, the addition of 0.01 μg/ml of anti-Blo t 5 did not cause 
any decreases in the binding of Blo t 5-specific IgE in patients' sera. However, pre-
incubation with 0.1 μg/ml, 1 μg/ml and 10 μg/ml of anti-Blo t 5 mAb resulted in 
significant dose-dependent reductions in the binding of Blo t 5-specific IgE in 
patients' sera. Pre-incubation with an isotype control antibody which is of the same 
IgG subclass but raised against a different allergen, did not elicit such inhibition. 
This strongly suggests that the antagonism observed in this anti-Blo t 5 competitive 















Figure 3.10: Experimental set up of inhibition ELISA to test the antagonistic 
potential of anti-Blo t 5 mAb on Blo t 5-specific IgE binding. 
Schematic diagram illustrating the experimental design of the inhibition ELISA. 
Maxisorp ELISA plates were coated with 1 μg of recombinant Blo t 5 protein, 
followed by a blocking step with 1% BSA. The wells were subsequently incubated 
with different concentrations with anti-Blo t 5 mAb, an isotype control mAb at the 
highest concentration used in the assay, or PBS. Blo t 5-specific IgE in the patients' 
sera were then allowed to interact with the immobilized Blo t 5 protein and the 
amount of Blo t 5-specific IgE bound was detected with a HRP-conjugated goat 
anti-human IgE secondary antibody. 
 






Figure 3.11: Inhibition ELISA for anti-Blo t 5 mAb.  
A Singaporean cohort of 25 patients sensitized to Blo t 5 were screened by ELISA 
for anti-Blo t 5 IgE reactivity, and six with the best binding activities were chosen 
for the inhibition ELISA (A). Inhibition ELISA was then performed with the serum 
of each of the six chosen patients. Patients' sera were incubated after pre-incubation 
with varying amounts of anti-Blo t 5 mAb or isotype control at the highest 
concentration (10 μg/ml). Dose-dependent reductions in patients' Blo t 5-specific 
IgE binding were observed when pre-incubated with 0.1 μg, 1 μg and 10 μg anti-
Blo t 5 mAb and not with the isotype control antibody (B). *P<0.05, **P<0.01, 
***P<0.0001.  




3.3  Discussion 
The first part of this study was driven by the current lack of monoclonal antibodies 
that target allergens arising from the B tropicalis species of HDMs. We have 
chosen Blo t 5 as our primary target based on its allergenicity. Using the traditional 
hydridoma technology, we have successfully generated a Blo t 5-specific murine 
monoclonal antibody of the IgG1 subclass and a κ light chain. Our anti-Blo t 5 mAb 
was shown to bind  the Blo t 5 protein with good specificity and high affinity. 
Sequence analysis also revealed that this mAb possess unique CDRs.  
In addition, epitope mapping analysis for the anti-Blot 5 mAb performed with 
linear peptides demonstrated that it binds to a discontinuous epitope which is 
located on an exposed surface of the Blo t 5 antigen. Interestingly, the binding 
epitope of our anti-Blo t 5 mAb coincides partially with a previously described 
major conformational IgE binding epitope. Four amino acid residues were 
reportedly crucial in forming the conformational IgE epitope and two of which lie 
in the region to which our mAb binds. The two amino acid residues were lysine 
and arginine at positions 54 and 57, respectively. We next generated Blo t 5 mutant 
proteins which carry a double mutation at K54 and R57, to determine the 
contributions of these two residues to the binding of our mAb to the Blo t 5 protein. 
Our results showed that a double mutation at K54 and R57 does not affect the 
binding of the anti-Blo t 5 mAb.  
Nevertheless, we proceeded with assessing the potential of our anti-Blo t 5 mAb as 
an allergen-specific antagonizing antibody. To accomplish this, we obtained sera 
from a Blo t 5-sensitive Singaporean patient cohort from our collaborators and 




assayed for a reduction in IgE binding to Blo t 5 in the presence of our anti-Blo t 5 
mAb. Results from the inhibition ELISA indicated that the presence of anti-Blo t 5 
mAb caused a significant dose-dependent reduction in binding by Blo t 5-specific 
IgE in patients' sera.  
As described earlier, the binding epitope of our mAb partially overlaps a potential 
conformational IgE binding site as described by Naik et. al. (2008). Whilst the 
critical amino acid residues of this reported conformational IgE binding site do not 
contribute significantly to the binding of our mAb, the observed inhibitory effect 
exerted by our anti-Blo t 5 could potentially be explained by two possible reasons. 
Firstly, the antagonistic ability of our mAb with Blo t 5-specific IgE in patients' 
serum may be due to a direct competition for Blo t 5 binding. Alternatively, our 
anti-Blo t 5 mAb may be binding the Blo t 5 antigen in a way that occludes the 
binding site of Blo t 5-specific IgE in patients' serum by steric hindrance or 
distorting the Blo t 5 protein conformation such that Blo t 5-specific IgE in patients' 
sera can no longer bind.  
These findings together signify that our anti-Blo t 5 mAb is a promising candidate 
which can potentially be utilized for therapeutic purposes for its antagonizing 
capacities as well as diagnostic purposes for its good Blo t 5 binding activity. The 
next step in this project was to investigate the in vivo effects of the mAb in the 







APPLICATION OF ANTI-BLO T 5 MAB IN A 















4.1  Introduction 
The availability of laboratory animal models has contributed tremendously to our 
understanding of respiratory diseases and provided a platform for testing potential 
therapeutic agents. It is now well-established that allergens of Blomia tropicalis 
play a major role in HDM sensitization and initiating allergic asthma in tropical 
and sub-tropical countries. Despite this, majority of the animal models of HDM-
induced allergic asthma have been developed using extracts from the 
Dermatophagoides species amd B tropicalis-induced murine asthma models are not 
as well-described.  
Our collaborators from Prof. David M Kemeny lab have established a novel murine 
model of severe asthma model with Blo t 5, the major allergen from B tropicalis. 
Blo t 5-specific TH2 cells were passively transferred to naive mice intravenously, 
followed by intra-nasal challenges with recombinant Blo t 5 protein. These mice 
display a severe asthmatic phenotype characterized by massive pulmonary 
eosinophilia, increases in serum IgE levels and dramatic airway remodeling. This 
model also reinforces the notion that a prominent TH2 signature is crucial in the 
pathogenesis and progression of allergic asthma.  
In this section of the study, we exploited this model to investigate in vivo effects of 
our anti-Blo t 5 mAb in the context of severe B tropicalis-induced severe allergic 
asthma. 
  




4.2  Results 
 
4.2.1 Anti - Blo t 5 mAb lowers inflammatory cell infiltration in 
BAL fluid of asthmatic mice 
Preliminary results from the inhibition ELISA performed to examine the 
antagonistic ability of our anti-Blo t 5 revealed that pre-incubation with our mAb 
hindered the binding of Blo t 5-specific IgE in patients' sera. Next, we investigated 
the therapeutic potential of anti-Blo t 5 mAb administration in a murine model of 
dust mite driven severe allergic asthma.  
Figure 4.1 illustrates the design of the in vivo experiment to examine the 
therapeutic effects of anti-Blo t 5 mAb administration. On day 0, naive mice were 
each intravenously injected with 5 million Blo t 5-specific TH2 cells. The next day, 
these mice were treated either with our anti-Blo t 5 mAb or a murine IgG1 isotype 
control antibody, followed by an intra-nasal challenge with 100 μg of Blo t 5 
protein. Intra-nasal challenges with Blo t 5 protein were administered every day for 
three consecutive days followed with a four day break. On the 16th day, the mice 
were sacrificed. Bronchoalveolar lavage (BAL) fluid and sera were collected from 
the mice for the analysis of cell infiltrates, cytokines and serological parameters 
respectively. 
Intra-nasal challenges with Blo t 5 upon transfer of Blo t 5-specific TH2 
lymphocytes induced severe breathing difficulties with significant morbidity. 
Activity levels of asthmatic mice were observed to be severely limited. 
Interestingly, mice which received our mAb as treatment displayed drastically 




improved asthma symptoms, with no visible breathing difficulties and normal level 
of physical activity (Movie S1).  
Analysis of the BAL fluids from asthmatic mice revealed a dramatic increase in 
total cell counts (Figure 4.2A). The number of infiltrated cells was significantly 
reduced from an average of 3 million cells to 1.6 million cells in the BAL fluid 
from mice treated with anti-Blo t 5 mAb. Notably, as shown in Figure 4.2B, 
eosinophil infiltration into the airways was approximately halved (from 1.5 million 
to 700,000 cells) with anti-Blo t 5 mAb administration. This reduction in cell 
counts was not observed for mice treated with an isotype control mAb, strongly 
suggesting that effect is specific and attributed to the treatment with anti-Blo t 5 
mAb. While the total cell count and number of eosinophils were found to be 
lowered in mice treated with anti-Blo t 5 mAb, neutrophil numbers in the BAL 















Figure 4.1: Experimental design of in vivo study with anti-Blo t 5 mAb. 
Five million Blo t 5-specific TH2 cells were passively transferred to naive mice 
intravenously on Day 0. On days 1 and 13, the mice were treated with anti-Blo t 5 
mAb or an isotype control antibody (red arrows). The mice were also challenged 
intra-nasally with 100 μg/ml of recombinant Blo t 5 protein (black arrows) for three 
consecutive times followed by a four day rest, repeated thrice. The mice were 












Figure 4.2: Analysis of cellular infiltrates in BAL fluid. 
Intranasal challenges with Blo t 5 protein post-transfer of the TH2 cells induced an 
influx of immune cells into the airways of the mice. Treatment with anti-Blo t 5 
mAb lowered the total cell count in the airways of these mice (A). The decrease in 
total cell count was attributed to reduced eosinophilia (B) and the number of 
neutrophils remained unchanged in the presence of our anti-Blo t 5 mAb.  
 
  




4.2.2 Anti-Blo t 5 mAb reduces total IgE & Blo t 5-specific IgE in 
the sera of treated mice 
To obtain an insight into the serological effects of anti-Blo t 5 mAb administration 
in severely asthmatic mice, sera were collected from blood obtained by cardiac 
punctures when the mice were sacrificed. The sera were then analyzed for total IgE 
levels and Blo t 5-specific IgG1 by ELISA. As depicted by Figure 4.3A, total 
serum IgE levels in severely asthmatic mice were significantly elevated A five-fold 
reduction in total IgE levels was observed in the sera from mice treated with anti-
Blo t 5 mAb as compared to untreated mice and mice treated with an isotype 
control antibody. 
However, in attempts to measure Blo t 5-specific IgE, we have observed that the 
detectable level of Blo t 5-specific IgE increased with increasing dilutions of sera 
(Figure 4.3B). The presence of Blo t 5-specific IgG1 antibodies could potentially 
have hampered the detection of Blo t 5-specific IgE by competing for binding to 
Blo t 5. This was overcome by pre-absorbing the sera with Protein G beads prior to 
incubation with Blo t 5 protein immobilized on the ELISA plate. This strategy was 
also previously reported to increase the sensitivity of measuring serum IgE levels. 
Pre-absorption with protein G beads depletes the sera of almost all IgG antibodies, 
including Blo t 5-specific IgG1 antibodies, which then enables us to delineate IgE 
levels specific for Blo t 5. Sera from mice treated with anti-Blo t 5 mAb had 
significantly lower levels of Blo t 5-specific IgE as compared to the other two 
groups of mice (Figure 4.3C). Blo t 5-specific IgG1 antibody levels were also 
elevated in the sera, especially in mice treated with anti-Blo t 5 mAb, which 
signifies successful administration of the treatment (Figure 4.4). 






Figure 4.3: Serum total and Blo t 5-specific IgE levels. 
(A) Asthmatic mice and mice treated with isotype antibody showed elevated serum 
levels of total IgE . Total serum IgE was dramatically decreased by approximately 
5-fold with the administration of anti-Blo t 5. (B) An inverse relationship was 
observed between the concentration of detectable IgE and the dilution of sera. The 
presence of high levels of Blo t 5-specific IgG1 in the sera could possibly explain 
for this observation and potentially interfere with the detection of Blo t 5-specific 
IgE. IgG antibodies were removed by pre-absorbing with protein G sepharose 
beads before detecting for Blo t 5-specific IgE by ELISA. Untreated mice 
displayed elevated levels of Blo t 5-specific IgE. Treatment with an isotype control 
antibody did not have any impact while treatment our anti-Blo t 5 mAb induced a 















Figure 4.4: Serum Blo t 5-specific IgG1 levels. 
Serum Blo t 5-specific IgG1 levels were increased in untreated mice and mice 
treated with an isotype control antibody. Mice given the anti-Blo t 5 mAb, 
expectedly displayed a higher level of Blo t 5-specific IgG1, signifying successful 









4.2.3 Anti-Blo t 5 mAb treatment does not alter the inflammatory 
cytokine profile of BAL fluid except Eotaxin 
We have established that anti-Blo t 5 administration in this Blo t 5-induced severe 
asthma model brought about a decrease in total cell, more specifically eosinophil 
counts in the airways. In addition, the levels of serum total and Blo t 5-specific IgE 
of anti-Blo t 5 mAb treated mice were also found to be dramatically lower 
compared to untreated and isotype control treated mice. Hence, to further elucidate 
the mechanism behind the decrease in eosinophilia, BAL fluid were assayed for 
cytokines and chemokines. As shown in Figure 4.5, asthmatic mice displayed 
elevated levels of Eotaxin and signature TH2 cytokines, IL-4, IL-5 and IL-13, in the 
BAL fluid. BAL fluid originating from mice treated with anti-Blo t 5 mAb showed 
a reduction in eotaxin levels in comparison to the untreated and isotype control 
antibody group (Figure 4.5A). Interestingly, levels of IL-4 (Figure 4.5B) and IL-
13 (Figure 4.5D) remained unaffected with the treatment with our anti-Blo t 5 
while levels of IL-5 (Figure 4.5C) was lowered marginally but insignificantly with 













Figure 4.5: Chemokine & cytokine levels in BAL fluid. 
(A) Eotaxin levels detected by ELISA revealed that intra-nasal challenges with Blo 
t 5 induced an increase in eotaxin in the BAL fluid. Anti-Blo t 5 mAb 
administration led to a suppression in eotaxin to a level that is almost comparable 
to that found in naive mice. Levels of IL-4, IL-5, and IL-13 in the BAL fluid were 
also measured by ELISA. Anti-Blo t 5 mAb treatment resulted in a slight decrease 
in IL-5 levels (C) but not in the levels of IL-4 (B) and IL-13 (D).   




4.2.4 Anti - Blo t 5 mAb ameliorates airway inflammation, mucus 
hyper-secretion and airway remodelling  
The infiltration of immune cells comprising of mainly eosinophils and neutrophils 
represents one of the key drivers of airway inflammation. In the murine asthma 
model used in this study, intra-nasal challenges with Blo t 5 induced a state of 
inflammation in the airways characterized by pronounced thickening of the 
bronchial epithelium and massive infiltration of inflammatory cells into 
peribronchial and perivasular regions (Figure 4.6B). Anti-Blo t 5 mAb 
administration ameliorates epithelial thickening and inflammatory cell infiltration 
(Figure 4.6D). H&E stains were scored based on a previously published scoring 
system, and it is evident that treatment with anti-Blo t 5 mAb significantly 
decreased the overall inflammatory status of the airways (Figure 4.8A). 
Mucus hyper-secretion is another hallmark of an asthmatic airway. Goblet cell 
hyperplasia and mucus hyper-secretion contribute to airway obstruction and 
breathing difficulties. Periodic acid Schiff's staining, a staining method used to 
detect polysaccharides, mucosubstances and mucin, was used to examine the extent 
of mucus hypersecretion. A positive stain for mucus is indicated by pink staining. 
As denoted by the black arrows in Figure 4.7B, globet cell hyperplasia, mucus 
hyper-secretion and mucus plugging were observed in the lungs of severely 
asthmatic mice. This phenomenon was majorly alleviated when the mice were 
treated with the anti-Blo t 5 mAb (Figure 4.7D and Figure 4.8B).  
Finally, a central feature of chronic inflammation of the airways, as in chronic 
asthma, is airway remodelling. Repeated injury-repair mechanisms bring about 
structural changes that ultimately compromise lung function. One such change is 




the thickening of the basement membrane due to an increase in connective tissue 
surrounding the basement membrane. Masson's trichrome stain allows for the 
visualization of collagen and the extent of airway remodeling. Deposition of 
collagen fibres (denoted by blue staining), indicative of airway remodeling and 
fibrosis, was observed around the bronchi of the asthmatic mice (Figure 4.9B). 
Treatment with the isotype control antibody did not resolve the airway remodeling 
(Figure 4.9C) but anti-Blo t 5 mAb administration attenuated the extent of airway 


















Figure 4.6: Hematoxylin & Eosin (H&E) staining. 
Structural changes in the lungs were examined by H&E staining. In contrast to 
healthy mice (A), lungs of mice which receive the polarized TH2 cells and 
subsequently challenged with Blo t 5 revealed the thickening of the bronchial 
epithelium and the infiltration of immune cells to the peribronchial and 
perivascular regions (B). This phenomenon was also observed in mice treated with 
an isotype control antibody (C) but showed a marked improvement in mice given 
anti-Blo t 5 mAb treatment (D). 
  






Figure 4.7: Periodic acid Schiff's (PAS) staining 
Periodic Acid Schiff (PAS) was used to examine the extent of mucus 
hypersecretion and goblet cell hyperplasia in the lungs of asthmatic mice. Healthy 
controls (A) showed no visible signs of mucus whereas asthmatic mice displayed 
mucus plugging as denoted by the pink staining (black arrows) (B). Mice treated 
with the isotype control antibody showed no improvement in the amount of mucus 
in the airways (C). Anti-Blo t 5 treatment, however, ameliorated mucus 












Figure 4.8: Scoring for H&E and PAS stains. 
The H&E and PAS lung sections were scored according to previously published 
scoring systems and expressed as inflammation and mucus scores in arbituary 
units, respectively. It is evident that anti-Blo t 5 treatment was effective in reducing 
airway inflammation and in alleviating key asthma hallmarks like mucus 
hypersecretion. 
 





Figure 4.9: Masson's trichrome staining (MTS) 
Airway remodelling was assessed based on the deposition of collagen around the 
airways. Lungs of asthmatic (B) and isotype control treated mice (C) showed 
similar extents of airway remodelling (denoted by the blue staining). Mice treated 
with anti-Blo t 5 mAb showed notable improvement in the structural integrity of 
the lungs (D). 




4.3  Discussion 
For the past 100 years, animal models of asthma have traditionally utilized 
ovalbumin (OVA), a protein found in egg white, as the key sensitizing agent
108
. 
OVA conjugated with Alum (Aluminium hydroxide), was administered intra-
peritoneally to mice, followed by an aerosol challenge with the allergen of 
interest
108-110
. The presence of alum propels the immune responses towards the TH2 
phenotype
108
. Hence, murine models of asthma induced by OVA were able to 
recapitulate central features of allergic asthma including eosinophilia, increased 
serum IgE levels, mucus secretion and bronchoconstriction. These traits place the 
OVA model at the prime position when selecting a murine model of allergic 
asthma for the development of novel therapeutics. 
While proven effective and undoubtedly informative, asthma models induced by 
OVA is highly artificial as OVA is not known to cause any form of asthma in 
man
108
. Secondly, the intra-peritoneal route of sensitization is unrealistic as the 
common route of sensitization for man is through the respiratory tract and 
sensitization with OVA using the respiratory route has not been very successful
108, 
111
. Lastly, multiple studies have demonstrated that long term exposure to OVA led 
to a state of tolerance instead of aggravated disease
109, 110, 112, 113
. This hinders the 
possibility of utilizing the OVA asthma model to study airway remodeling and 
largely limits its relevance as asthma is a chronic respiratory disease.  
In the past decade, efforts have been channeled into establishing an asthma mouse 
model that bears closer resemblance to the asthmatic phenotype observed in 
humans. More importantly, the pathogenesis of human asthma has been shown to 




be strongly associated with sensitization to allergens originating from HDMs. One 
of the first optimized HDM-induced asthma models was generated by 
administering HDM extracts intra-nasally and displayed asthma-like lung 
inflammation with airway hyper-responsiveness and elevated serum IgE levels
114
. 
Furthermore, the usage of HDM extracts enables for intra-nasal sensitization and 
chronic exposure results in airway remodeling that more closely mimics the natural 
disease progression in humans. The availability of a highly relevant Blo t 5-induced 
murine asthma model enabled the investigation of the potential therapeutic effects 
of our mAb in the context of severe allergic asthma.  
Allergic inflammation in the airways of established murine asthma models is 
mediated by a complex interplay of allergen-specific IgE antibodies, TH2 family of 
cytokines and TH2-related immune cells. In the presence of TH2 cytokines IL-4 and 
IL-13, activated B cells undergo class switching to produce IgE
30
 which are then 
able to bind to their high-affinity receptor (FcεRI) present on effector cells such as 
mast cells, eosinophils and basophils
53
. Repeated exposure to the allergen results in 
the cross-linking of IgE and triggers the degranulation of mast cells. Degranulation 
of cells lead to a sudden release of inflammatory mediators such as histamine, 
prostaglandins and leukotrienes which are responsible for causing asthma 
symptoms such as bronchoconstriction and mucus hypersecretion
53, 108
. Antigen 
presentation cells like dendritic cells also express FcεRI and the engagement of 
these receptors by IgE promotes their migration to the regional lymph nodes where 
the processed antigens are presented to TH cells
30, 115
. IgE also binds to its low 
affinity receptor, CD23, expressed on the surface of activated B cells. Allergen-IgE 
complexes bound to CD23 promote facilitated antigen presentation (FAP) to TH 








Mice which received the passive transfer of TH2 cells and subjected to intranasal 
challenges of Blo t 5 protein showed a stark increase in serum total IgE and Blo t 5-
specific IgE, signifying a state of allergy. With the administration of our anti-Blo t 
5 mAb, we observed a five-fold reduction in the serum total IgE and significantly 
lower level of Blo t 5-specific IgE. This suppression of serum total and allergen-
specific IgE is indicative of dampened hypersensitivity and could have contributed 
to an alleviation of asthma symptoms. Interestingly, analysis of the BAL fluid 
revealed that levels of TH2 cytokines IL-4 and IL-13 remained largely unchanged, 
suggesting that our mAb could be negatively regulating IgE production via a 
different mechanism. 
One immune cell, the eosinophil, plays an elemental role in the pathophysiology 
and persistence of allergic asthma. The eosinophil develops in the bone marrow 
and the TH2 cytokine IL-5 is crucial in the maturation, differentiation, survival and 
function of the eosinophil
117-120
. In response to an aeroallergen, early degranulation 
of resident mast cells stimulates the vascular endothelial cells to secrete 
chemokines which promote eosinophil migration to the lungs and subsequent 
eosinophilia. Eotaxin (CCL11) is the major chemokine orchestrating the 
recruitment of eosinophils to the site of allergen exposure by binding specifically to 
its high affinity receptor, CCR3 expressed on the surface of eosinophils
121-124
. The 
synergism between IL-5 and eotaxin in promoting eosinophilia has been widely 
studied. Interleukin-5 was shown to prime eosinophils to chemoattractants whereas 
eotaxin was responsible for directing the actual migration to the site of 






. Hence, whilst IL-5 is critical for the development of 
eosinophils and potentially amplify the effects of chemokines on eosinophil 
migration, recruitment of eosinophils to specific tissues and their subsequent 
activity within these sites might be IL-5-independent
117
. 
In the Blo t 5-induced asthma model used in this study, the increment in total cell 
count in the airways could be attributed to an influx of eosinophils and to a lesser 
extent, neutrophils. We found that treatment with anti-Blo t 5 mAb significantly 
reduced the infiltration of eosinophils into the airways but did not have any impact 
neutrophilia. Eotaxin levels in the BAL fluid of mice treated with anti-Blo t 5 mAb 
were lower than their untreated and isotype control treated counterparts. There was, 
however, no difference in IL-5 levels between the untreated, isotype control treated 
and mAb treated groups. Given the well-defined roles of IL-5 and eotaxin in 
promoting eosinophilia, it is plausible that the presence of our anti-Blo t 5 mAb 
does not interfere with the priming of eosinophils. The diminished eosinophilia 
observed in mAb treated mice was therefore an effect of reduced chemotaxis to the 
airway due to lower levels of eotaxin present. 
Lastly, airway remodelling, consequent of repeated injury-repair processes, is 
commonly observed in chronic asthma. Structural changes including the deposition 
of extracellular matrix (ECM) proteins like collagen are prominent hallmarks of 
airway remodelling. Notably, eosinophils have also been shown to be important 
contributors to airway remodelling
19, 121, 128, 129
. Given the role of eosinophils in 
airway remodeling, the reduced eosinophilia observed with mAb treatment could 







IN VITRO APPLICATION OF ANTI-BLO T 5 














5.1  Introduction 
In the previous chapter, we examined the in vivo effects of our anti-Blo t 5 mAb in 
a murine model of severe asthma. We showed that the administration of anti-Blo t 
5 mAb decreased the influx of inflammatory cells, more specifically, eosinophils 
into the airways and dramatically suppressed serum total and Blo t 5-specific IgE 
levels. Also, lung histology displayed an improvement in structural architecture 
and reduced remodeling in the presence of anti-Blo t 5 mAb. These observations 
could potentially have contributed to an amelioration of asthma symptoms after 
intranasal aerosol Blo t 5 challenges.  
Experimental results discussed up to this point were obtained with the vanilla 
murine IgG1 monoclonal antibody generated via the hybridoma method. To assess 
if our anti-Blo t 5 mAb was capable of inhibiting human basophil activation, 
chimeric variants in which the originally murine constant region (Fc) of the 
antibody was replaced with human IgG constant domains were constructed. In 
addition, as the Fc domains of antibodies are crucial in orchestrating different 
downstream effector mechanisms due to differential binding to Fc receptors, we 
sought to examine the functional differences between the pro-inflammatory IgG1 
and the anti-inflammatory IgG4 subclasses. As such, in this chapter, we report the 
generation of chimeric anti-Blo t 5 monoclonal antibodies and explore their 
capacities in inhibiting allergen-induced basophil activation.  
 
 





5.2  Results 
5.2.1 Cloning and expression of chimeric anti-Blo t 5 antibodies  
We have constructed human IgG1, IgG1-LALA and IgG4-S228P chimeric versions 
of the anti-Blo t 5 mAb (Figure 5.1A). The IgG1-LALA variant carries a L234A 
and L235A double mutation which have been shown to reduce Fc receptor 
binding
130, 131
, while the IgG4-S228P variant carries a S228P mutation which 
reportedly eliminates the Fab arm exchange phenomenon commonly associated 
with IgG4 antibodies
132-136
.   
The variable regions of the heavy and light chains were amplified by PCR with 
specific primers. Additionally, these primers also contained restriction enzyme sites 
required for the insertion into the pTT5 expression vectors. Sequencing was 
performed at each stage of cloning to ensure that no mutations were introduced. 
Ligated heavy and light chain plasmids were co-transfected into HEK-6E 
suspension cells using polyethyleneimine (PEI). Expressed antibodies in the cell 
culture supernatants were then purified by affinity binding to protein A beads. 
Integrities of the purified antibodies were verified by SDS-PAGE under reducing 
and non-reducing conditions. The chimeric antibodies were assembled properly 
with a heavy and light chain (Figure 5.1B) and were correctly folded into full 
length IgG antibodies as depicted by bands at 150kDa and larger on a non-reducing 
gel (Figure 5.1C). 
 
  






Figure 5.1: Cloning and expression of chimeric anti-Blo t 5 mAb. 
Chimeric antibodies were constructed such that the original murine IgG1 Fc 
domain was replaced by a human IgG1, human IgG1-LALA and human IgG4-
S228P Fc domains (A). Plasmids containing the respective heavy and light chains 
were co-transfected into HEK-6E suspension cells. Antibodies were purified from 
culture supernatants with Protein A beads and were analyzed with SDS-PAGE 
under reducing (B) and non-reducing (C) conditions. Expressed antibodies all 
contained a heavy and a light chain as seen by the bands at 50 and 25 kDa, 
respectively (B). In addition, the chimeric antibodies were properly assembled into 
full-length antibodies as depicted by the band at 150kDa on the non-reducing SDS-
PAGE gel (C). 
  





5.2.2 Affinity determination of purified chimeric antibodies 
In order for the purified chimeric anti-Blo t 5 mAbs to be used for further 
experiments, it was important to ensure that they still bind to the Blo t 5 protein 
with the same or similar affinities. Hence, binding affinities of the purified 
chimeric anti-Blo t 5 antibodies were determined by performing an ELISA as 
described in Chapter 3 to verify that the specificity and affinity of the antibody are 
not adversely affected by the molecular manipulations. The ELISA plate was 
coated with recombinant Blo t 5 protein at different concentrations, followed by 
incubation with serially diluted anti-Blo t 5 chimeric antibodies. The respective 
binding curves for the different concentrations were plotted and antibody 
concentrations giving the half-maximal responses at different Blo t 5 
concentrations were determined. Using the above values, the affinity constant, KAFF 
and the dissociation constant, KD, could then be calculated. From the graphs shown 
in Figure 5.2, all the expressed and purified chimeric antibodies retained binding 
affinities to the Blo t 5 protein. The binding affinities of the human IgG1, human 
IgG1-LALA, and human IgG4-S228P variants to Blo t 5 protein were calculated to 
be 0.2268 x 10
-9
 M (Figure 5.2A), 0.1482 x 10
-9
 M (Figure 5.2B) and 0.6121 x 10
-
9
 M (Figure 5.2C) respectively.  
 






Figure 5.2: Affinity determination of purified chimeric antibodies by ELISA. 
The dissociation constant KD was calculated based on the binding curves obtained 
by serially diluting the different purified chimeric variants of the anti-Blo t 5 mAb 
and recombinant Blo t 5 protein.  





5.2.3 Basophil activation test (BAT) on human basophils  
Basophils are the rarest subset of cells found in the blood, with less than 1% of 
total white blood cell counts in healthy individuals. Despite their rarity, basophils 
are crucial effector cells in inflammatory reactions, especially in allergic diseases. 
Not only do they contribute to the manifestation of allergic symptoms through the 
release of immune mediators like histamine upon degranulation, they also play a 
central role in propelling the TH2 phenotype through the secretion of the key TH2 
cytokine, IL4. Hence, the inhibition of basophil activation may be useful in the 
pathogenesis of allergy. 
The Basophil Activation Test (BAT) is a sensitive and reliable in vitro test that 
relies on the usage of specific markers for basophil identification and the 
measurement of basophil activation by flow cytometry. The BAT has also been 
highly useful in allergy diagnosis. The schematic diagram (Figure 5.3) illustrates 
the experimental design of the BAT conducted in this study. The Chemoattractant 
Receptor homologous molecule expressed on TH2 lymphocytes (CRTH2) was 
chosen as the marker to identify basophils in whole blood. Whilst CRTH2, also 
known as the prostaglandin D2 receptor (DP2), is a transmembrane G-protein 
coupled receptor previously suggested as a highly specific marker for TH2 cells
137, 
138
, it was also found to be highly expressed on basophils and has also been verified 
as an accurate basophil marker in several studies
139
.  
The activation status of basophils was assessed by the expression of the marker 
CD63. CD63 is a member of the tetraspanin family of proteins. Originally 
identified as a platelet activation marker, CD63 was later found to be anchored in 





the histamine-containing granules within basophils
140
. Cross-linking of FcεRI by 
IgE-allergen complexes triggers the migration and fusion of granule vesicles with 
the plasma membrane and results in the release of inflammatory mediators such as 
histamine and leukotriene C4 to the extracellular space. This fusion between the 
granules and the plasma membrane during basophil degranulation also leads to the 
exposure of CD63 on the surface, making it detectable with antibodies
141
. As such, 
an upregulation in CD63 expression levels can be correlated with an increase in 
basophil activation and degranulation. 
Representative plots for two donors are shown in Figure 5.4. The lymphocyte 
population was gated on the forward-side scatter and the number of lymphocytes 
differed amongst individuals, with both donors having around an average of 3% 





 cells within the lymphocyte population. As 
highlighted earlier, CRTH2 is also expressed by TH2 lymphocytes. Hence, gating 
for HLA-DR- negative cells distinguishes the basophils from the T lymphocytes 
expressing CRTH2. Basophils were then observed as a distinct subset of cells. In 
both cases, this gating strategy reliably identifies basophils in whole blood and 














Figure 5.3: Schematic diagram illustrating the experimental design of the 
human basophil activation test (BAT). 
Basophils in whole blood will be identified by a positive staining for CRTH2, a 
prostaglandin D2 receptor found to be expressed exclusively on TH2 cells as well 
as basophils. Attributing to its expression on histamine-containing granules and its 
consequent exposure on the surface, an upregulation of CD63 expression is used to 











Figure 5.4: Representative plots depicting gating for basophils in whole blood. 
Basophil gating for two donors. A first gate was made around the lymphocyte 
population in the side scatter (SSC) versus forward scatter (FSC) plot. A second 
gate was then placed at the cell singlet population in the FSC-H versus FSC-A plot, 










5.2.4 Application of chimeric anti-Blo t 5 antibodies in BAT 
The BAT was employed to firstly, assess whether our chimeric anti-Blo t 5 mAbs 
were able to suppress basophil activation upon stimulation, and secondly, whether 
there are any differences in the antagonistic potentials of the different chimeric 
anti-Blo t 5 mAbs. As mentioned earlier, the chimeric constructs differ in their Fc 
domains which vary their binding to FcRs and may in turn contribute to differing 
inhibitive abilities.  
Donors were assayed for good anti-Blo t 5 and anti-Blo t extract IgE responses, and 
donors who were found to exhibit both favourable anti-Blo t 5 and anti-Blo t 
extract IgE responses were selected for the BAT experiment (Figure 5.5). Blood 
was collected in EDTA tubes and whole blood was stained with the antibody 
cocktail before stimulation. Stimulation was induced by the addition of whole B 
tropicalis mite extract and was allowed to proceed for 30mins at 37°C. 
Representative plot depicting basophil activation is shown in Figure 5.6. Basal 
expression of CD63 was low for unstimulated basophils (Figure 5.6A). As a 
positive control, anti-IgE was added to activate the basophils by cross-linking 
surface IgE bound to FcεRI. In comparison with unstimulated cells, the addition of 
anti-IgE resulted in an approximately 10-fold increase in basophil activation as 
reflected by the increase in CD63 expression (Figure 5.6B). Similar level of 
activation was also observed when the basophils were incubated with Blo t whole 
mite extract (Figure 5.6C). Basophil activation for donors used in this study are 
expressed as stimulation indexes with respect to the unstimulated (Figure 5.6D). 





The next step in the BAT experiment was to determine whether the anti-Blo t 5 
chimeric mAbs were able to antagonize allergen-induced basophil activation, and 
should they inhibit basophil activation, whether the different Fc domains 
contributed to any notable differences in antagonistic ability. To accomplish this, 
different concentrations of each chimeric antibody variant were added to the 
stimulation mixture and the samples were subsequently analyzed by flow 
cytometry. 
Presence of the anti-Blot 5 chimeric antibodies elicited an inhibition on basophil 
activation as depicted by the stimulation indexes in Figure 5.7. The degree of 
inhibition seemingly differs amongst donors, with two donors exhibiting a  
reduction in basophil activation (Figure 5.7A and Figure 5.7B). This inhibition 
was, however, not observed for one of the donors (Figure 5.7C). Lastly, figure 
5.7D shows the summarized BAT results for all four donors with inhibition of 
CD63 expression calculated as percentages. Co-incubation with the chimeric anti-
Blo t 5 antibodies elicited an inhibition in BAT in comparison with the isotype 
control used at the highest concentration (100ug/ml). Interestingly but not 
unexpectedly, the degree of inhibition is highest for the human IgG4-S228P variant 












Figure 5.5: Donor serum screening for anti-Blo t 5 and anti-Blo t extract IgE 
responses. 
ELISA plates were coated overnight with recombinant Blo t 5 protein or Blo t 
whole mite extract and incubated with sera from nine donors. Anti-Blo t 5 and anti-
Blo t extract IgE were then detected and donors exhibiting favourable IgE 
































































Figure 5.6: Representative plots depicting basophil activation. 
Unstimulated basophils express CD63 at a low level (A). Upon IgE cross-linking 
by anti-IgE, CD63 expression is dramatically upregulated (B). Incubation with Blo 
t whole mite extract activates basophils to a similar extent as anti-IgE (C). CD63 
expression on basophils from selected donors in the presence of anti-IgE and Blo t 
extract are expressed as stimulation indexes in comparison to unstimulated 
(incubation with PBS only) (D).   
 
 






Figure 5.7: Inhibition of basophil activation by anti-Blo t 5 chimeric 
antibodies 
The presence of anti-Blo t 5 chimeric antibodies inhibits basophil activation to 
different extents. Basophils from donor 5 (A) were inhibited to a lesser extent than 
donor 8 (B) and to a larger extent as compared to donor 9 (C). Inhibition of CD63 









5.3  Discussion 
Since its development in 1991 by Knol et. al, the BAT is currently widely utilized 
in various aspects of allergy studies. The BAT has been validated as a specific 
means to diagnose many IgE-mediated allergic diseases including allergies to food 
products
142-146
, drugs like antibiotics
146-150
 and venom hypersensitivity
146, 151-153
. In 
addition, the BAT was also shown to be a reliable diagnostic tool for inhalant 





More recently, the application of the basophil activation test was extended to 
monitoring the success of immunotherapy
146, 157-159
.  
Based on its superior sensitivity, we have chosen the flow cytometry-based 
basophil activation test as the in vitro functional assay for examining the chimeric 
anti-Blo t 5 mAbs. Traditionally, a common strategy to identify basophils in whole 
blood samples was by staining for surface IgE. However, significant inter-
individual variability for surface IgE expression and other immune cells such as 
monocytes and dendritic cells have been shown to also express IgE
146, 160, 161
 make 
surface IgE an unfavourable marker for identifying basophils from whole blood 
samples.  
In contrast, surface expression of CRTH2 is restricted to basophils, eosinophils and 
T lymphocytes. Basophils can be easily differentiated from eosinophils based on 
the size scatter and further separated from T lymphocytes with the use of a 
secondary marker like HLA-DR or CD3. Whilst the use of this gating strategy for 
basophil recognition has not been widely reported, studies employing this method 
have validated its accuracy and reliability. In congruence with what has been 





reported thus far, we have shown that this gating strategy readily distinguishes 
basophils as a distinct population of cells in whole blood and that this method of 
basophil identification is reproducible for all the donors tested in this study. 
The release of histamine, leukotrienes and other mediators from basophil 
degranulation occurs via two known pathways - Anaphylactic degranulation 
(AND) and piecemeal degranulation (PMD). AND involves the fusion of 
histamine-containing granules to form large degranulation sacs which then directly 
fuse with the plasma membrane for the release of its contents
162, 163
. On the other 
hand, PMD involves the shuttling of small vesicles to the plasma membrane
162, 163
. 
As such, AND is associated with gross morphological changes and is a rapid 
secretory event which is completed within minutes of stimulation
162
. The fusion of 
large granules with the plasma membrane for the extrusion of mediators also 
allows for CD63 to be expressed on the surface of basophils
163-165
. Hence, several 
studies have linked the expression of CD63 to AND occurrence. 
While both AND and PMD have to be considered when examining total histamine 
release during a basophil degranulation event, the trigger for AND appears to be 
IgE-mediated as anti-IgE was found to be the strongest stimulus for AND in 
basophils
162
. As such, the contribution of AND to histamine release in a type I IgE-
mediated hypersensitivity coupled with the relationship between AND and CD63 
expression makes CD63 a highly relevant basophil activation marker. 
In this study, chimeric anti-Blo t 5 antibodies were constructed by molecular 
engineering and the purified chimeric variants did not perform differently from its 
murine counterpart. The expressed chimeric anti-Blo t 5 antibodies were  then 





tested for their ability to inhibit allergen-induced basophil activation in which 
increasing concentrations of chimeric antibodies or isotype control antibody were 
pre-incubated with B tropicalis extract. Following which, basophils obtained from 
B tropicalis sensitized donors were then exposed to the antibody-allergen mixture. 
We found that incubation of the B tropicalis extract with all variants of chimeric 
anti-Blo t 5 mAbs inhibited allergen-induced CD63 expression on basophils. 
Furthermore, the IgG4-S228P variant appeared to be the strongest antagonist in 
comparison to the other two IgG1 variants. 
As highlighted earlier, successful SIT relies on the induction of protective allergen-
specific IgG antibodies, particularly of the IgG4 subclass
96, 166-168
. While their 
protective role in allergy is still widely debated, IgG4 antibodies arguably act as 
blocking antibodies in allergy by competing with IgE for allergen binding, 
blocking the release of inflammatory mediators from activated mast cells and 
basophils and decreasing the IgE-mediated antigen presentation ability of B cells to 
T cells
166, 169, 170
. Moreover, IgG4 is able to bind to IgE-allergen complexes and 
subsequently bind to FcγRIIB receptors to inhibit degranulation of effector cells169. 
The allergen-blocking activity of the IgG4 subclass of antibodies can also be 
enhanced by the Fab arm exchange reaction, which result in bispecific antibodies 
that are functionally monomeric
96, 97, 171
. These properties are in favour of the 
development of a non-responsive immune system when it encounters the allergen.  
Since the IgG4-S228P variant has a point mutation which prevents the Fab arm 
exchange phenomenon, the contribution of the Fab arm exchange reaction to its 
antagonistic capacity may be discounted. Moreover, the IgG1-LALA, which does 
not bind Fc receptors as well as the wild-type IgG1 variant, exhibited better 





inhibitive capability. Our results therefore suggest that the binding to FcγR may 
instead play a more major role in regulating basophil activation. Additionally, our 
data also hints at the likelihood of utilizing IgG4 antibodies as antagonists in 
allergic diseases by modulating basophilic activity. 
We noticed some heterogeneity in the ability of anti-Blo t 5 chimeric antibodies to 
inhibit basophil activation. The extent of inhibition appeared to be stronger for 
some donors than others. This heterogeneity could potentially be explained by 
several reasons. Firstly, the presence of a plethora of antigenic proteins in the 
whole mite extract used. While Blo t 5 is the major allergen, it is evident that 
blocking Blo t 5 alone is insufficient to fully suppress basophil activation as donors 
may also be sensitized to other allergenic components in the extract. Secondly, the 
activation of basophils is influenced not only by the amount but also the diversity 
and affinity of Blo t 5-specific IgE. Given that Blo t 5 has reportedly two major IgE 
binding epitopes, it is possible that the binding of our anti-Blo t 5 to a single 
epitope is inadequate in causing a complete inhibition. This is especially so if the 
IgE response of an individual to Blo t 5 is heterogeneous.  
Nonetheless, we have shown that targeting the major allergen may serve to dampen 
basophil activation in the presence of a clinically relevant stimulus and our data 
provides a strong indication that the usage of IgG4 antibodies as anti-allergenic 







GENERATION OF FULLY HUMAN ANTI-













6.1  Introduction 
In the previous chapters, we have reported the generation of a mAb targeting Blo t 
5, the major allergen of Blomia tropicalis and described its antagonistic ability in 
vivo in a murine model of severe allergic asthma. Using molecular cloning 
techniques, we have also constructed chimeric variants of this anti-Blo t 5 mAb in 
which the Fc regions were replaced with human Fc and investigated their capacity 
in inhibiting human basophil activation upon allergen stimulation. 
While chimeric and humanized mAbs have been immensely useful as therapeutics, 
their utility in the clinical setting is still largely limited by immunogenicity 
originating from the non-human portions. Conversely, these concerns would not 
apply for antibodies derived directly from humans. In the recent endeavors to 
antibody discovery, several other novel high throughput screening techniques 
resulting in fully human antibodies have emerged and one of the means by which 
fully human antibodies may be isolated is by phage antibody display.  
The phage display methodology involves the expression of the antigen binding 
fragments (Fab) of antibodies on the surface of filamentous phage via fusion with 
the phage coat protein. Immune libraries constructed from individuals or 
convalescent patients represent the Fab repertoire from which high affinity 
antibodies against specific targets can be isolated.Based on a protocol optimized by 
our collaborators at DSO, we constructed an IgG immune library from an asthmatic 
individual who is highly allergic to HDMs. Using this immune library, we sought 
to isolate fully human antibodies targeting the major allergens of D pteronyssinus. 





6.2  Results 
6.2.1 Construction of a human immune library 
The workflow of constructing a human immune library is outlined in Figure 6.1. B 
cells were purified from whole blood obtained from an allergic donor using the 
EasySep™ Human B Cell Enrichment Kit. Isolated B cells were assessed for purity 
and phenotype by staining with anti-CD3, anti-CD19 and anti-CD27 antibodies and 
subsequently analyzed by flow cytometry. Live lymphocytes (52.2%) were selected 
by forward and side scatter. 99.9% of the live cells were CD3- and CD19+, 
indicating the high purity of B cells without contamination by any T cells (Figure 
6.2B). In addition, memory B cells constituted 23.7% of the total B cell population 
purified as identified as being double positive for CD19 and CD27 (Figure 6.2C). 
RNA was extracted from the entire population of isolated B cells and reversed 
transcribed. After which, variable regions of the heavy and light chains belonging 
to the IgG, kappa (κ) and lambda (λ) subclasses respectively, were amplified by 
two rounds of PCR. By utilizing reverse primers which bind the IgG constant 
region, the first round of PCR amplifies the IgG-derived heavy chain variable 
regions, respectively (Figure 6.3A). PCR products from the first round were 
subjected to a second round of PCR, with a concoction of primers binding to the J-
regions of the heavy chain variable regions. In addition, primers used in the 
secondary PCR contained SfiI and XhoI restriction sites for subsequent cloning 
(Figure 6.3B). The light chain variable genes of kappa and lambda families were 
amplified using forward primers binding to the beginning of the variable domains 
and reverse primers which bound the kappa and lambda constant domains, 





respectively. Similarly, light chain PCR products were re-amplified with primers 
tagged with AscI and ApaLI restrictions (Figure 6.3B). 
The two-step cloning method was adopted in this study as it was described to be 
efficacious for generating large sized and diversified libraries
172
. As such, separate 
libraries were first constructed for the heavy and light chain. The heavy chain 
repertoire was then digested and cloned into the phagemid vector containing the 
light chain repertoire to obtain a combined library of vectors inserted with both the 
heavy and light variable domains. In order to assess the diversity of the library, 24 
clones were picked from each the heavy and light chain libraries and sequenced. 
Sequences were validated using the IgBLAST database and classified according to 
their V-D-J gene families for heavy and V-J gene families for light chains. The 
number of clones with unique gene sequences can then be calculated. As shown in 
Table 6.1, the heavy and light chain libraries contained 660,625 and 346,920 
unique clones respectively, and the combined library had over 10 million clones 
possessing unique heavy and light chain variable domains. 
Equipped with this immune library, we seek to isolate fully human antibodies 
targeting Der p 1, Der p 2 and Der p 5, the major allergens originating from the 












Figure 6.1: Schematic diagram of human immune library construction. 
Blood was collected from an asthmatic donor who is highly sensitive to house dust 
mites. B cells were isolated and total RNA was extracted. Extracted RNA was 
reverse transcribed and the V-regions of heavy and light chains were amplified by 
PCR using specific primer pairs. The heavy and light chain libraries were 
constructed separately by cloning the V-regions into pCES-1 phagemid vectors and 
electroporated into TG1 bacteria. A final combined library was made by cloning 
the heavy V-regions into the phagemid vector containing the light variable 
domains. The plasmid vector was then again electroporated into TG1 bacteria. TG1 
bacteria bearing the phagemids were infected with M13KO7 helper phages. The 
resultant infected phages expressing the heavy and light variable domains on the 
surface were recovered for subsequent selection processes.  
 






Figure 6.2: Qualitative analysis of B cells isolated from whole blood. 
Live lymphocytes were gated on the forward and side scatter (A) and purified B 
cells identified as CD3-CD19+ cells, constituted 99.9% of the cell population 
analyzed (B). Phenotypes of the isolated B cells were also assessed and close to 










Figure 6.3: PCR amplification of heavy and light chain variable domains. 
(A) Total mRNA extracted from the B cells of the donor was reverse transcribed to 
cDNA, followed by two rounds of PCR amplification. Primers were designed to 
amplify the variable regions of the heavy and light chains. The second round of 
PCR was conducted with primers containing restriction sites for subsequent 
cloning into the pCES phagemid vector. PCR products were run on an agarose gel 










6.2.2 Panning of the human immune library 
The constructed human immune library was panned against Der p 1, Der p 2 and 
Der p 5 for four rounds each. Figure 6.4A depicts the panning cycle. Antigens Der 
p 1, Der p 2 and Der p 5 were immobilized overnight on immunotubes and blocked 
with skimmed milk. Following which, polyclonal phages expressing the Fab 
domains of the immune library on the pIII protein were allowed to bind. Unbound 
phages were removed by washing and bound phages were eluted with trypsin. An 
aliquot of the eluted phages were frozen and stored, while the remainder was used 
to re-infect TG1 bacteria for the next round of selection.  
Panning was carried out for the three major allergens of D pteronyssinus, namely 
Der p 1, Der p 2, and Der p 5. Four rounds of panning was performed for each of 
the antigen and eluted polyclonal phages were verified for enrichment of specific 
phages by ELISA after the final round of panning. In comparison to the unpanned 
library, the panning process resulted in a significant enrichment in the Der p 1-
specific (Figure 6.4B), Der p 2-specific (Figure 6.4C), and Der p 5-specific 
(Figure 6.4D) phages. Cross-reactivity of the polyclonal phages obtained from the 
panning process was assessed by incubating the phages with the respective 
antigens. As shown in Figure 6.4B and Figure 6.4C, polyclonal phages obtained 
from panning were relative specific to Der p 1 and Der p 2, respectively, with low 
cross-reactivity to other closely related antigens. Similarly, panning with Der p 5 
gave rise to polyclonal phages which were specific for only Der p 5 and not for its 
homologue Blo t 5 (Figure 6.4D). 
  








Figure 6.4: Panning procedure for isolation of Der p 1, Der p 2 and Der p 5-
specific phages. 
(A) Schematic illustration of the panning process. Briefly, immunotubes were 
coated overnight with 10 μg/ml of antigen before blocking with skimmed milk. 
Following which, immunotubes were incubated with the phages. Unbound phages 
were subsequently removed by washing and bound phages were eluted with 
trypsin. Eluted phages were used to infect new E.coli cultures for further 
amplification of allergens-specific phages. After four rounds of panning, polyclonal 
phages were verified for binding activity to (B) Der p 1, (C) Der p 2, and (D) Der p 
5. Panning successfully enriched for phages specific for the respective allergens. 
Furthermore, there was limited cross-reactivity to other related allergens. 
  





6.3  Discussion & Future Work 
Since its introduction by George Smith in 1985
173
, phage display has 
revolutionized the methods employed for antibody discovery. The phage display 
technology allows for the isolation of antigen binding fragments of antibodies. This 
process is conducted entirely in vitro, with no immune system required during the 
isolation process
174
. This bypasses the laborious processes of animal immunization 
and Epstein-Barr Virus (EBV) immortalization of human antibody-secreting B 




The phage display technique involves the creation of libraries which contain a large 








. In our study, we 
have constructed a human IgG immune library from an individual who is highly 
allergic to the major allergens of the HDM D. pteronyssinus. This immune library 
consists of over 10 million unique heavy and light variable chain pairings. Given 
the high levels of diversity, these immune libraries are extremely useful for the 
isolation of high affinity antibodies against targeted antigens. By carefully 
designing the biopanning process, we have successfully enriched for polyclonal 
phages specific for the clinically important Der p allergens. Moreover, cross-
reactivity to the related allergens remained low, highlighting the robustness of this 
methodology. Future work on this immune library include the isolation of 
monoclonal phages and the conversion of the monoclonal phages to full length 
IgGs. 





Analyzing the binding epitopes of the isolated antibodies from this IgG Fab library 
may reveal the presence of immunodominant epitopes on the allergens. These 
characterization data will provide insights into the immune mechanisms that shape 
T and B cell responses towards allergens. Apart from generating an IgG immune 
library, this technique also potentially paves the way to understanding IgE 
responses to allergens. Traditionally, studies conducted on IgE antibodies were 
impeded by the rarity of IgE and IgE-producing B cells in human serum and blood, 
respectively
178
. These challenges were circumvented with the technique of 
constructing IgE immune libraries. Steinberger and colleagues (1996) first 
constructed a Fab IgE library from the peripheral blood of a patient who was 
allergic to grass pollens
179
. Following which, several groups have attempted at 
generating IgE immune libraries and screening against different allergens such as 
egg proteins
180
 and Der p 2
181
. Moreover, IgE antibodies isolated from the panning 
of IgE immune libraries were reportedly a decent representation of the specificities 
of serum IgE present in the patient
182
.  
With the necessary expertise and reagents in our lab, we can also generate an IgE 
immune library which can then be employed in the panning process against the 
same allergens as the IgG immune library. Similar characterization work will then 
be carried for the IgE antibodies pulled out after panning to determine their binding 
epitopes. It would be an interesting investigation as to whether the IgE and IgG 
antibodies target similar epitopes on these allergens. The presence of common 
epitopes not only hints at the potential of using these IgG antibodies as therapeutic 
agents, it could also potentially influence the way house dust mite peptide 




















Allergic asthma is a respiratory disorder which affects a sizable proportion of the 
world's population. Individuals suffering from allergic asthma often exhibit 
observable difficulties in breathing and wheezing as result of bronchoconstriction, 
mucus hypersecretion and airway hyper-reactivity. Allergic asthma is perpetuated 
by chronic inflammation of the airways attributing to a dysregulated and often 
skewed immune response towards the TH2 phenotype.  
Singapore has one of the highest asthma fatality rates in the world
9
. 
Epidemiological studies have established an intricate link between sensitization to 
house dust mite (HDM) allergens and the development of allergies, with more than 
90% of atopic population sensitized to Blomia tropicalis, Dermatophagoides 
pteronyssinus or both
183
. Owing to their ubiquitous presence, constant exposure to 
high concentrations of HDM allergens all year round, tropical countries are 
experiencing a phenomenon known as 'mite fever' whereby HDMs are the major 
cause of respiratory allergies
184
. Despite their co-existence and dual sensitization 
profiles, IgE responses targeting allergens originating from B. tropicalis have 
limited cross-reactivity with allergens from D pteronyssinus
43, 185, 186
.  
As highlighted in the introduction, pharmacological agents only serve to provide 
symptomatic relief. Allergen-specific immunotherapy (SIT) remains the only 
disease-specific therapy available that can alter the course of allergic disease with 
long-term protective effects. The goal of SIT - to establish a state of immuno-
tolerance to the specific allergen, has remained constant over the years regardless 
of changes to the route of administration and formula
168
. While SIT for HDM 
allergy has proven relatively efficacious in some instances, this form of therapy is 
nonetheless limited by several factors.  





Firstly, the traditional SIT involves the administration of allergen extracts 
subcutaneously (SCIT). This route of administration has to be performed by a 
highly trained individual and may cause adverse systemic side effects such as 
anaphylaxis
187, 188
. The sublingual route (SLIT) of allergen extract administration 
was introduced as part of efforts to improve the safety profile of immunotherapy 
with whole HDM extracts. Yet, SLIT is significantly plagued with issues such as 
consistencies in extract formulation, dosage standardization and patient adherence.  
Secondly and more importantly, the fundamental aspect of SIT is the modification 
of the immune system such that hypersensitivity to the allergen is dampened. 
However, the use of allergen extracts in SIT often induce a diversity of polyclonal 
IgG antibodies with varying specificities and reactivity. A proportion of IgG 
antibodies engendered by SIT do not react with allergens, while some may 
recognize allergens but are incapable of blocking IgE
189, 190
. Furthermore, 
Denepoux and colleagues (2000) have reported that the presence of non-blocking 
allergen-specific IgG antibodies may enhance IgE binding to allergens and can 
potentially aggravate the anaphylactic reaction
191
. 
In view of these shortcomings, the search for the best therapeutic strategies for 
allergic disease is still ongoing. Current studies on allergen-SIT has undoubtedly 
contributed to the understanding of how our immune system responds to invading 
allergens and are crucial in the design of future therapies for allergic diseases. The 
induction of allergen-specific IgG antibodies over the course of immunotherapy 
has hinted at the possibility of utilizing this as a strategy. Ideally, allergen-specific 
IgG antibodies which have the correct epitope specificity and can inhibit IgE 









The governing aim for this study was therefore to explore the potential of utilizing 
allergen-specific monoclonal antibodies as a novel treatment modality for HDM-
driven allergic asthma. To achieve this, we first required an antibody candidate 
which ideally exhibits exquisite specificity and affinity for a clinically relevant 
allergen. The allergen of choice for this study was Blo t 5, the major allergen of 
HDM species B tropicalis. Blo t 5 was chosen based on its widespread sensitization 
profile, prevalence in the tropics and its close association to the pathogenesis of 
allergic asthma. In addition, with an optimized protocol, we were able to stably 
express and purify recombinant Blo t 5 from E coli cultures.  
The classical hybridoma technology was exploited to generate the Blo t 5-specific 
monoclonal antibodies. Despite the low percentage of anti-Blo t 5 positive 
hybridoma clones, selected polyclonal antibodies displayed good binding activity 
to Blo t 5. After several rounds of subcloning by limiting dilution, the monoclonal 
antibody candidate subsequently used in this study was selected based on superior 
binding affinity to the Blo t 5 protein. Epitope mapping studies with western and 
immuno-dot blot revealed that this mAb binds a linear epitope on an exposed 
surface of the Blo t 5 protein. As highlighted in Chapter 3, our antibody targets a 
region of Blo t 5 previously implicated as a conformational IgE binding epitope
49
. 
As such, we assessed the antagonistic potential of our mAb in an inhibition ELISA 
with sera from a Singaporean cohort of Blo t 5-sensitized patients. We observed a 
dose-dependent inhibition of Blo t 5-specific IgE binding from allergic patients' 
sera when co-incubated with increasing concentrations of anti-Blo t 5 mAb.  





One critical mechanism through which protective antibodies elicited by successful 
allergen-specific immunotherapy can exert their anti-allergic effects is to compete 
with IgE for allergen binding. Competition with free and cell-bound IgE for 
allergen binding allows for the inhibition of effector cell degranulation and IgE-
facilitated antigen presentation to T cells and subsequent T cells activation
166, 189, 
190, 192
. Studies conducted by Pree et al. (2007) and Gardermaier et al. (2010a) have 
proven that it is unnecessary for protective IgG antibodies induced by allergen-
specific immunotherapy to target exactly the same epitopes as those targeted by 
IgE. These antibodies are still capable of inducing protective effects if they bind 
overlapping parts of the IgE epitopes or cause sufficient steric hindrance such that 
IgE antibodies can no longer bind
193, 194
. In concordance with these findings, results 
from epitope analysis and inhibition ELISA implicate that the competitive capacity 
of our anti-Blo t 5 mAb could be attributed to the steric hindrance brought about by  
binding to an overlapping IgE epitope. 
With this, we proceeded to examine the in vivo effects of mAb treatment in a 
murine model of Blo t 5-driven severe allergic asthma. In collaboration with Prof. 
Kemeny's group, the murine asthma model used in this study involves the transfer 
of polarized Blo t-5 specific TH2 lymphocytes and subsequently challenging the 
mice intra-nasally with Blo t 5 protein. In Chapter 4, we reported the impact of 
anti-Blo t 5 mAb treatment on airway inflammation, serum IgE and lung 
architecture. Anti-Blo t 5 mAb treatment lowered the infiltration of eosinophils into 
the airways as a result of suppressed eotaxin levels. In addition to suppressing total 
and Blo t 5-specific IgE in the serum, mAb treatment also evidently alleviated 
airway remodelling which accompanies severe asthma. Most importantly, we 





showed that mice receiving the anti-Blo t 5 did not exhibit any observable 
asthmatic symptoms as compared to the untreated and isotype control treated mice.  
The usage of allergen-specific antibodies as treatment modalities in allergic asthma 
models have been previously described. Yoshino et al. (2014) examined the use of 
OVA-specific monoclonal Fabs obtained from papain cleavage in an OVA-driven 
asthmatic model and found that intra-tracheal administration of OVA-specific Fabs 
downregulated asthmatic responses
195
. The same author also described the use of  
monoclonal Fabs specific for the major allergen of Japanese Cedar Pollen (JCP) in 
an allergic rhinitis murine model induced by JCP. They reported a decrease in mast 
cells, eosinophils and goblet cell hyperplasia with the treatment of the Fabs
196
. 
Similarly, Flicker et al. (2012) demonstrated that passive immunization with 
allergen-specific IgG polyclonal antibodies was capable of treating and preventing 
pollen-induced respiratory allergies in mice
197
. 
To our knowledge, no study has explored the effects of administering allergen-
specific full-length IgG1 monoclonal antibodies in animal models. Murine IgG1 
antibodies have a debatable role in allergy. Whilst they were reported to potentially 
worsen asthma symptoms and enhance the risk of systemic anaphylaxis
133, 198
, other 
studies have described the anti-inflammatory properties of these antibodies in 
allergic asthma based on the binding preference to low affinity inhibitory FcγR 
(FcγRIIB)199, 200. In line with the latter, our results have detailed the therapeutic 
effects of administering allergen-specific murine IgG1 mAb in severe allergic 
asthma driven by a clinically relevant HDM allergen, Blo t 5.     





To support the results obtained from the in vivo study, we next sought to study the 
in vitro effects of our anti-Blo t 5 mAb on human basophil activation. The anti-Blo 
t 5 murine mAb was engineered to generate chimeric variants in which the Fc 
domains were substituted with the Fc portions of human IgG1 and IgG4 subclass 
antibodies without adversely affecting their binding affinity to Blo t 5. The 
chimeric antibodies were next investigated for their ability to inhibit human 
basophil activation upon allergen stimulation and we found that the human IgG4-
S228P variant was the strongest inhibitor.  
The notion of IgG4 being protective anti-allergic antibodies is not a recent one. 
Back to the 1980s, Aalberse et al. (1983) first reported that the therapeutic effects 
of SIT were mainly attributed to allergen-specific IgG4 antibodies
201, 202
. Similarly, 
Nakagawa and Miyamoto (1985) have also pointed out the correlation between 
increases in IgG4 levels post-immunotherapy and their role as blocking antibodies 
in asthmatics and in bee keepers
203
. Works on delineating the role of IgG4 as 
blocking antibodies are still largely ongoing till this day. In the recent years, 
various studies have surveyed patients who have undergone successful 
immunotherapy for food allergens like peanut
204
 and aeroallergens like HDM
205
. In 
support of findings reported more than two decades ago, these studies have 
consistently pinpointed a correlation between raised levels of IgG4 antibodies and 
an improvement in clinical symptoms including reduced use to medication.  
Despite evidence supporting the benefits of IgG4 blocking antibodies, studies have 
also revealed no real correlation between the increases in IgG4 levels and 
improvements in clinical symptoms
102, 188
. Hence, quantitative measurements of 
IgG4 levels might not be the optimal surrogate marker for determining the success 







. Instead, functional assays demonstrating the blocking 
capacity of IgG4 antibodies are of considerable importance and may better reflect 
clinical efficacy
102
. As such, in this study, we have employed a functional assay to 
examine differences in inhibitory effects between the different chimeric variants. 
We believe that the findings from this assay are therefore more translatable to 
clinical efficacy as compared to conventional inhibitions assays. 
IgG4 is the only IgG subclass antibody that binds both FcγRIIb and the activating 
FcγRs with equal affinity206. In contrast, IgG1 antibodies are skewed towards 
binding to activating FcγRs. The inhibition of effector cell responses can result 
from the co-ligation of FcγRIIb with the activating FcγRs207, 208. To this date, it 
remains uncertain whether the interaction of allergen-specific IgG4 and FcγRIIb 
has the potential to block FcεRI signalling. Kepley et al. (2000) showed that the 
cross-linking of FcγRIIb with FcεRI leads to an inhibition of IgE-mediated 
basophil activation
209
. Given the limited current understanding of the interactions 
between IgG4 and FcγRII receptors, it is challenging to draw conclusions on 
whether the inhibition we have observed in our basophil activation test is a 
FcγRIIb-mediated inhibition. Owing to its superior affinity, it is more likely that 
the inhibitory effect we observed is attributed to a direct competition between our 
IgG4 antibodies and receptor-bound IgE for allergen binding. Nonetheless, we 
have included the human IgG1-LALA chimeric variant in our study and showed 
that it is more capable of inhibiting allergen-induced basophil activation than its 
wild-type counterpart. As such, our data hints at the possibility that FcγR 
interactions were involved in orchestrating basophil activation. More confirmatory 





studies would have to be carried out to further elucidate the FcγRII-related 
mechanisms behind this observed antagonism. 
Another aspect that we addressed as part of the human basophil activation test was 
whether the antibody subclass is a crucial determinant of the inhibitory activity. 
Dodev and colleagues proposed, using antibodies with identical specificities but 
different subclasses, that antibody specificity is the critical factor to effectively 
inhibit the cross-linking of IgE receptors by competing for allergen binding
210
. In 
our study, the use of IgG1 and IgG4 antibodies allowed us to discriminate between 
these two subclasses. Our data revealed that IgG4 antibodies performed slightly 
better as antagonists when compared to IgG1. While it would have been more 
informative to include the other subclasses as part of this study, our main 
motivation to examine IgG1 and IgG4 stems from the fact that these two are the 
main subclasses of IgG antibodies that are commonly elevated after allergen 
immunotherapy. Since our IgG1 and IgG4 anti-Blo t 5 chimeric antibodies do not 
differ vastly in their binding affinities to Blo t 5, we can speculate that this 
difference in antagonistic capacity lies in the interactions with FcγRs. 
In the final chapter, Chapter 6, we described the construction of a human immune 
library generated from a donor who is highly allergic to HDM D pteronyssinus. We 
also showed that this immune phage library is robust enough to isolate polyclonal 
phages with targeted specificities for the major allergens of D pteronyssinus, 
namely Der p 1, Der p 2 and Der p 5. Moreover, the panning procedure was 
successful in minimizing cross-reactivity of isolated phages to the different 
antigens used in the panning process. Future work on this library would include the 





isolation of monoclonal phages specific for the above-mentioned allergens and the 
cloning and expression of the selected phages into fully human full-length IgGs. 
Whilst chimerization and humanization of mAbs have greatly improved the safety 
profiles of mouse-derived antibodies and have led to the birth of many therapeutic 
agents, the existence of murine components in these antibodies still result in 
considerable immunogenicity. As such, therapeutic strategies in the biologics 
sphere are gearing towards fully human monoclonal antibodies. Recent 
technologies have revolutionized the development and isolation of fully human 
antibodies. Some of the newer methods through which fully human antibodies are 
derived include the usage of transgenic mice, single B cell screening and Next 
Generation Sequencing (NGS). Despite this, phage display remains an attractive 
option owing to its ease of manipulation and cost-effectiveness
177
. In addition, once 
the phage library is constructed it can be easily stored for prolong periods of time 
and is sufficient for multiple rounds of screening
177
. On the other hand, other 
methods either involve the destruction of samples or are limited by the definite 
antibody production as in single B cell screening
177
. 
As such, this human immune library which we have constructed would be 
immensely useful whether for the isolation of fully human antibodies against  
selected allergen or mapping the human antibody repertoire developed against key 
HDM epitopes. Resolving the immunodominant epitopes on allergens could 
potentially provide deeper insights into the immune responses engendered upon 
allergen encounter and can potentially influence the way treatments are 
administered for allergic diseases. 





In conclusion, we have shown in this study that allergen-specific monoclonal 
antibodies have the potential to be used as therapeutic agents in allergic diseases 
driven by well-defined allergens. The next step would be to perform clinical studies 
directly in allergic patients. To accomplish this, technologies, like phage display, to 
generate fully human allergen-specific monoclonal antibodies will be of great 
utility. Equipped with fully human allergen-specific monoclonal antibodies, we 
will be able to perform non-invasive analyses based upon skin prick tests to 
evaluate if passive immunization with allergen-specific IgG4 antibodies is an 
efficacious strategy in the treatment and prevention of allergies. Overall, this study 
has important implications on the current understanding of allergic asthma and may 
impact upon future design of targeted therapeutics for an allergic disease lacking an 















1. Kim YM, Kim YS, Jeon SG, Kim YK. Immunopathogenesis of allergic 
asthma: more than the th2 hypothesis. Allergy Asthma Immunol Res 2013; 
5:189-96. 
2. Holgate ST. A brief history of asthma and its mechanisms to modern 
concepts of disease pathogenesis. Allergy Asthma Immunol Res 2010; 
2:165-71. 
3. Sakula A. Henry Hyde Salter (1823-71): a biographical sketch. Thorax 
1985; 40:887-8. 
4. Holgate ST. Pathophysiology of asthma: what has our current 
understanding taught us about new therapeutic approaches? J Allergy Clin 
Immunol 2011; 128:495-505. 
5. Kay AB. The early history of the eosinophil. Clin Exp Allergy 2015; 
45:575-82. 
6. Lemanske RF, Jr., Busse WW. 6. Asthma. The Journal of allergy and 
clinical immunology 2003; 111:S502-19. 
7. Murphy K, Travers P, Walport M, Janeway C. Janeway's immunobiology. 
8th ed. New York: Garland Science; 2012. 
8. Oglesby IK, McElvaney NG, Greene CM. MicroRNAs in inflammatory 
lung disease--master regulators or target practice? Respiratory research 
2010; 11:148. 
9. Masoli M, Fabian D, Holt S, Beasley R, Global Initiative for Asthma P. The 
global burden of asthma: executive summary of the GINA Dissemination 
Committee report. Allergy 2004; 59:469-78. 
10. Braman SS. The global burden of asthma. Chest 2006; 130:4S-12S. 
11. Lim TK, Chay OM. Fatal asthma in Singapore. Ann Acad Med Singapore 
2012; 41:187-8. 





12. Murdoch JR, Lloyd CM. Chronic inflammation and asthma. Mutat Res 
2010; 690:24-39. 
13. Lemanske RF, Jr., Busse WW. 6. Asthma. J Allergy Clin Immunol 2003; 
111:S502-19. 
14. Cockcroft DW. How best to measure airway responsiveness. Am J Respir 
Crit Care Med 2001; 163:1514-5. 
15. Valenta R, Ball T, Focke M, Linhart B, Mothes N, Niederberger V, et al. 
Immunotherapy of allergic disease. Adv Immunol 2004; 82:105-53. 
16. Murdoch JR, Lloyd CM. Resolution of allergic airway inflammation and 
airway hyperreactivity is mediated by IL-17-producing {gamma}{delta}T 
cells. Am J Respir Crit Care Med 2010; 182:464-76. 
17. Lloyd CM, Robinson DS. Allergen-induced airway remodelling. The 
European respiratory journal : official journal of the European Society for 
Clinical Respiratory Physiology 2007; 29:1020-32. 
18. Galli SJ, Tsai M, Piliponsky AM. The development of allergic 
inflammation. Nature 2008; 454:445-54. 
19. Holgate ST. The airway epithelium is central to the pathogenesis of asthma. 
Allergol Int 2008; 57:1-10. 
20. Davies DE, Wicks J, Powell RM, Puddicombe SM, Holgate ST. Airway 
remodeling in asthma: new insights. J Allergy Clin Immunol 2003; 
111:215-25; quiz 26. 
21. Cibella F, Cuttitta G, Bellia V, Bucchieri S, D'Anna S, Guerrera D, et al. 
Lung function decline in bronchial asthma. Chest 2002; 122:1944-8. 
22. Montefort S, Roche WR, Holgate ST. Bronchial epithelial shedding in 
asthmatics and non-asthmatics. Respir Med 1993; 87 Suppl B:9-11. 





23. Valenta R, Ferreira F, Focke-Tejkl M, Linhart B, Niederberger V, Swoboda 
I, et al. From allergen genes to allergy vaccines. Annual review of 
immunology 2010; 28:211-41. 
24. Lambrecht BN, Hammad H. The role of dendritic and epithelial cells as 
master regulators of allergic airway inflammation. Lancet 2010; 376:835-43. 
25. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-
specific immunotherapy. Nature reviews. Immunology 2006; 6:761-71. 
26. Holgate ST. Innate and adaptive immune responses in asthma. Nat Med 
2012; 18:673-83. 
27. Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in 
health and disease. Nat Rev Immunol 2013; 13:9-22. 
28. Kay AB. The role of eosinophils in the pathogenesis of asthma. Trends Mol 
Med 2005; 11:148-52. 
29. Fahy JV. Eosinophilic and neutrophilic inflammation in asthma: insights 
from clinical studies. Proc Am Thorac Soc 2009; 6:256-9. 
30. Barnes PJ. Pathophysiology of allergic inflammation. Immunol Rev 2011; 
242:31-50. 
31. Schneider E, Thieblemont N, De Moraes ML, Dy M. Basophils: new 
players in the cytokine network. Eur Cytokine Netw 2010; 21:142-53. 
32. Yoshimoto T, Yasuda K, Tanaka H, Nakahira M, Imai Y, Fujimori Y, et al. 
Basophils contribute to T(H)2-IgE responses in vivo via IL-4 production 
and presentation of peptide-MHC class II complexes to CD4+ T cells. Nat 
Immunol 2009; 10:706-12. 
33. Perrigoue JG, Saenz SA, Siracusa MC, Allenspach EJ, Taylor BC, 
Giacomin PR, et al. MHC class II-dependent basophil-CD4+ T cell 





interactions promote T(H)2 cytokine-dependent immunity. Nat Immunol 
2009; 10:697-705. 
34. Lloyd CM, Hessel EM. Functions of T cells in asthma: more than just 
T(H)2 cells. Nat Rev Immunol 2010; 10:838-48. 
35. Ozdemir C, Akdis M, Akdis CA. T-cell response to allergens. Chem 
Immunol Allergy 2010; 95:22-44. 
36. Lloyd CM, Robinson DS. Allergen-induced airway remodelling. Eur Respir 
J 2007; 29:1020-32. 
37. Holgate ST, Davies DE, Lackie PM, Wilson SJ, Puddicombe SM, Lordan 
JL. Epithelial-mesenchymal interactions in the pathogenesis of asthma. J 
Allergy Clin Immunol 2000; 105:193-204. 
38. Holgate ST, Lackie PM, Howarth PH, Roche WR, Puddicombe SM, 
Richter A, et al. Invited lecture: activation of the epithelial mesenchymal 
trophic unit in the pathogenesis of asthma. Int Arch Allergy Immunol 2001; 
124:253-8. 
39. Chua KY, Cheong N, Kuo IC, Lee BW, Yi FC, Huang CH, et al. The 
Blomia tropicalis allergens. Protein and peptide letters 2007; 14:325-33. 
40. Yi FC, Shek LP, Cheong N, Chua KY, Lee BW. Molecular cloning of 
Blomia tropicalis allergens--a major source of dust mite allergens in the 
tropics and subtropics. Inflammation & allergy drug targets 2006; 5:261-6. 
41. Tsai JJ, Yi FC, Chua KY, Liu YH, Lee BW, Cheong N. Identification of the 
major allergenic components in Blomia tropicalis and the relevance of the 
specific IgE in asthmatic patients. Annals of allergy, asthma & 
immunology : official publication of the American College of Allergy, 
Asthma, & Immunology 2003; 91:485-9. 
42. Arruda LK, Vailes LD, Platts-Mills TA, Fernandez-Caldas E, Montealegre 
F, Lin KL, et al. Sensitization to Blomia tropicalis in patients with asthma 





and identification of allergen Blo t 5. American journal of respiratory and 
critical care medicine 1997; 155:343-50. 
43. Chew FT, Lim SH, Goh DY, Lee BW. Sensitization to local dust-mite 
fauna in Singapore. Allergy 1999; 54:1150-9. 
44. Milian E, Diaz AM. Allergy to house dust mites and asthma. Puerto Rico 
health sciences journal 2004; 23:47-57. 
45. Colloff MJ, Spieksma FT. Pictorial keys for the identification of domestic 
mites. Clinical and experimental allergy : journal of the British Society for 
Allergy and Clinical Immunology 1992; 22:823-30. 
46. Kidon MI, Chiang WC, Liew WK, Lim SH, See Y, Goh A, et al. 
Sensitization to dust mites in children with allergic rhinitis in Singapore: 
does it matter if you scratch while you sneeze? Clin Exp Allergy 2005; 
35:434-40. 
47. Chew FT, Zhang L, Ho TM, Lee BW. House dust mite fauna of tropical 
Singapore. Clinical and experimental allergy : journal of the British Society 
for Allergy and Clinical Immunology 1999; 29:201-6. 
48. Chan SL, Ong TC, Gao YF, Tiong YS, Wang de Y, Chew FT, et al. 
Nuclear magnetic resonance structure and IgE epitopes of Blo t 5, a major 
dust mite allergen. Journal of immunology 2008; 181:2586-96. 
49. Naik MT, Chang CF, Kuo IC, Kung CC, Yi FC, Chua KY, et al. Roles of 
structure and structural dynamics in the antibody recognition of the allergen 
proteins: an NMR study on Blomia tropicalis major allergen. Structure 
2008; 16:125-36. 
50. Liaw SH, Chen HZ, Liu GG, Chua KY. Acid-induced polymerization of the 
group 5 mite allergen from Dermatophagoides pteronyssinus. Biochemical 
and biophysical research communications 2001; 285:308-12. 





51. Shek LP, Chong AR, Soh SE, Cheong N, Teo AS, Yi FC, et al. Specific 
profiles of house dust mite sensitization in children with asthma and in 
children with eczema. Pediatr Allergy Immunol 2010; 21:e718-22. 
52. Kuo IC, Cheong N, Trakultivakorn M, Lee BW, Chua KY. An extensive 
study of human IgE cross-reactivity of Blo t 5 and Der p 5. The Journal of 
allergy and clinical immunology 2003; 111:603-9. 
53. Hamid Q, Tulic M. Immunobiology of asthma. Annu Rev Physiol 2009; 
71:489-507. 
54. Gallelli L, Busceti MT, Vatrella A, Maselli R, Pelaia G. Update on 
anticytokine treatment for asthma. Biomed Res Int 2013; 2013:104315. 
55. Walsh GM. An update on biologic-based therapy in asthma. 
Immunotherapy 2013; 5:1255-64. 
56. Walsh GM. Anti-IL-4/-13 based therapy in asthma. Expert Opin Emerg 
Drugs 2015; 20:349-52. 
57. Landolina NA, Levi-Schaffer F. Eosinophils as a pharmacological target for 
the treatment of allergic diseases. Curr Opin Pharmacol 2014; 17:71-80. 
58. Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol 
2015; 16:45-56. 
59. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. 
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, 
double-blind, placebo-controlled trial. Lancet 2012; 380:651-9. 
60. Landolina N, Levi-Schaffer F. Monoclonal antibodies: the new magic 
bullets for allergy: IUPHAR Review 17. Br J Pharmacol 2016; 173:793-803. 
61. Akdis CA. Therapies for allergic inflammation: refining strategies to induce 
tolerance. Nat Med 2012; 18:736-49. 





62. Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, et al. 
Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, 
versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised 
dose-ranging study. Lancet Respir Med 2014; 2:879-90. 
63. Mukherjee M, Sehmi R, Nair P. Anti-IL5 therapy for asthma and beyond. 
World Allergy Organ J 2014; 7:32. 
64. Babu KS, Arshad SH, Holgate ST. Omalizumab, a novel anti-IgE therapy 
in allergic disorders. Expert opinion on biological therapy 2001; 1:1049-58. 
65. Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nature 
reviews. Immunology 2008; 8:218-30. 
66. Galvao VR, Castells MC. Hypersensitivity to biological agents-updated 
diagnosis, management, and treatment. J Allergy Clin Immunol Pract 2015; 
3:175-85; quiz 86. 
67. Fanta CH. Asthma. The New England journal of medicine 2009; 360:1002-
14. 
68. Global Initiative for Asthma. Global Strategy for Asthma Management and 
Prevention, 2016. Available from www.ginasthma.org 2016. 
69. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. 
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in 
collaboration with the World Health Organization, GA(2)LEN and 
AllerGen). Allergy 2008; 63 Suppl 86:8-160. 
70. Cooke RA, Barnard JH, Hebald S, Stull A. Serological Evidence of 
Immunity with Coexisting Sensitization in a Type of Human Allergy (Hay 
Fever). J Exp Med 1935; 62:733-50. 
71. Loveless MHSMJ. Humoral antibody and tissue tolerance induced in pollen 
sensitive individuals by specific therapy: Preliminary report. S. Med. J. 
1940. 





72. Loveless MH. Immunological studies of pollinosis: I. The presence of two 
antibodies related to the same pollen-antigen in the serum of treated hay 
fever patients. J Allergy Clin Immunol 1940; 11. 
73. Shamji MH, Durham SR. Mechanisms of immunotherapy to aeroallergens. 
Clinical and experimental allergy : journal of the British Society for Allergy 
and Clinical Immunology 2011; 41:1235-46. 
74. Valenta R, Ball T, Focke M, Linhart B, Mothes N, Niederberger V, et al. 
Immunotherapy of allergic disease. Advances in immunology 2004; 
82:105-53. 
75. Wachholz PA, Durham SR. Induction of 'blocking' IgG antibodies during 
immunotherapy. Clinical and experimental allergy : journal of the British 
Society for Allergy and Clinical Immunology 2003; 33:1171-4. 
76. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-
specific immunotherapy with recombinant grass pollen allergens. J Allergy 
Clin Immunol 2005; 116:608-13. 
77. Valenta R. The future of antigen-specific immunotherapy of allergy. Nat 
Rev Immunol 2002; 2:446-53. 
78. Karamloo F, Schmid-Grendelmeier P, Kussebi F, Akdis M, Salagianni M, 
von Beust BR, et al. Prevention of allergy by a recombinant multi-allergen 
vaccine with reduced IgE binding and preserved T cell epitopes. Eur J 
Immunol 2005; 35:3268-76. 
79. Kussebi F, Karamloo F, Rhyner C, Schmid-Grendelmeier P, Salagianni M, 
Mannhart C, et al. A major allergen gene-fusion protein for potential usage 
in allergen-specific immunotherapy. J Allergy Clin Immunol 2005; 
115:323-9. 
80. Chen KW, Fuchs G, Sonneck K, Gieras A, Swoboda I, Douladiris N, et al. 
Reduction of the in vivo allergenicity of Der p 2, the major house-dust mite 
allergen, by genetic engineering. Mol Immunol 2008; 45:2486-98. 





81. Chen KW, Focke-Tejkl M, Blatt K, Kneidinger M, Gieras A, Dall'Antonia 
F, et al. Carrier-bound nonallergenic Der p 2 peptides induce IgG antibodies 
blocking allergen-induced basophil activation in allergic patients. Allergy 
2012; 67:609-21. 
82. Nouri HR, Varasteh A, Vahedi F, Chamani J, Afsharzadeh D, Sankian M. 
Constructing a hybrid molecule with low capacity of IgE binding from 
Chenopodium album pollen allergens. Immunol Lett 2012; 144:67-77. 
83. Moingeon P. Update on immune mechanisms associated with sublingual 
immunotherapy: practical implications for the clinician. J Allergy Clin 
Immunol Pract 2013; 1:228-41. 
84. Poddighe D, Licari A, Caimmi S, Marseglia GL. Sublingual 
immunotherapy for pediatric allergic rhinitis: The clinical evidence. World 
J Clin Pediatr 2016; 5:47-56. 
85. Calderon MA, Kleine-Tebbe J, Linneberg A, De Blay F, Hernandez 
Fernandez de Rojas D, Virchow JC, et al. House Dust Mite Respiratory 
Allergy: An Overview of Current Therapeutic Strategies. J Allergy Clin 
Immunol Pract 2015; 3:843-55. 
86. Mackenzie KJ, Anderton SM, Schwarze J. Peptide immunotherapy for 
childhood allergy - addressing translational challenges. Clin Transl Allergy 
2011; 1:13. 
87. Incorvaia C, Montagni M, Ridolo E. The efficiency of peptide 
immunotherapy for respiratory allergy. Expert Rev Clin Pharmacol 2016:1-
7. 
88. Larche M. Mechanisms of peptide immunotherapy in allergic airways 
disease. Ann Am Thorac Soc 2014; 11 Suppl 5:S292-6. 
89. Gupta K, Kumar S, Das M, Dwivedi PD. Peptide based immunotherapy: a 
pivotal tool for allergy treatment. Int Immunopharmacol 2014; 19:391-8. 





90. O'Hehir RE, Prickett SR, Rolland JM. T Cell Epitope Peptide Therapy for 
Allergic Diseases. Curr Allergy Asthma Rep 2016; 16:14. 
91. Muller U, Akdis CA, Fricker M, Akdis M, Blesken T, Bettens F, et al. 
Successful immunotherapy with T-cell epitope peptides of bee venom 
phospholipase A2 induces specific T-cell anergy in patients allergic to bee 
venom. J Allergy Clin Immunol 1998; 101:747-54. 
92. Larche M, Wraith DC. Peptide-based therapeutic vaccines for allergic and 
autoimmune diseases. Nat Med 2005; 11:S69-76. 
93. Hochweller K, Anderton SM. Kinetics of costimulatory molecule 
expression by T cells and dendritic cells during the induction of tolerance 
versus immunity in vivo. Eur J Immunol 2005; 35:1086-96. 
94. Campbell JD, Buckland KF, McMillan SJ, Kearley J, Oldfield WL, Stern 
LJ, et al. Peptide immunotherapy in allergic asthma generates IL-10-
dependent immunological tolerance associated with linked epitope 
suppression. J Exp Med 2009; 206:1535-47. 
95. Nirula A, Glaser SM, Kalled SL, Taylor FR. What is IgG4? A review of the 
biology of a unique immunoglobulin subtype. Current opinion in 
rheumatology 2011; 23:119-24. 
96. Jutel M, Akdis CA. Immunological mechanisms of allergen-specific 
immunotherapy. Allergy 2011; 66:725-32. 
97. van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, 
Martinez-Martinez P, Vermeulen E, et al. Anti-inflammatory activity of 
human IgG4 antibodies by dynamic Fab arm exchange. Science 2007; 
317:1554-7. 
98. Zhao D, Lai X, Tian M, Jiang Y, Zheng Y, Gjesing B, et al. The Functional 
IgE-Blocking Factor Induced by Allergen-Specific Immunotherapy 
Correlates with IgG4 Antibodies and a Decrease of Symptoms in House 
Dust Mite-Allergic Children. Int Arch Allergy Immunol 2016; 169:113-20. 





99. Lai X, Li J, Xiao X, Liu E, Zhang C, Wang H, et al. Specific IgG4 
Production during House Dust Mite Immunotherapy among Age, Gender 
and Allergic Disease Populations. International archives of allergy and 
immunology 2012; 160:37-46. 
100. O'Hehir RE, Gardner LM, de Leon MP, Hales BJ, Biondo M, Douglass JA, 
et al. House dust mite sublingual immunotherapy: the role for transforming 
growth factor-beta and functional regulatory T cells. American journal of 
respiratory and critical care medicine 2009; 180:936-47. 
101. James LK, Shamji MH, Walker SM, Wilson DR, Wachholz PA, Francis JN, 
et al. Long-term tolerance after allergen immunotherapy is accompanied by 
selective persistence of blocking antibodies. The Journal of allergy and 
clinical immunology 2011; 127:509-16 e1-5. 
102. Shamji MH, Ljorring C, Francis JN, Calderon MA, Larche M, Kimber I, et 
al. Functional rather than immunoreactive levels of IgG4 correlate closely 
with clinical response to grass pollen immunotherapy. Allergy 2012; 
67:217-26. 
103. Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of allergen-IgE 
binding to B cells by IgG antibodies after grass pollen immunotherapy. The 
Journal of allergy and clinical immunology 2003; 112:915-22. 
104. Myou S, Leff AR, Myo S, Boetticher E, Tong J, Meliton AY, et al. 
Blockade of inflammation and airway hyperresponsiveness in immune-
sensitized mice by dominant-negative phosphoinositide 3-kinase-TAT. J 
Exp Med 2003; 198:1573-82. 
105. McMillan SJ, Xanthou G, Lloyd CM. Manipulation of allergen-induced 
airway remodeling by treatment with anti-TGF-beta antibody: effect on the 
Smad signaling pathway. J Immunol 2005; 174:5774-80. 
106. Sturm EM, Kranzelbinder B, Heinemann A, Groselj-Strele A, Aberer W, 
Sturm GJ. CD203c-based basophil activation test in allergy diagnosis: 





characteristics and differences to CD63 upregulation. Cytometry B Clin 
Cytom 2010; 78:308-18. 
107. Chan SL, Ong TC, Gao YF, Tiong YS, Wang de Y, Chew FT, et al. 
Nuclear magnetic resonance structure and IgE epitopes of Blo t 5, a major 
dust mite allergen. J Immunol 2008; 181:2586-96. 
108. Stevenson CS, Birrell MA. Moving towards a new generation of animal 
models for asthma and COPD with improved clinical relevance. Pharmacol 
Ther 2011; 130:93-105. 
109. Kumar RK, Herbert C, Foster PS. The "classical" ovalbumin challenge 
model of asthma in mice. Curr Drug Targets 2008; 9:485-94. 
110. Fuchs B, Braun A. Improved mouse models of allergy and allergic asthma--
chances beyond ovalbumin. Curr Drug Targets 2008; 9:495-502. 
111. Birrell MA, Van Oosterhout AJ, Belvisi MG. Do the current house dust 
mite-driven models really mimic allergic asthma? Eur Respir J 2010; 
36:1220-1. 
112. Swirski FK, Sajic D, Robbins CS, Gajewska BU, Jordana M, Stampfli MR. 
Chronic exposure to innocuous antigen in sensitized mice leads to 
suppressed airway eosinophilia that is reversed by granulocyte macrophage 
colony-stimulating factor. J Immunol 2002; 169:3499-506. 
113. Van Hove CL, Maes T, Joos GF, Tournoy KG. Prolonged inhaled allergen 
exposure can induce persistent tolerance. Am J Respir Cell Mol Biol 2007; 
36:573-84. 
114. Cates EC, Fattouh R, Wattie J, Inman MD, Goncharova S, Coyle AJ, et al. 
Intranasal exposure of mice to house dust mite elicits allergic airway 
inflammation via a GM-CSF-mediated mechanism. J Immunol 2004; 
173:6384-92. 





115. Olin JT, Wechsler ME. Asthma: pathogenesis and novel drugs for treatment. 
BMJ 2014; 349:g5517. 
116. Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol 
2008; 8:205-17. 
117. Adamko D, Odemuyiwa SO, Moqbel R. The eosinophil as a therapeutic 
target in asthma: beginning of the end, or end of the beginning? Curr Opin 
Pharmacol 2003; 3:227-32. 
118. Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood 1992; 
79:3101-9. 
119. Clutterbuck EJ, Hirst EM, Sanderson CJ. Human interleukin-5 (IL-5) 
regulates the production of eosinophils in human bone marrow cultures: 
comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood 1989; 
73:1504-12. 
120. Yamaguchi Y, Hayashi Y, Sugama Y, Miura Y, Kasahara T, Kitamura S, et 
al. Highly purified murine interleukin 5 (IL-5) stimulates eosinophil 
function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic 
factor. J Exp Med 1988; 167:1737-42. 
121. Kariyawasam HH, Robinson DS. The role of eosinophils in airway tissue 
remodelling in asthma. Curr Opin Immunol 2007; 19:681-6. 
122. Pease JE, Williams TJ. Eotaxin and asthma. Curr Opin Pharmacol 2001; 
1:248-53. 
123. Conroy DM, Williams TJ. Eotaxin and the attraction of eosinophils to the 
asthmatic lung. Respir Res 2001; 2:150-6. 
124. Pope SM, Zimmermann N, Stringer KF, Karow ML, Rothenberg ME. The 
eotaxin chemokines and CCR3 are fundamental regulators of allergen-
induced pulmonary eosinophilia. J Immunol 2005; 175:5341-50. 





125. Palframan RT, Collins PD, Williams TJ, Rankin SM. Eotaxin induces a 
rapid release of eosinophils and their progenitors from the bone marrow. 
Blood 1998; 91:2240-8. 
126. Schweizer RC, van Kessel-Welmers BA, Warringa RA, Maikoe T, 
Raaijmakers JA, Lammers JW, et al. Mechanisms involved in eosinophil 
migration. Platelet-activating factor-induced chemotaxis and interleukin-5-
induced chemokinesis are mediated by different signals. J Leukoc Biol 
1996; 59:347-56. 
127. Simson L, Foster PS. Chemokine and cytokine cooperativity: eosinophil 
migration in the asthmatic response. Immunol Cell Biol 2000; 78:415-22. 
128. Venge P. The eosinophil and airway remodelling in asthma. Clin Respir J 
2010; 4 Suppl 1:15-9. 
129. Humbles AA, Lloyd CM, McMillan SJ, Friend DS, Xanthou G, McKenna 
EE, et al. A critical role for eosinophils in allergic airways remodeling. 
Science 2004; 305:1776-9. 
130. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker 
JM, et al. Fc receptor but not complement binding is important in antibody 
protection against HIV. Nature 2007; 449:101-4. 
131. Hezareh M, Hessell AJ, Jensen RC, van de Winkel JG, Parren PW. Effector 
function activities of a panel of mutants of a broadly neutralizing antibody 
against human immunodeficiency virus type 1. J Virol 2001; 75:12161-8. 
132. Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, 
Thorpe SJ, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange 
with endogenous human IgG4 in vivo. Nat Biotechnol 2009; 27:767-71. 
133. Angal S, King DJ, Bodmer MW, Turner A, Lawson AD, Roberts G, et al. A 
single amino acid substitution abolishes the heterogeneity of chimeric 
mouse/human (IgG4) antibody. Mol Immunol 1993; 30:105-8. 





134. Bloom JW, Madanat MS, Marriott D, Wong T, Chan SY. Intrachain 
disulfide bond in the core hinge region of human IgG4. Protein Sci 1997; 
6:407-15. 
135. Schuurman J, Perdok GJ, Gorter AD, Aalberse RC. The inter-heavy chain 
disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. 
Mol Immunol 2001; 38:1-8. 
136. Silva JP, Vetterlein O, Jose J, Peters S, Kirby H. The S228P mutation 
prevents in vivo and in vitro IgG4 Fab-arm exchange as demonstrated using 
a combination of novel quantitative immunoassays and physiological 
matrix preparation. J Biol Chem 2015; 290:5462-9. 
137. Cosmi L, Annunziato F, Galli MIG, Maggi RME, Nagata K, Romagnani S. 
CRTH2 is the most reliable marker for the detection of circulating human 
type 2 Th and type 2 T cytotoxic cells in health and disease. Eur J Immunol 
2000; 30:2972-9. 
138. Nagata K, Tanaka K, Ogawa K, Kemmotsu K, Imai T, Yoshie O, et al. 
Selective expression of a novel surface molecule by human Th2 cells in 
vivo. J Immunol 1999; 162:1278-86. 
139. Boumiza R, Debard AL, Monneret G. The basophil activation test by flow 
cytometry: recent developments in clinical studies, standardization and 
emerging perspectives. Clin Mol Allergy 2005; 3:9. 
140. Azorsa DO, Hyman JA, Hildreth JE. CD63/Pltgp40: a platelet activation 
antigen identical to the stage-specific, melanoma-associated antigen ME491. 
Blood 1991; 78:280-4. 
141. Knol EF, Mul FP, Jansen H, Calafat J, Roos D. Monitoring human basophil 
activation via CD63 monoclonal antibody 435. J Allergy Clin Immunol 
1991; 88:328-38. 





142. Ocmant A, Mulier S, Hanssens L, Goldman M, Casimir G, Mascart F, et al. 
Basophil activation tests for the diagnosis of food allergy in children. Clin 
Exp Allergy 2009; 39:1234-45. 
143. Sabato V, van Hengel AJ, De Knop KJ, Verweij MM, Hagendorens MM, 
Bridts CH, et al. Basophil activation reveals divergent patient-specific 
responses to thermally processed peanuts. J Investig Allergol Clin Immunol 
2011; 21:527-31. 
144. Raap U, Wieczorek D, Schenck F, Kapp A, Wedi B. The basophil 
activation test is a helpful diagnostic tool in anaphylaxis to sesame with 
false-negative specific IgE and negative skin test. Allergy 2011; 66:1497-9. 
145. Lee JY, Jin HJ, Park JW, Jung SK, Jang JY, Park HS. A case of korean 
ginseng-induced anaphylaxis confirmed by open oral challenge and 
basophil activation test. Allergy Asthma Immunol Res 2012; 4:110-1. 
146. McGowan EC, Saini S. Update on the performance and application of 
basophil activation tests. Curr Allergy Asthma Rep 2013; 13:101-9. 
147. Leysen J, Sabato V, Verweij MM, De Knop KJ, Bridts CH, De Clerck LS, 
et al. The basophil activation test in the diagnosis of immediate drug 
hypersensitivity. Expert Rev Clin Immunol 2011; 7:349-55. 
148. Gomez E, Blanca-Lopez N, Torres MJ, Requena G, Rondon C, Canto G, et 
al. Immunoglobulin E-mediated immediate allergic reactions to dipyrone: 
value of basophil activation test in the identification of patients. Clin Exp 
Allergy 2009; 39:1217-24. 
149. Gamboa P, Sanz ML, Caballero MR, Urrutia I, Antepara I, Esparza R, et al. 
The flow-cytometric determination of basophil activation induced by 
aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is useful 
for in vitro diagnosis of the NSAID hypersensitivity syndrome. Clin Exp 
Allergy 2004; 34:1448-57. 





150. Sanz ML, Gamboa P, de Weck AL. A new combined test with 
flowcytometric basophil activation and determination of sulfidoleukotrienes 
is useful for in vitro diagnosis of hypersensitivity to aspirin and other 
nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol 2005; 
136:58-72. 
151. Ebo DG, Hagendorens MM, Bridts CH, De Clerck LS, Stevens WJ. 
Hymenoptera venom allergy: taking the sting out of difficult cases. J 
Investig Allergol Clin Immunol 2007; 17:357-60. 
152. Ebo DG, Hagendorens MM, Schuerwegh AJ, Beirens LM, Bridts CH, De 
Clerck LS, et al. Flow-assisted quantification of in vitro activated basophils 
in the diagnosis of wasp venom allergy and follow-up of wasp venom 
immunotherapy. Cytometry B Clin Cytom 2007; 72:196-203. 
153. Korosec P, Erzen R, Silar M, Bajrovic N, Kopac P, Kosnik M. Basophil 
responsiveness in patients with insect sting allergies and negative venom-
specific immunoglobulin E and skin prick test results. Clin Exp Allergy 
2009; 39:1730-7. 
154. Sanz ML, Sanchez G, Gamboa PM, Vila L, Uasuf C, Chazot M, et al. 
Allergen-induced basophil activation: CD63 cell expression detected by 
flow cytometry in patients allergic to Dermatophagoides pteronyssinus and 
Lolium perenne. Clin Exp Allergy 2001; 31:1007-13. 
155. Ebo DG, Bridts CH, Hagendorens MM, Aerts NE, De Clerck LS, Stevens 
WJ. Basophil activation test by flow cytometry: present and future 
applications in allergology. Cytometry B Clin Cytom 2008; 74:201-10. 
156. Erdmann SM, Heussen N, Moll-Slodowy S, Merk HF, Sachs B. CD63 
expression on basophils as a tool for the diagnosis of pollen-associated food 
allergy: sensitivity and specificity. Clin Exp Allergy 2003; 33:607-14. 





157. Erzen R, Kosnik M, Silar M, Korosec P. Basophil response and the 
induction of a tolerance in venom immunotherapy: a long-term sting 
challenge study. Allergy 2012; 67:822-30. 
158. Zitnik SE, Vesel T, Avcin T, Silar M, Kosnik M, Korosec P. Monitoring 
honeybee venom immunotherapy in children with the basophil activation 
test. Pediatr Allergy Immunol 2012; 23:166-72. 
159. Erdmann SM, Sachs B, Kwiecien R, Moll-Slodowy S, Sauer I, Merk HF. 
The basophil activation test in wasp venom allergy: sensitivity, specificity 
and monitoring specific immunotherapy. Allergy 2004; 59:1102-9. 
160. Hausmann OV, Gentinetta T, Fux M, Ducrest S, Pichler WJ, Dahinden CA. 
Robust expression of CCR3 as a single basophil selection marker in flow 
cytometry. Allergy 2011; 66:85-91. 
161. Abuaf N, Rostane H, Rajoely B, Gaouar H, Autegarden JE, Leynadier F, et 
al. Comparison of two basophil activation markers CD63 and CD203c in 
the diagnosis of amoxicillin allergy. Clin Exp Allergy 2008; 38:921-8. 
162. Dvorak AM. Ultrastructural studies of human basophils and mast cells. J 
Histochem Cytochem 2005; 53:1043-70. 
163. MacGlashan D, Jr. Expression of CD203c and CD63 in human basophils: 
relationship to differential regulation of piecemeal and anaphylactic 
degranulation processes. Clin Exp Allergy 2010; 40:1365-77. 
164. Dvorak AM. Cell biology of the basophil. Int Rev Cytol 1998; 180:87-236. 
165. Hennersdorf F, Florian S, Jakob A, Baumgartner K, Sonneck K, Nordheim 
A, et al. Identification of CD13, CD107a, and CD164 as novel basophil-
activation markers and dissection of two response patterns in time kinetics 
of IgE-dependent upregulation. Cell Res 2005; 15:325-35. 
166. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-
specific immunotherapy. Nat Rev Immunol 2006; 6:761-71. 





167. Akkoc T, Akdis M, Akdis CA. Update in the mechanisms of allergen-
specific immunotheraphy. Allergy Asthma Immunol Res 2011; 3:11-20. 
168. Akdis CA, Akdis M. Advances in allergen immunotherapy: aiming for 
complete tolerance to allergens. Sci Transl Med 2015; 7:280ps6. 
169. Wachholz PA, Durham SR. Induction of 'blocking' IgG antibodies during 
immunotherapy. Clin Exp Allergy 2003; 33:1171-4. 
170. van Neerven RJ, Knol EF, Ejrnaes A, Wurtzen PA. IgE-mediated allergen 
presentation and blocking antibodies: regulation of T-cell activation in 
allergy. Int Arch Allergy Immunol 2006; 141:119-29. 
171. Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an 
odd antibody. Clin Exp Allergy 2009; 39:469-77. 
172. de Haard HJ, van Neer N, Reurs A, Hufton SE, Roovers RC, Henderikx P, 
et al. A large non-immunized human Fab fragment phage library that 
permits rapid isolation and kinetic analysis of high affinity antibodies. J 
Biol Chem 1999; 274:18218-30. 
173. Smith GP. Filamentous fusion phage: novel expression vectors that display 
cloned antigens on the virion surface. Science 1985; 228:1315-7. 
174. Thie H, Meyer T, Schirrmann T, Hust M, Dubel S. Phage display derived 
therapeutic antibodies. Curr Pharm Biotechnol 2008; 9:439-46. 
175. Bazan J, Calkosinski I, Gamian A. Phage display--a powerful technique for 
immunotherapy: 1. Introduction and potential of therapeutic applications. 
Hum Vaccin Immunother 2012; 8:1817-28. 
176. Little M, Kipriyanov SM, Le Gall F, Moldenhauer G. Of mice and men: 
hybridoma and recombinant antibodies. Immunol Today 2000; 21:364-70. 
177. Chan CE, Lim AP, MacAry PA, Hanson BJ. The role of phage display in 
therapeutic antibody discovery. Int Immunol 2014; 26:649-57. 





178. Edwards MR, Collins AM, Ward RL. The application of phage display in 
allergy research: characterization of IgE, identification of allergens and 
development of novel therapeutics. Curr Pharm Biotechnol 2001; 2:225-40. 
179. Steinberger P, Kraft D, Valenta R. Construction of a combinatorial IgE 
library from an allergic patient. Isolation and characterization of human IgE 
Fabs with specificity for the major timothy grass pollen allergen, Phl p 5. J 
Biol Chem 1996; 271:10967-72. 
180. Bernhisel-Broadbent J, Dintzis HM, Dintzis RZ, Sampson HA. 
Allergenicity and antigenicity of chicken egg ovomucoid (Gal d III) 
compared with ovalbumin (Gal d I) in children with egg allergy and in mice. 
J Allergy Clin Immunol 1994; 93:1047-59. 
181. Christensen LH, Riise E, Bang L, Zhang C, Lund K. Isoallergen variations 
contribute to the overall complexity of effector cell degranulation: effect 
mediated through differentiated IgE affinity. J Immunol 2010; 184:4966-72. 
182. Valenta R, Steinberger P, Duchene M, Kraft D. Immunological and 
structural similarities among allergens: prerequisite for a specific and 
component-based therapy of allergy. Immunol Cell Biol 1996; 74:187-94. 
183. Yi FC, Shek LP, Cheong N, Chua KY, Lee BW. Molecular cloning of 
Blomia tropicalis allergens--a major source of dust mite allergens in the 
tropics and subtropics. Inflamm Allergy Drug Targets 2006; 5:261-6. 
184. Andiappan AK, Puan KJ, Lee B, Nardin A, Poidinger M, Connolly J, et al. 
Allergic airway diseases in a tropical urban environment are driven by 
dominant mono-specific sensitization against house dust mites. Allergy 
2014; 69:501-9. 
185. Chew FT, Zhang L, Ho TM, Lee BW. House dust mite fauna of tropical 
Singapore. Clin Exp Allergy 1999; 29:201-6. 





186. Kuo IC, Cheong N, Trakultivakorn M, Lee BW, Chua KY. An extensive 
study of human IgE cross-reactivity of Blo t 5 and Der p 5. J Allergy Clin 
Immunol 2003; 111:603-9. 
187. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the 
same language: The World Allergy Organization Subcutaneous 
Immunotherapy Systemic Reaction Grading System. J Allergy Clin 
Immunol 2010; 125:569-74, 74 e1-74 e7. 
188. Eifan AO, Calderon MA, Durham SR. Allergen immunotherapy for house 
dust mite: clinical efficacy and immunological mechanisms in allergic 
rhinitis and asthma. Expert Opin Biol Ther 2013; 13:1543-56. 
189. Flicker S, Gadermaier E, Madritsch C, Valenta R. Passive immunization 
with allergen-specific antibodies. Curr Top Microbiol Immunol 2011; 
352:141-59. 
190. Flicker S, Valenta R. Renaissance of the blocking antibody concept in type 
I allergy. Int Arch Allergy Immunol 2003; 132:13-24. 
191. Denepoux S, Eibensteiner PB, Steinberger P, Vrtala S, Visco V, Weyer A, 
et al. Molecular characterization of human IgG monoclonal antibodies 
specific for the major birch pollen allergen Bet v 1. Anti-allergen IgG can 
enhance the anaphylactic reaction. FEBS Lett 2000; 465:39-46. 
192. Wachholz PA, Durham SR. Mechanisms of immunotherapy: IgG revisited. 
Curr Opin Allergy Clin Immunol 2004; 4:313-8. 
193. Pree I, Reisinger J, Focke M, Vrtala S, Pauli G, van Hage M, et al. Analysis 
of epitope-specific immune responses induced by vaccination with 
structurally folded and unfolded recombinant Bet v 1 allergen derivatives in 
man. J Immunol 2007; 179:5309-16. 
194. Gadermaier E, Flicker S, Aberer W, Egger C, Reider N, Focke M, et al. 
Analysis of the antibody responses induced by subcutaneous injection 





immunotherapy with birch and Fagales pollen extracts adsorbed onto 
aluminum hydroxide. Int Arch Allergy Immunol 2010; 151:17-27. 
195. Yoshino S, Mizutani N, Matsuoka D, Sae-Wong C. Intratracheal exposure 
to Fab fragments of an allergen-specific monoclonal antibody regulates 
asthmatic responses in mice. Immunology 2014; 141:617-27. 
196. Yoshino S, Mizutani N. Intranasal exposure to Fab fragments of a 
monoclonal antibody IgG1 to the major allergen Cry j1 of Japanese cedar 
pollen (JCP) suppresses JCP-induced allergic rhinitis. Br J Pharmacol 2016. 
197. Flicker S, Linhart B, Wild C, Wiedermann U, Valenta R. Passive 
immunization with allergen-specific IgG antibodies for treatment and 
prevention of allergy. Immunobiology 2013; 218:884-91. 
198. Miyajima I, Dombrowicz D, Martin TR, Ravetch JV, Kinet JP, Galli SJ. 
Systemic anaphylaxis in the mouse can be mediated largely through IgG1 
and Fc gammaRIII. Assessment of the cardiopulmonary changes, mast cell 
degranulation, and death associated with active or IgE- or IgG1-dependent 
passive anaphylaxis. J Clin Invest 1997; 99:901-14. 
199. Ishikawa Y, Kobayashi K, Yamamoto M, Nakata K, Takagawa T, Funada 
Y, et al. Antigen-Specific IgG ameliorates allergic airway inflammation via 
Fcgamma receptor IIB on dendritic cells. Respir Res 2011; 12:42. 
200. Vrtala S, Ball T, Spitzauer S, Pandjaitan B, Suphioglu C, Knox B, et al. 
Immunization with purified natural and recombinant allergens induces 
mouse IgG1 antibodies that recognize similar epitopes as human IgE and 
inhibit the human IgE-allergen interaction and allergen-induced basophil 
degranulation. J Immunol 1998; 160:6137-44. 
201. Aalberse RC, van der Gaag R, van Leeuwen J. Serologic aspects of IgG4 
antibodies. I. Prolonged immunization results in an IgG4-restricted 
response. J Immunol 1983; 130:722-6. 





202. Aalberse RC, Dieges PH, Knul-Bretlova V, Vooren P, Aalbers M, van 
Leeuwen J. IgG4 as a blocking antibody. Clin Rev Allergy 1983; 1:289-302. 
203. Nakagawa T, Miyamoto T. The role of IgG4 as blocking antibodies in 
asthmatics and in bee keepers. Int Arch Allergy Appl Immunol 1985; 
77:204-5. 
204. Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, Kulis M, et al. 
Clinical efficacy and immune regulation with peanut oral immunotherapy. J 
Allergy Clin Immunol 2009; 124:292-300,  e1-97. 
205. Zhao D, Lai X, Tian M, Jiang Y, Zheng Y, Gjesing B, et al. The Functional 
IgE-Blocking Factor Induced by Allergen-Specific Immunotherapy 
Correlates with IgG4 Antibodies and a Decrease of Symptoms in House 
Dust Mite-Allergic Children. Int Arch Allergy Immunol 2016; 169:113-20. 
206. James LK, Till SJ. Potential Mechanisms for IgG4 Inhibition of Immediate 
Hypersensitivity Reactions. Curr Allergy Asthma Rep 2016; 16:23. 
207. Daeron M, Jaeger S, Du Pasquier L, Vivier E. Immunoreceptor tyrosine-
based inhibition motifs: a quest in the past and future. Immunol Rev 2008; 
224:11-43. 
208. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, 
et al. Specificity and affinity of human Fcgamma receptors and their 
polymorphic variants for human IgG subclasses. Blood 2009; 113:3716-25. 
209. Kepley CL, Cambier JC, Morel PA, Lujan D, Ortega E, Wilson BS, et al. 
Negative regulation of FcepsilonRI signaling by FcgammaRII 
costimulation in human blood basophils. J Allergy Clin Immunol 2000; 
106:337-48. 
210. Dodev TS, Bowen H, Shamji MH, Bax HJ, Beavil AJ, McDonnell JM, et al. 
Inhibition of allergen-dependent IgE activity by antibodies of the same 
specificity but different class. Allergy 2015; 70:720-4. 
